orchid chemicals & pharmaceuticals limitedorchidpharma.com/downloads/orchid_ar_08-09.pdf ·...
TRANSCRIPT
Regd. Office
‘Orchid Towers’ 313, Valluvar Kottam High Road, Nungambakkam, Chennai 600034, India
Tel : (91)-44-28211000 Fax : (91)-44-28211002 e-mail: [email protected]
Website: www.orchidpharma.com Health portal: www.healthorchid.com
Orchid Chemicals& Pharmaceuticals Limited
Annual Report 2008-09
3mm Spine20901409_Orchid_AR_2k8-2k9_Ordinary_Cover:Layout 2 03/09/09 7:08 PM Page 1
3mm Spine
FORWARD-LOOKING STATEMENTIn this Annual Report we have disclosed forward-looking
information to enable investors to comprehend our prospects and
take informed investment decisions. This report and other
statements that we periodically make contain forward-looking
statements that set out anticipated results based on the
management’s plans and assumptions. We have tried wherever
possible to identify such statements by using words such as
‘anticipate’, ‘estimate’, ‘expects’, ‘projects’, ‘intends’, ‘plans’,
‘believes’, ‘targets’ and words of similar substance in connection
with any discussion of future performance.
We cannot guarantee that these forward-looking statements will
be realized, although we believe we have been prudent in our
assumptions. The achievement of results is subject to risks,
uncertainties and estimates taken as assumptions. Should known
or unknown risks or uncertainties materialize, or should underlying
assumptions prove inaccurate, actual results could vary materially
from those anticipated, estimated or projected.
CONTENTS
Corporate information 01 Strategic review 02 Directors’ Report 04 Corporate Governance Report 13
General shareholders’ information 20 Management discussion and analysis 26 Financial section 31
20901409_Orchid_AR_2k8-2k9_Ordinary_Cover:Layout 2 03/09/09 7:08 PM Page 2
1Annual Report 2008-09
CORPORATE INFORMATION
Board of DirectorsChairmanShri R Narayanan
Managing DirectorShri K Raghavendra Rao
Deputy Managing DirectorDr C Bhaktavatsala Rao
DirectorsDr M R Girinath
Dr I Seetharam Naidu
Shri Deepak Vaidya
Shri S Jeyakumar (IDBI Nominee)
Shri Anil Thadani
Chief Financial OfficerMr S Krishnan
Company SecretaryMrs Bhoomijha Murali
Management TeamDr B Gopalan Executive Director
Mr Ashutosh Ojha President & Chief Executive - Domestic Formulations
Dr Gautam Kumar Das President – Technical (API)
Dr R Buchi Reddy Senior Vice President - Chemical Development (NPNC)
Mr S Chandan Kumar Senior Vice President - Manufacturing (API)
Ms Edna Braganza Senior Vice President - International Marketing & Procurement
Mr Kalidindi V Raju Senior Vice President - Manufacturing (Formulations)
Mr S Mani Senior Vice President - Safety, Health & Environment & CSR
Mr S Nammalvar Senior Vice President - Projects & Engineering Services (API)
Mr S Sridharan Senior Vice President - Information Technology
Mr S Arun Kumar Vice President - Regulatory Affairs (Formulations)
Mr P N Deshpande Vice President - Production & Technical (API)
Mr C R Dwarakanath Vice President - Corporate Safety, Health & Environment
Mr Gurmeet Singh Vice President - Commercial (API)
Dr P Y Naidu Vice President - Analytical Research & Quality Control
Mr V S Padalkar Vice President - Projects & Maintenance (API)
Mr K C Pathak Vice President - PPIC & Outsourcing (API)
Mr M S Rangesh Vice President - Human Resources
Mr Satish Haribhau Joshi Vice President - Quality Assurance (Formulations)
Dr U P Senthil Kumar Vice President - Chemical Development
Mr B M Sundaram Vice President - International Marketing (Latin America & Africa)
Mr A Suresh Babu Vice President - Corporate Affairs
BankersAllahabad Bank Andhra Bank Axis Bank Bank of Baroda
Bank of India Canara Bank Federal Bank ICICI Bank Limited
IDBI Bank Limited IFCI Limited Indian Bank Punjab National Bank
Punjab & Sind Bank SICOM Limited South Indian Bank Limited
State Bank of Hyderabad State Bank of India Syndicate Bank
Union Bank of India
AuditorsStatutory AuditorsSNB Associates
Chartered Accountants
No 12, 3rd Floor, Gemini Parsn Complex
121, Anna Salai , Chennai 600 006
Tamil Nadu, India
Cost AuditorsShri V Kalyanaraman
Cost Accountant
No.4 (Old No.12), Second Street, North Gopalapuram
Chennai 600 086, Tamil Nadu, India
The fiscal 2008-09 was challenging for us. In an environment of global
financial meltdown, we encountered additional constraints with key product
approvals delayed, capex programmes increasing debt and interest as well as
an unprecedented currency fluctuation denting profitability. Consequently,
revenue growth was muted and margins declined.
Despite the odds we completed our asset build-up and the current year will
mark the beginning of a new growth wave centred around product
diversification leading to higher returns.
Strategic direction I must briefly recap some developments. In our initial growth phase, we
achieved a dominant status as a global cephalosporin antibiotic API player.
The more recent phase saw us diversify our asset base to cover not only APIs
but also finished dosage forms (FDFs) and extend beyond cephalosporins into
penicillins and carbapenems in the antibiotics range and several non-penicillin,
non-cephalosporin products in the lifestyle product range. We established a
strong presence in the US cephalosporin generics market and are poised to
replicate our success in other antibiotic and non-antibiotic areas.
Over five years, we invested significant funds to strengthen capabilities, create
facilities and expand capacities. A large part of these investments was funded
by debt so that the Company could capitalise on market opportunities with
speed. The reliance on debt has no doubt translated into a temporarily higher
interest liability but will be mitigated once our product diversification strategy
starts paying off.
Our investments are focused on global scale capabilities in four verticals –
cephalosporins – orals and injectables, penicillin injectables, carbapenems and
non-antibiotics, several of them as Para IV FTF applications. Currently, 85-90%
of the Company’s turnover is still derived from cephalosporins, even as we
committed investments in other verticals. This created a significant stress on
our operations last fiscal. With the recent and envisaged product approvals
and the resulting product-market diversification, the revenue contribution is
anticipated to change.
Cephalosporins: We enjoy a dominant status in the US cephalosporin generics
market, in the form of marketing partnerships with Apotex and a leading
distribution house. We are poised to extend our coverage to the EU with two
major pan-European alliances with Actavis and Hospira. Plans are also afoot
to launch novel dosage forms in this segment, to ensure continued niche
positioning.
Penicillins: Revenues from this segment commenced with the launch of
Piperacillin-Tazobactam injections in Australia, Europe and Canada in 2008-09.
We anticipate a launch in the US in 2009-10 based on likely regulatory
approval. In each of the markets, the Company hopes to carve out a significant
share.
Carbapenems: Carbapenems is another futuristic segment where your
Company has a unique development and manufacturing position globally, on
an end-to-end basis in APIs and dosage forms. The revenue from this segment
are anticipated to accrue from this fiscal and increase subsequently.
Other product segments: Orchid has developed a significant product pipeline
covering other lifestyle categories such as central nervous system,
cardiovascular, anti-emetic, gastro-intestinal and pain management drugs. A
few approvals have already been received and there will be significant product
launches in this segment in this fiscal and beyond.
Although each segment will continue to grow, the relative contribution from
cephalosporins will progressively decline while that from penicillin injections,
carbapenems and oral non-cephalosporins will increase. As our investments
begin yielding significant returns, our financial profile will get deleveraged and
profitability strengthened.
Key growth engines Product pipeline: Orchid’s robust pipeline is expected to catalyse growth in the
following ways:
We expect to launch around a dozen products in the cephalosporin and
other categories in the US and the EU in 2009-10 with an estimated market
size of US$2.6 billion (pre-patent expiry).
The already launched high value products namely Cefdinir and Cefepime
among others, in the US will continue to generate sizeable revenue from
2009-10.
The pipeline of carbapenems represents a major first mover opportunity and
could improve with newer carbapenems getting added.
As we extend our marketing alliances to cover additional products and
additional markets, we will enhance product-market scope.
The recently completed second antibiotic injectables line for certain niche
dosage forms will help us access an attractive market segment.
Our launch of Piperacillin-Tazobactam injections in Australia, Europe and
Canada in 2008-09 should significantly grow our business and profitability
in the coming years
API alliances: Apart from ensuring continued growth in API business, we also
entered into agreements with select corporations to supply select antibiotic
bulk actives on a long-term basis. These APIs will be sourced by them after
22 Orchid Chemicals & Pharmaceuticals Ltd.
THE NEXT GROWTH WAVEStrategic review
K Raghavendra Rao, Managing Director shares his perspectives on Orchid’s future growth
Dear Shareholders,
approvals by the regulatory authorities for site variation. This arrangement
will enhance our asset utilisation and improve our revenue as well as
profitability.
Paragraph IV first-to-file products: Within a short span of entering the non-
antibiotic product range, Orchid filed 7 ANDAs with US FDA as Paragraph IV,
first-to-file (FTF) filings out of a total of 21 non-antibiotic ANDA filings in the
US. We are also working on additional Para IV FTF applications for products
with a large estimated market. These Para IV FTF products should drive a
greater share of our business.
Japan – new focusWe have also embarked on a new initiative to diversify our presence in the
exacting Japanese market.
Japan is the second largest pharmaceutical market and the second highest
healthcare spender. The pharmaceutical sales in the Japanese market increased
by 3% from US$66.6 bn in 2007 to US$68.6 bn in 2008. The Japanese
government is committed to increase the share of generics from the current
low of 4% to as high as 30% in the years to come. Orchid, with its balanced
coverage of antibiotic and lifestyle products, is well suited to meet the
requirements of the Japanese society, which is marked by an ageing population
and spiralling healthcare costs.
During fiscal 2009, we established Orchid Pharma Japan to support our foray
into Japan. We have so far filed three DMFs for Japan with more in the pipeline
in 2009-10 and beyond. While continuing discussions on potential API sales,
we are discussing an initial basket of generic dosage form products with
potential partners.
Innovation – new chemical entitiesThe Company reinforced its drug discovery focus with an acceleration of
discovery and development activities in the selected therapeutic areas of
diabetes, pain management, oncology and anti-infective products. A rich
compound library was developed in these areas with several interesting
discovery hits and pre-clinical leads. Two new chemical entities in the
inflammatory and oncology areas are undergoing regulatory toxicology studies
and could be positioned for Phase I studies upon successful conclusion.
We are also undertaking the development and manufacture of an anti-
coagulant drug candidate initially discovered and developed through Phase I
by Merck & Co., Inc, US. We invested in Diakron Pharmaceuticals Inc, which has
an exclusive license agreement with Merck for the compound. Our investment
in Diakron will eventually result in majority control. The compound is a novel
investigational oral anticoagulant drug with considerable potential.
We also entered into a major collaboration and licencing agreement with
Merck & Co., Inc for the discovery of novel anti-infective drugs. Under the
agreement, Orchid will identify and develop novel anti-bacterial and anti-
fungal compounds as clinically validated drug candidates. We will undertake
discovery and candidate development through Phase II a human clinical trials.
Merck will consider late stage clinical development and subsequent
commercialisation based on regulatory approvals. The alliance with the global
pharma major for research-based novel discovery not only provides attractive
milestone and royalty payments but also enhances Orchid’s brand as an
innovation-led organisation.
The multi-pronged strategy of proprietary drug discovery, collaborative drug
discovery and fee-for-service projects will ensure that the risk-reward
equations inherent in the complex drug discovery processes are balanced for
optimal value.
CRAMSApart from generics and proprietary discovery initiatives, we are also
introducing our unique abilities of undertaking custom research and
manufacturing services to select innovator companies. Orchid, with its world-
class multi-therapeutic, R&D and manufacturing infrastructure and
competencies covering the total spectrum of pharmaceutical value chain, is
attractively positioned to undertake wide ranging development and
manufacturing projects covering discovery, optimisation, pre-clinical, clinical
and commercial supplies. Our strategy will be to work with fewer partners but
on a broader and deeper spectrum to provide a total complement of products
and services for such preferred partners.
We are now at the cusp of the next growth phase, which will result in
substantial business development and robust year-on-year growth across all
our high-value verticals.
I wish to take this opportunity to thank the shareholders and all our other
stakeholders for their continued support to our growth plans.
Regards,
K Raghavendra Rao
33Annual Report 2008-09
44 Orchid Chemicals & Pharmaceuticals Ltd.
Your Directors have pleasure in presenting the 17th Annual Report of your Company along with the audited statement of accounts for the financial year ended
March 31, 2009. The Report also includes the Management’s Discussion and Analysis Report in accordance with the guidelines on Corporate Governance and the
consolidated financial statements.
The highlights of the financial results for 2008-09 are given below
PerformanceDuring 2008-09, your Company achieved a turnover and operating income of
Rs. 1191.44 crore compared to Rs. 1238.92 crore in 2007-08. Earnings before
interest and tax (EBIT) was at Rs. 51.03 crore compared to Rs. 248.40 crore of
last fiscal.
After providing for interest expenses of Rs. 155.19 crore (Rs. 81.13 crore previous
fiscal) and depreciation of Rs. 129.97 crore (Rs. 97.67 crore previous fiscal), the
loss before tax of the Company was Rs. 36.85 crore, compared to the previous
year’s profit before tax of Rs. 238.54 crore. Net loss after tax stood at Rs. 52.17
crore, compared to the net profit after tax of Rs. 184.54 crore in the previous
fiscal. The profitability figures reflect the impact of adoption of the modified AS
11 accounting treatment and the impact of buyback (and cancellation) of
Foreign Currency Convertible Bonds (FCCBs) of the face value of US$37.80
million aggregate face value of the 2012 Bonds and US$2.25 million aggregate
face value of the 2010 Bonds, both at applicable discounts.
Your Company’s active pharmaceutical ingredients are increasingly being
supplied to the Company’s own generic formulations, representing an
integrated pharmaceutical operation.
Pharmaceuticals businessYour Company’s formulations business was at Rs. 627.49 crore during the fiscal,
compared to Rs. 682.50 crore in 2007-08. A large part of this business was
contributed by the US generics business. The consolidated turnover of all the
five divisions of the domestic formulations segment grew by 23.81% to
Rs. 92.78 crore compared to the previous financial year of Rs. 74.94 crore. Your
Company also sold Rs. 540.87 crore of active pharmaceutical ingredients (APIs)
during the fiscal, compared to Rs. 520.37 crore in the previous fiscal. This
excludes the captive sale to the Company’s formulations business.
DIRECTORS’ REPORT
(Rs. lakh)
Particulars Year ended March 31, 2009 Year ended March 31, 2008
Sales and operating income 119144.04 123891.62
Other income 2284.88 124.20
Total expenditure 103328.46 89408.94
Gross profit 18100.46 34606.87
Interest and finance charges 15518.60 8112.63
Gross profit after interest but before depreciation and taxation 2581.86 26494.24
Depreciation 12997.21 9766.78
Profit/(Loss) from ordinary activities before exceptional items (10415.35) 16727.46
Exceptional item 6730.53 7126.67
Profit / (Loss) before tax (3684.82) 23854.13
Provision for taxation
- Current and deferred tax 1371.65 5250.52
- Fringe benefit tax 161.00 150.00
Profit / (Loss) after tax (5217.47) 18453.61
Add: Surplus brought forward 8157.47 4010.15
Surplus available 2940.00 22463.78
Appropriations:
- Transfer to general reserve -- 12000.00
- Excess provision of dividend for earlier year written back (963.71) (1129.82)
- Dividend 915.84 2936.99
- Tax on distributed profits 155.65 499.14
Balance carried to balance sheet 2832.22 8157.47
55Annual Report 2008-09
A highlight of the performance this year includes the introduction of its
premium Piperacillin-Tazobactam injection product in Canada in distribution
partnership with Apotex and in Europe, Australia and New Zealand in
distribution partnership with Hospira based on respective regulatory approvals.
However, the regulatory approval for the product in the US is yet to be
accorded by US FDA due to the ongoing review of the innovator’s Citizen
Petition. The US generics business and the overall formulations business
turnover would have been higher had the Company received the approval for
this key injectable product. The review of the ANDAs for the product is however
making progress. Orchid has been impressing upon FDA the need to accord
speedy approval for the product.
DividendYour Directors recommend a 10% dividend (Re. 1 per equity share of Rs. 10
each) for the year ended March 31, 2009 subject to the approval of
shareholders at the ensuing Annual General Meeting. Under the Income Tax
Act, 1961, the receipt of dividend is tax-free in the hands of the shareholders.
Regulatory filings and approvalsYour Company achieved significant progress in the filing of DMFs (Drug Master
Files) and ANDAs (Abbreviated New Drug Applications). Till date, your Company
has filed 72 US DMFs and 58 ANDAs (29 in the cephalosporin segment, 21 in
NPNC (non-penicillin, non-cephalosporin) segment, 5 in the penicillin segment
and 3 in the carbapenems segment to support its US generics thrust. With 26
ANDAs for cephalosporin products already approved, the Company ranks the
highest in terms of approval record in the antibiotics space.
In the EU market, Orchid increased its dossier registrations and marketing
authorisations (MAs) to 29 (23 in cephalosporin segment, 3 in the NPNC
segment, 2 in the carbapenems segment and 1 in the penicillin segment). A few
dossiers are also in the advanced stages of submission.
The total count of ANDAs approved till date increased to 31, out of which 26
are in the cephalosporin segment and 5 in the NPNC segment.
AlliancesDuring 2008-09, your Company extended certain of its generics partnership
arrangements to include additional products and additional regions. These new
arrangements will provide significant revenue boost in the years to come.
During the year, your Company undertook the development and manufacture
of an anti-coagulant drug candidate initially discovered and developed through
Phase I by Merck & Co., Inc., USA (“Merck”). Towards this end, your Company
invested in Diakron Pharmaceuticals Inc. (“Diakron”), a US based drug discovery
and development company which has an exclusive license agreement with
Merck for the compound. This investment in Diakron, through a combination
of services and cash at competitive valuation, will eventually result in a
majority control for your Company.
Your Company and Merck & Co., Inc, USA, established a strategic research
collaboration and license agreement focused on the discovery, development
and commercialisation of novel agents for the treatment of bacterial and
fungal infections. Under this agreement, Orchid would discover and develop
New Chemical Entities (NCEs) upto Phase II (a) proof-of-concept stage beyond
which the NCEs will be developed through larger Phase II and Phase II(a)
human clinicals by Merck and commercialised based on regulatory approvals.
Your Company will receive success milestone linked payments and also
royalties upon commercialisation.
Your Company also strengthened its relationship with Pfizer, Inc. in both animal
health and human health fields in terms of a number of projects in Custom
Research and Manufacturing Services (CRAMS) domain.
Drug discoveryOrchid’s core proprietary programmes cover the areas of diabetes,
inflammation, oncology and anti-infective therapeutic programmes. Newer
programmes in obesity and CNS are being contemplated. Over 10 lead
compounds are in various stages of pre-clinical and clinical development. In the
area of inflammation, new compounds in PDE IV area are making progress
while in the oncology area new HDAC inhibitor compounds are showing
significant promise. It is proposed to take one lead each from these areas to
regulatory toxicology studies this year and position them for first-in-man
dosing studies next fiscal.
Orchid is also engaged in discussions with select innovator companies for
further collaboration arrangements and prospective licensing opportunities.
AwardsDuring the year, your Company’s sterile carbapenem API facility at Aurungabad
was conferred with the Facility of the Year 2009 award for Regional Excellence
by Interphex. Orchid was also facilitated with TERI Corporate Environmental
Award in appreciation of its efforts for source reduction of pollutants by
process transformation. The Company also received recognition for its
initiatives in the field of corporate social responsibility.
Intellectual propertyDuring the year, Orchid continued to accelerate the IPR work on a number of
products. The total number of patent applications filed by Orchid in various
national and international patent offices so far was 644 (including process,
formulation, NCE, NDDS, biotech and nanotech areas). As of March 31, 2009,
371 patent applications were published while 99 patents were granted
cumulatively.
GDRs and FCCBsYour Company issued FCCBs during November 2005, which were listed on the
Luxembourg Stock Exchange and during February 2007, which are listed on
the Singapore Exchange Limited. The FCCBs due in 2010 are termed 2010 Bonds
and those due in 2012 are termed 2012 Bonds.
In terms of the Reserve Bank of India’s A.P. (DIR Series) Circular No. 39 dated
December 08, 2008, the Company explored the possibilities of buying back the
FCCBs.
During the year, the Company bought back 2012 Bonds to the extent of
US$37.80 million and 2010 Bonds worth US$2.25 million at applicable
reasonable discounts. The total outstanding of 2010 Bonds after the buyback
was US$17.46 million and that of 2012 Bonds was US$137.20 million. The
status of FCCBs after the said buyback was as follows
66 Orchid Chemicals & Pharmaceuticals Ltd.
Description 2010 Bonds 2012 Bonds
FCCB value US$42.50 million US$175 million
Conversion into equity done so far US$22.79 million Nil
Redemption value (%) of the book value 147.17% 142.77%
FCCBs bought back so far 2.25 million 37.80 million
Issue of warrantsThe 50,00,000 warrants issued to Promoter/Promoter Group(s) in March 2007were convertible into equity shares within 18 months from the date ofallotment (i.e. till August 31, 2008).
During the year, 45,60,000 warrants were converted into shares, by the warrantholders. The Allotment Committee of the Board approved the conversions at itsmeetings held on August 13, 2008 and August 29, 2008. The balance 4,40,000warrants were not converted within the stipulated time. Hence, the 10%advance paid by the allottees on the unexercised warrants amounting to Rs. 89.14 lakh was forfeited.
Employees stock option planDuring the year, your Company allotted 31,300 equity shares of Rs. 10 each,pursuant to exercise of options granted under the ‘ORCHID - ESOP 1999’ and‘ORCHID - ESOP 2005’ schemes to the employees of the Company. The detailsof options granted to employees and the status of such options as on March31, 2009 are given in Annexure V to this Report.
Your Company also formulated a stock option plan viz., Orchid - ESOP 2007 forgrant of 5,00,000 options to the employees of subsidiary companies eitherworking in India or overseas, or a Director of the Company (excluding thePromoter Directors). The said scheme was approved by the shareholders at theAnnual General Meeting held on July 19, 2007. As of March 31, 2009, yourCompany did not grant any options under this scheme.
Listing of equity shares Your Company's equity shares are presently listed on the National Stock
Exchange of India Limited (NSE), Bombay Stock Exchange Limited (BSE) and the
Madras Stock Exchange Limited (MSE). The Company has got listing approval
from the above stock exchanges for the listing of 45,91,300 equity shares
issued during the year. The convertible bonds issued during 2005-06 are listed
on the Luxembourg Stock Exchange and the London Stock Exchange. The
convertible bonds issued by the Company during 2006-07 are listed on the
Singapore Stock Exchange.
Overseas joint venturesNCPC Orchid Pharmaceuticals Company Limited, ChinaYour Company’s 50:50 joint venture in China, NCPC Orchid Pharmaceuticals
established for manufacture of sterile cephalosporin APIs continued to perform
well. The joint venture is profitable with a significant sales turnover of
US$44.13 million during the year in the Chinese market. The Company
maintained its considerable share for its key injectable cephalosporin API
products in the Chinese markets.
SubsidiariesOrchid Research Laboratories Limited, India (ORLL) ORLL achieved progress in the therapeutic areas of anti-infective, anti-
inflammation, anti-cancer and anti-diabetes drug discovery. The new lead
molecules in inflammation and cancer areas are in various stages of discovery
and pre-clinical development. The selected molecules from the applicable
therapeutic areas will be taken up for GLP regulatory toxicology studies this
year and are likely to be taken up for human clinical studies during the next
fiscal.
ORLL established a world-class integrated infrastructure for discovery and
development of new drug candidates. Apart from pursuing own proprietary
drug discovery programmes, ORLL is also open to collaborate with innovative
companies and specialist discovery companies on their targets and programmes
to discover and develop new medicines to meet global healthcare needs. The
Company's state-of-the-art infrastructure, diversified NCE pipeline and
approach of strategic partnerships will make ORLL a formidable drug discovery
entity in the global pharma space.
Bexel Pharmaceuticals, Inc., USA (Bexel)In continuation of the planned work, Bexel, during the year, completed in
respect of its anti-diabetes molecule BLX-1002, Phase II (a) proof-of-concept
studies in human volunteers. Also studies conducted by a reputed overseas
research institute in animal models indicated certain underlying mechanistic
properties of the drug. An agreement was drawn up with the institute to
conduct further studies which will throw light on the mechanism of action of
this compound.
Orchid Pharmaceuticals, Inc. - USAOrchid Pharmaceuticals, Inc., is a wholly-owned Delaware-based subsidiary of
the Company and is also the 100% holding company of Orgenus Pharma, Inc.
Orgenus reported a satisfactory year in the US market. Orgenus continued to
support the Company in its current business relationships and also provided the
required services with respect to ground operations and regulatory processes.
It also continued to explore new strategic business expansion opportunities
for the Company.
Orchid Europe Limited, United Kingdom Orchid Europe Limited (OEL) was incorporated to support the generic foray into
the EU market. During 2008-09, the DCP application of Tazobactum Piperacillin
was successfully completed and the product was launched in the EU market in
distribution partnership with Hospira. OEL also received marketing
authorisations for its products in Italy and France. The Company’s partners also
received three marketing approvals for certain cephalosporin and non-
cephalosporin products.
During the year, OEL and the Company signed dossier licensing deals with
certain additional partners. OEL is well established on the path of supporting
the generics plans of Orchid in Europe.
Orchid Pharmaceuticals (South Africa) Pty Ltd., South AfricaYour Company’s wholly-owned subsidiary, Orchid Pharmaceuticals (SouthAfrica) Pty Ltd, was incorporated to register and market bulk drugs andformulations. As Orchid’s facilities were successfully audited by MCC andreceived the approval for cephalosporin and penicillin injectable dosage formfacilities, the registration activities of the South African subsidiary would behelpful.
Orchid Pharmaceuticals (South Africa) Pty Ltd received approval for a
7
cephalosporin injectable generic product. A number of cephalosporin products
were also submitted to the regulatory authority and the approvals in respect
of the same are awaited.
The Company entered into an exclusive marketing tie-up for five antibiotic
products with a local distribution partner. The dossiers for the same were
submitted to MCC and are at different stages of the registration process. The
Company reached an advanced stage of negotiations for marketing four
products from its non-antibiotic range. During the financial year 2009-10, the
Company expects to obtain few more approvals for its products, the dossiers
for which are already submitted.
Orchid Pharma Japan KKThe Company made good progress in finalising an initial basket of generic
dosage form products for Japan filings and developing detailed activity plans
for three prioritised injectable dosage form products targeted for filing in 2010.
In addition, a broader list of potential products was also developed, for
progressive development and filing. The Company is also exploring the
arrangements for API marketing.
Your Company received the approval under Section 212(8) of the Companies
Act, 1956, from the Ministry of Corporate Affairs seeking exemption from
attaching the Annual Report of subsidiary companies with the Annual Report
of the Company and to provide the accounts in the same manner as certified
by overseas auditors in the respective countries where the subsidiaries are
situated. The statement as required under Section 212 was prepared and the
same is given as part of the consolidated accounts in the Report.
The consolidated financial statements of the subsidiaries duly audited are
presented along with the accounts of your Company. The annual accounts of
subsidiary companies are kept at the Company’s registered office and also at
the respective registered office of the subsidiaries for inspection and shall be
made available to the members seeking such information.
Fixed depositThe Company did not accept any fixed deposits and as such, no amount of
principal or interest was outstanding as of the balance sheet date.
Directors’ responsibility statementIn accordance with the provisions of Section 217 (2AA) of the Companies Act,
1956, your Directors confirm:
That in preparation of the annual accounts for 2008-09, the applicable
accounting standards were followed along with proper explanation relating to
material departures, if any.
That the Directors selected such accounting policies and applied them
consistently and made judgments and estimates that were reasonable and
prudent so as to give a true and fair view of the state of affairs of the Company
at the end of the financial year (March 31, 2009) and of the profit or loss of
the Company for that period (2008-09).
That the Directors took proper and sufficient care to maintain adequate
accounting records in accordance with the provisions of the Companies Act,
1956, for safeguarding the assets of the Company and for preventing and
detecting fraud and other irregularities.
That the Directors prepared the annual accounts for 2008-09 on a going
concern basis.
Safety excellence journeyAt Orchid, safety is accorded the highest importance by the top management
and is cascaded all the way down. The Company formed a Central Safety
Committee (CSC) chaired by the Managing Director, which is responsible for
steering the Company on its safety excellence journey.
Continuous efforts with respect to safety, training and education are Orchid’s
commitment to the safety management programme. Orchid’s safety journey
includes not only employees but also contractors. A system of reporting and
investigating all near-miss incidents helps in preventing incidents by
identifying root causes and implementing the appropriate corrective and
preventive actions. Learnings from these incidents are shared with all
employees across locations.
Considerable progress was made in the process safety area also. Significant
numbers of scientists, engineers and operating personnel are trained in hazard
analysis and risk reduction techniques. Your Company made significant
progress in the safety excellence journey by competency building and
developing several safety standards and procedures and implementing them.
Corporate social responsibilityWith the mission of developing a sustainable society, Orchid Trust was
registered for the community development activities of Orchid. In recognition
of its activities, Tamil Nadu Government selected Orchid’s initiative as the best
Corporate Social Responsibility (CSR) initiative for the year 2008-09.
As a part of its CSR activities, Orchid established educational facilities in a
nearby village to cater to the needs of children. Orchid Trust intends to support
various educational activities.
Orchid also evolved strategies to prepare the unemployed rural youth to realise
their dreams. Activities like educational rally, sports events and women
empowerment by imparting income generating skills including skill training
like tailoring classes were also taken up.
Conservation of energyYour Company has always been striving hard in the field of energy
conservation. Several measures to conserve energy and to reduce associated
costs were taken during 2008-09 as well. The particulars in respect to
conservation of energy as required under Section 217 (1) (e) of the Companies
Act, 1956, are given in Annexure I to this Report.
Foreign collaborationThe particulars in respect of R&D/technology absorption, as required under
Section 217 (1)(e) of the Companies Act, 1956, are given in Annexure II to this
Report.
Foreign exchange earnings and outgoThe particulars in respect of foreign exchange earnings and outgo, as required
under Section 217 (1)(e) of the Companies Act, 1956, are given in Annexure III
to this Report.
Particulars of employeesInformation as per Section 217(2A) of the Companies Act, 1956, read with
7Annual Report 2008-09
88 Orchid Chemicals & Pharmaceuticals Ltd.
Companies (Particulars of Employees) Rules, 1975 forms a part of this Report.
However, as per the provisions of Section 219(1)(b)(iv) of the Companies Act,
1956, the report and accounts are being sent to all members of the Company
excluding the aforesaid information. Any member interested in obtaining a
copy of the particulars may write to the Secretary at the Company’s registered
office.
Corporate governanceThe spirit of good Corporate Governance remains integral to the Company’s
corporate philosophy. The Company follows the code of Corporate Governance
issued by the stock exchanges for listed companies. For 2008-09, all
information relating to Corporate Governance is given in Annexure IV to this
Report. A compliance certificate from the statutory auditors is appended to
this Report. General shareholders information is given in Annexure VI.
DirectorsResignation of Dr. Anzaghi Piergiorgio and Shri S. Andi
Dr. Anzaghi Piergiorgio, who has been a Director of Orchid, resigned from the
Board during October 2008. The Board places on record its appreciation for
the contributions made by Dr. Anzaghi Piergiorgio as a Director.
The IDBI Bank Limited withdrew the nomination of Shri S. Andi and nominated
Shri S. Jeyakumar as its nominee in his place. The Board places on record its
appreciation for the contribution made by Shri S. Andi and welcomes Shri S.
Jeyakumar.
Retirement of Directors by rotationIn accordance with the provisions of the Companies Act, 1956, and the Articles
of Association of the Company, Dr. I. Seetharam Naidu and Dr. M. R. Girinath
retire by rotation at the ensuing Annual General Meeting and being eligible
offer themselves for re-appointment.
AuditorsThe existing statutory auditors, M/s SNB Associates, Chartered Accountants,
retire at the forthcoming Annual General Meeting, and being eligible, offer
themselves for re-appointment.
Auditor’s report Note No. 30 in the notes on accounts of Schedule ‘Q’ to the Standalone
Financial Statements explains the point referred to in point 5(b) of the Auditor’s
Report on Standalone accounts.
Cost auditThe Central Government prescribed that an audit of the cost accounts
maintained by the Company in respect of bulk drugs and formulations be
conducted under Section 233B of the Companies Act, 1956. Consequently, your
Company appointed Shri V. Kalyanaraman, B.Sc., FICWA, as Cost Auditor for
2008-09, with the consent of the Central Government, for the audit of cost
accounts maintained by the Company in respect of both bulk drugs and
formulations.
AcknowledgementsYour Directors are thankful to the Bank of India, IDBI Bank Limited, State Bank
of India, Axis Bank Limited, ICICI Bank Limited, Indian Bank, Union Bank of
India, Allahabad Bank, Canara Bank, Punjab National Bank, Bank of Baroda
and other public sector and private sector banks and institutions for meeting
the long-term and working capital needs of the Company’s expanding
operations and also to the holders of FCCBs and GDRs for their support.
The Directors are grateful to the Central and State Governments and the
Central DCGI and State FDAs for their continued support to the Company’s
expansion plans. Your Board places on record its appreciation of the support
provided by the customers, suppliers and equipment vendors to the Company.
Your Directors are also thankful to the vendors, distributors and agents for
their continued support.
Your Directors are thankful to the esteemed shareholders for their support and
encouragement. The Directors acknowledge the commitment and contribution
of all employees to the growth of the Company.
For and on behalf of the Board
Place: Chennai R. NarayananDate: June 29, 2009 Chairman
Sl. Particulars Orchid Europe Orgenus Orchid Bexel Orchid Pharma Orchid Orchid
No. Limited, Pharmaceuticals Pharmaceuticals Pharmaceuticals Japan KK Pharmaceuticals Research
United Kingdom Inc., USA Inc., USA Inc., USA Japan SA (Proprietary) Laboratories
Limited Ltd., India
South Africa
Financial year of the April - March April - March April - March Jan-Dec April - March March - Feb April - MarchSubsidiary
£ Rs. $ Rs. $ Rs. lakh $ Rs. Jpy Rs. lakh S. A. Rs. Rs. Rs. lakh
lakh lakh lakh Rand lakh
1 Capital 10000.00 7.24 100000.00 50.65 200100 101.36 18374777 9307.28 30000000 153.98 230033 11.78 148766000 1487.66
2 Reserves (678158.00) (490.75) 55458.00 28.09 (896) (0.45) (23969611) (12141.21) (131542) (0.68) (204996) (10.50) (463756554) (4637.57)
3 Other Liabilities 832618.00 602.52 126526.00 64.09 -- -- 5780719 2928.08 135000 0.69 25 0.00 424430091 4244.30
4 Total Liabilities 164460.00 119.01 281984.00 142.83 199204 100.90 185885 94.16 30003458 153.99 25061 1.28 109439537 1094.40
5 Total Assets 164460.00 119.01 281984.00 142.83 199204 100.90 185885 94.16 30003458 153.99 25061 1.28 109439537 1094.40
6 Details of investment -- -- -- -- -- -- -- -- -- -- -- -- 59908750 599.09
7 Turnover 520014.00 376.31 710542.00 359.91 -- -- -- -- -- -- -- -- 24347088 243.47
8 Profit /(Loss) before Taxation (128403) (92.92) (27934.00) (14.15) (196) (0.10) (904527) (458.17) 3458 0.02 (118349) (6.06) (150134367) (1501.34)
9 Provision for Taxation 30752 22.25 5431.00 2.75 -- -- -- -- 135000 0.69 -- -- 625000 6.25
10 Profit /(Loss) after Taxation (97651) (70.67) (33365.00) (16.90) (196) (0.10) (904527) (458.17) (131542) (0.68) (118349) (6.06) (150759367) (1507.59)
11 Proposed Dividend -- -- -- -- -- -- -- -- -- -- -- -- -- --
12 The net aggregate of profit/(loss) for the current period of the Subsidiary so far as it concerns the members of the holding Company
a) Dealt with or (70.67) (16.90) (0.10) (458.17) (0.68) (6.06) (1,507.59)provided for in the accounts of the holding company
b) Not dealt with Nil Nil Nil Nil Nil Nil Nil or provided for in the accounts of the holding company
13 The net aggregate of profit/(loss) for previous financial years of the Subsidiary so far as it concerns the members of the holding company
a) Dealt with or provided (356.65) 35.07 7.09 (5,133.81) (0.68) (4.66) (3,129.97)
for in the accounts of
the holding company
b) Not dealt with or Nil Nil Nil Nil Nil Nil Nil
provided for in the
accounts of the
holding company
Note:i) Indian equivalent of figures have been arrived at by applying the year end rate 1£ = Rs. 72.365, 1 South African Rand = Rs. 5.12, 1 Japanese Yen = Re.0.51 and 1US$ = Rs. 50.65 and do not form part of the reports of OrchidEurope Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., Orchid Pharma Japan KK and Orchid Pharmaceuticals SA (Proprietary) Limited
ii) Holding Company’s interest is as stated in the Schedule Q Notes to accounts 26(a).
iii) Shares held by the holding company in the subsidiary is as stated in the Schedule E of the audited accounts
99Annual Report 2008-09
STATEMENT PURSUANT TO SECTION 212 OF THE COMPANIES ACT, 1956, RELATING TO SUBSIDIARY COMPANIES
On behalf of the BoardK. Raghavendra Rao
Managing Director
Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduDeputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
1010 Orchid Chemicals & Pharmaceuticals Ltd.
Year ended March 31, 2009 Year ended March 31, 2008A Power and fuel consumption1 Electricity
a) PurchasedUnit 89802147 62438009Total amount (Rs. lakh) 3372.83 2502.89Rate per unit (Rs.) 3.76 4.01
b) Own generationi) Through diesel generator
Units 5709853 4626973Units per litre of diesel oil 3.28 3.45 Cost per unit (Rs.) 9.09 7.52
ii) Through furnace oil generatorUnits 8049144 31431684Units per litre of fuel oil 4.24 4.25 Cost per unit (Rs.) 5.48 3.98
2 CoalQuantity (tonnes) 15944.20 NilTotal cost (Rs. lakh) 693.65 NilAverage rate per tonne (Rs.) 4350.50 Nil
Information under Section 217(1)(e) of the Companies Act, 1956, read with
Companies (Disclosure of Particulars in the Report of Board of Directors) Rules,
1988 and forming part of Directors’ Report for the year ended March 31, 2009.
Annexure I – Conservation of Energya) Energy conservation measures takenThe following energy conservation measures were taken at the manufacturing
plants :
Utilisation of grid power and wheeling instead of captive power plant
resulted in reduction of cost/unit by 10%
The coal fired boiler was commissioned. Oil fired boiler was less utilised and
kept as a stand-by. This resulted in an appreciable reduction in the
cost/tonne of steam
Energy efficient compact fluorescent lamps were installed
For condensing solvent vapors, CT water was used instead of “+10” water
Air cooled screw chillers were replaced by water cooled centrifugal ones,
resulting in 10-15% reduction in specific energy consumption
The chiller set points were optimised to save energy
Reduction of effluents by usage of water from sparkler filter and hot water
In-house process development resulted in reduction of solvent/water
quantity, thereby reducing energy consumption in recovering solvents
Conversion of batch distillation to continuous distillation to avoid the batch
start/stop energy losses
Timers were installed in selected blowers to optimise the energy
consumption
By active energy conservation awareness campaign, 30 suggestions were
implemented, resulting in savings of Rs. 25 lakh
b) Additional investments and proposals, if any, being implementedfor reduction of consumption of energySome proposals that are considered / being implemented for saving energy
are:
Implementation of feasible energy conservation suggestions selected from
employee suggestion scheme, with a saving potential of around Rs. 100 lakh
Reduction of effluents, by reusing the evaporator condensate as the make-
up water for chiller cooling towers
Reduction of steam consumption in the effluent treatment plants
Minimising the usage of energy intensive solvents to reduce the energy
consumption
Using CT water instead of energy intensive +10 water for condensing
solvents
Routine energy audits to avoid avoidable losses like air and nitrogen leaks,
among others
c) Impact of the measures (a) and (b) above for reduction of energyconsumption and consequent impact on the cost of production ofgoodsDue to the various energy conservation activities implemented, mentioned in
(a) above, there was a reduction in power consumption by around 20,000 units
per day and 33 tonnes of steam per day, leading to a saving of around
Rs. 1,119 lakh annually which includes benefits of coal fired boiler.
Further, the energy conservation measures proposed to be taken up by the
Company as mentioned in (b) above are expected to bring in savings of around
Rs. 490 lakh annually.
d) Total energy consumption and energy consumption per unit of production
ANNEXURE TO THE DIRECTORS’ REPORT
1111Annual Report 2008-09
Year ended March 31, 2009 Year ended March 31, 20083 Furnace oil
Quantity (KL) 10775.15 21784.32
Total cost (Rs. lakh) 2684.10 3698.85
Average rate (Rs. per KL) 24910.06 16979.41
4 Others / internal generation
i) Windmills *
Quantity (in units) 1401063 1599451
Cost per unit (Rs.) 2.70 2.70
ii) Gas based *
Quantity (in units) 38592091 26060118
Cost per unit (Rs.) 2.85 2.95
B Consumption per unit of production
Products with details
Bulk drugs - oral and sterile (in MT) 688 680
Electricity (Rs. lakh per MT) 5.11 5.02
Furnace oil (Rs. lakh per MT) 3.62 5.25
Coal (Rs. lakh per MT) 1.01 Nil
Others Nil Nil
* Units generated are wheeled to our manufacturing facilities
Annexure II - Technology AbsorptionI. Research and Development1. Specific areas in which research and development activities have beencarried out by the Company during the year. The Company carries out research and development in the areas of
Cephalosporins and Carbapenems as well as Non-Penicillin, Non-Cephalosporin
(NPNC) products.
R&D also works on the cost reduction of various molecules to continue to stay
competitive in the dynamic international markets.
Orchid’s process research division has also undertaken a custom research
project for a major MNC, to carry out synthesis of NCEs (New Chemical
Entities) required for its Drug Discovery Project. R&D has also undertaken
development of manufacturing technology for a new drug substance for
subsequent collaborative supply to the innovator. In another important project,
R&D has carried out the synthesis and profiling of impurities for a Japanese
Company.
R&D has also undertaken CRAMS project on betalactams and supplied
Kilogram quantities of a monobactam made as per customer’s requirement.
2. Benefits derived as a result of the above R&D activities.Cost reduction processes developed for various molecules would provide
competitive advantage and bring in financial benefits to the Organization in
several regulated and emerging markets.
New molecules developed under custom research project would strengthen
the relationship with the MNCs’ discovery units.
New products developed and implemented in respective manufacturing
locations on betalactam class of drugs would help in filing the dossiers with
regulatory agencies in various potential markets, for subsequent approval and
business development.
The development of manufacturing technology for a new drug substance would
position the Company formidably in partnering the innovator on value chain
development.
New filings in Japan or preparations for filing in Japan are achieved with the
studies and developments made at R&D. Initiatives with Japanese Companies
in the CRAMS area will lead to progressive toeholds in this challenging market.
3. Future plan of action.
It is proposed to continue development of new generic APIs, with new non-
infringing patentable processes, to support generics thrust. Emphasis will be
placed on high quality cost-effective development with a goal of faster time-
to-market.
It is also proposed to take up more Custom Research Projects from Innovator
companies and establish relationships for developing CRAMS and discovery
projects in different therapeutic groups.
The biotech group has been focusing on biotransformation technologies for
more efficient manufacture of intermediates and APIs. The group could
commercialize the enzymatic manufacture of select APIs which not only
improved the overall yield but also reduced level of effluent generation.
Several technologies are in advanced stages of development and which would
elevate biotech contribution significantly and facilitate effective environmental
management. Biotech group has broadened its focus recently on NPNC
molecules in addition to Ceph APIs. Effective advancement of these initiatives
and technologies would enhance the innovative profile of our organization.
1212 Orchid Chemicals & Pharmaceuticals Ltd.
b) Total foreign exchange earnings and outgo (Rs. lakh)
Year ended March 31, 2009 Year ended March 31, 2008
1. Earnings in foreign exchange during the year
F.O.B value of exports 93202.59 100855.60
Export of services (net of TDS) 2714.89 4123.10
2. C.I.F. value of imports (on cash basis)
Raw materials 28214.51 19598.04
Capital goods 8175.49 7064.07
Spare parts, components and consumables 5953.24 4174.66
3. Expenditure in foreign currency during the year (on cash basis)
Travelling expenses 256.23 139.12
Interest and bank charges 2071.04 783.07
Consultancy fees 1899.67 1431.43
Royalty / technical knowhow 103.93 201.50
Others 3277.12 3130.60
4. Dividend remittances in foreign currency during the year
Net dividend 105.45 425.68
5. Total foreign exchange used (2+3+4) 50056.68 36948.17
4. Expenditure on R&D
The R&D outlay was as follows
(Rs. lakh)
Year ended Year ended March 31, 2009 March 31, 2008
a) Capital 812.15 2564.00
b) Recurring 4633.46 4519.07
c) Total 5445.61 7083.07
d) Total R&D expenditure as a 4.53% 5.67%
percentage of the total turnover
II Technology absorption, adaptation and innovationI. Research and Development1. Efforts in brief, made towards technology absorption, adaptation andinnovation.
Orchid has established considerable in-house strengths in the areas of its
research with enhanced capabilities which add value in the global research
arena. World-class infrastructure has been established for the purpose.
Chemistry, Biology and other disciplines are reinforced from time to time.
Orchid’s research personnel attend overseas conferences periodically to
showcase their developments and also to gain insights into contemporary
scientific and technological developments. They are also encouraged to patent
their inventions and publish their works, where appropriate.
2. Benefits derived as a result of the above efforts, e.g. product improvement,cost reduction, product development, import substitution, etc.
As a result of the various R&D and technology innovation efforts, your
Company has been able to develop over 25 APIs in various therapeutic areas
in R&D and upscale then in various API plants. An increasing number of them
have been in the areas of lifestyle diseases covering pain management,
cardiovascular, central nervous system, anti-emetic, anti-diabetic and other
categories. Several formulations have also been developed covering these areas.
The Company has also conducted custom research and pre-clinical/clinical
supply activities for multinational companies. Research in biotechnology has
been helpful in introducing certain cost-effective and environmental friendly
processes in the API field.
3. Imported technology (imported during the last 5 years reckoned fromthe beginning of the financial year):
a) Technology No new technology has been
imported by Orchid during
the year.
b) Year of import Not applicable.
c) Has this technology been fully absorbed Not applicable.
d) If not fully absorbed, areas where this Not applicable.
has not taken place, reasons thereof
and future plans of action.
Annexure III - Foreign exchange earnings & outgoa) Activities relating to exports, initiatives taken to increase exports,development of new export markets for products and services, and exportplans.
With an emphasis on the regulated generic markets, the Company is focusing
in an increasing measure on the sale and distribution of APIs and generics in
regulated markets including the United States, Canada, Europe, Japan, and
Australia, as applicable.
1. Company's philosophy on code of CorporateGovernanceOrchid has been committed to high standards of Corporate Governance
practices. The Company believes that a sound Corporate Governance policy
drives healthy business growth and is an important instrument of enhancing
investor confidence. Orchid complies with the Corporate Governance code
enshrined in Clause 49 of the Listing Agreement.
2. Board of DirectorsThe Chairman of the Board of Directors is a Non-Executive, Independent
Director. The Board has a composition of two Executive Directors and six Non-
Executive Directors. Four out of eight Directors are Independent Directors.
Composition and category of Directors as of March 31, 2009 was as follows:
1313Annual Report 2008-09
CORPORATE GOVERNANCE REPORTAnnexure IV to the Director’s Report
Sl Name(s) of Director(s) Category Number of Directorships Number of Board Committee
no. held in other Indian companies @ memberships held in other companies*
1 Shri R. Narayanan Non-Executive – Independent 11 5
2 Shri K. Raghavendra Rao Promoter and Executive Director 1 None
3 Dr C. Bhaktavatsala Rao Executive Director 1 None
4 Dr M. R. Girinath Non-Executive – Independent None None
5 Dr I. Seetharam Naidu Non-Executive – Independent None None
6 Shri S. Jeyakumar Non-Executive – Independent
(IDBI Nominee) None None
7 Shri Deepak Vaidya Non-Executive 6 5
8 Shri Anil Thadani / Non-Executive
Shri Raj Rajkumar is an Alternate 1 None
Director to Shri Anil Thadani
@ Excludes foreign companies, private limited companies and alternate directorships. * Includes only membership in Audit and Investor Grievance Committee.
None of the Directors are related to each other.
Board meetingsAttendance Record of the DirectorsFive Board meetings were held during the year from April 01, 2008 to March 31, 2009. The dates on which the meetings were held were April 13, May 29, July
30, and October 30 in 2008 and on January 28, 2009. The attendance records of all Directors are as under:
Name(s) of Director(s) Number of Board meetings Last AGM attendance
Held Attended
Shri R. Narayanan 5 5 Present
Shri K. Raghavendra Rao 5 5 Present
Dr C. Bhaktavatsala Rao 5 4 Present
Dr M. R. Girinath 5 4 Present
Dr I. Seetharam Naidu 5 5 Present
Shri Deepak Vaidya 5 2 Present
Shri Subramanian Andi1 3 2* Not present
Shri S. Jeyakumar1 2 2 Not present
Dr Anzaghi Piergiorgio2 3 1 Not present
Shri Anil Thadani / Shri Raj Rajkumar 5 4 Not present
1 Industrial Development Bank of India Limited (IDBI) withdrew the nomination of Shri Subramanian Andi and appointed Shri S. Jeyakumar, as its nominee on
the Board with effect from September 08, 2008.
2 Resigned from the Board with effect from October 03, 2008.
* At the request of IDBI, Shri A. U. Ashok Katara attended the meeting held on July 30, 2008 on behalf of Shri Subramanian Andi
1414 Orchid Chemicals & Pharmaceuticals Ltd.
3. Audit CommitteeThe Company constituted an Audit Committee consisting of Non-Executive
Directors during 1998. The terms of reference of the Audit Committee include
a. Review of:Financial statements before submission to the Board
Draft financial statements and Auditors' Report (before submission to theBoard)
Accounting policies and practices
Risk management policies and practices
Compliance with stock exchange and legal requirements concerningfinancial statements
Related party transactions
The internal control systems and internal audit reports and their compliancethereof
Compliance with accounting standards, and
b. Recommending the appointment of auditors and fixing their fee.Four meetings were held during the year from April 01, 2008 to March 31,
2009 i.e on May 29, July 30, October 30 in 2008 and on January 28 in 2009.
The constitution of the Committee and the attendance of each member of the
Committee as on March 31, 2009 are given below:
Name Category Number of meetings
Held Attended
Shri R. Narayanan, Non-Executive 4 4
Chairman – Independent
Dr M. R. Girinath Non-Executive 4 3
– Independent
Dr I. Seetharam Non-Executive 4 4
Naidu – Independent
Shri Deepak Vaidya* Non-Executive 4 3
Shri Subramanian Non-Executive 2 1@
Andi1 – Independent
Shri S. Jeyakumar1 Non-Executive 2 2
– Independent
* Shri Raj Rajkumar attended the meeting held on January 28, 2009 on behalf
of Shri Deepak Vaidya
@ At the request of IDBI, Shri A. U. Ashok Katara attended the meeting held
on July 30, 2008 on behalf of Shri Subramanian Andi
1 Industrial Development Bank of India Limited (IDBI) withdrew the
nomination of Shri Subramanian Andi and appointed Shri S. Jeyakumar, as
its nominee on the Board with effect from September 08, 2008.
The Chairman of the Audit Committee, Shri R. Narayanan was present at the
Annual General Meeting of the Company held on September 29, 2008.
The Company Secretary is the Secretary of the Audit Committee.
4. Remuneration CommitteeThe Remuneration Committee determines and recommends the remuneration
payable to the Executive Directors on the basis of their performance as well as
Company’s performance, subject to consents as may be required.
The Non-Executive Directors are not paid any remuneration except for the
sitting fees for attending the Board meetings /Committee meetings.
The remuneration to the Executive Directors comprises a fixed salary and other
perquisites. The leave travel allowance is paid as per the Company rules.
Provident Fund and Superannuation are provided for as per the Company's
policy. Wherever applicable the perquisites are considered a part of
remuneration and taxed as per Income Tax laws. The commission recommended
by the Remuneration Committee to the Board is paid to the Managing Director
in accordance with the provisions of the Companies Act, 1956.
The Remuneration Committee comprises Shri R. Narayanan, Chairman, Dr M.
R. Girinath, Dr I. Seetharam Naidu, Shri Deepak Vaidya and Shri S. Jeyakumar,
all Non-Executive Directors. The Committee deals with all elements of
remuneration package, stock options, service contracts, etc. of all whole-time
directors. One meeting of Remuneration Committee was held during the year
2008-09 on May 29, 2008 and all the members of the committee attended
the meeting.
Details of remuneration paid to Directors for the year 2008-09 are given below:
(Rs. lakh)
Name(s) of Director(s) Remuneration paid during the year 2008-09
Salary Commission/ Sitting Totalbonus / fees
incentive
Shri R. Narayanan,
Chairman – – 5.40 5.40
Shri K. Raghavendra
Rao 202.57 0.10 – 202.67
Dr C. Bhaktavatsala
Rao 140.67 0.10 – 140.77
Dr M. R. Girinath – – 2.20 2.20
Dr I. Seetharam Naidu – – 2.80 2.80
Shri Deepak Vaidya – – 1.00 1.00
Shri Subramanian Andi,
Nominee – IDBI1 – – 0.80 0.80*
Shri S. Jeyakumar,
Nominee – IDBI1 – – 0.80 0.80*
Dr Anzaghi Piergiorgio2 – – 0.20 0.20
Shri Anil Thadani /
Shri Raj Rajkumar – – 1.00 1.00
* Sitting fees of Rs. 1.60 lakh paid directly to IDBI Limited.
1 Industrial Development Bank of India Limited (IDBI) withdrew thenomination of Shri Subramanian Andi and appointed Shri S. Jeyakumar, asits nominee on the Board with effect from September 08, 2008.
2 Resigned from the Board with effect from October 03, 2008.
1515Annual Report 2008-09
8. Details of Annual/Extraordinary General meetingsLocation and start time of the General Meetings held in the past three years
Year AGM / EGM Location Special resolutions passed Date Time
2008 AGM Kalaignar Arangam 1. Reappointment of September 29, 2008 10.00 AM
“Anna Arivalayam” Deputy Managing Director
367-369, Anna Salai
Teynampet
Chennai – 600 018
The Company has made an application to Central Government to approve the
remuneration paid to the Managing Director and Deputy Managing Director,
as the minimum remuneration payable, on account of inadequacy of profits, for
the Financial Year 2008-09. Approval is awaited.
The shares held by Directors as on March 31, 2009 are given below:
Name(s) of Director(s) Number of Shares
Shri R. Narayanan 26,697
Shri K. Raghavendra Rao 69,25,173
Dr C. Bhaktavatsala Rao 15
Dr M. R. Girinath 4,80,934
Dr I. Seetharam Naidu 3,32,430
Shri Deepak Vaidya Nil
Shri S. Jeyakumar Nil
Shri Anil Thadani Nil
Shri Raj Rajkumar 70,000
5. Compensation CommitteePursuant to the SEBI (Employee Stock Option Scheme and Employee StockPurchase Scheme) Guidelines, 1999, a Compensation Committee wasconstituted in 1999 to consider the following:
1. Quantum of options to be granted to each employee and in aggregate.
2. The conditions under which options vested in employees may lapse in caseof termination of employment due to misconduct.
3. The exercise period within which the employee should exercise the optionand that option would lapse on failure to exercise the option within theexercise period.
4. The specified time period within which the employee shall exercise thevested options in the event of termination or resignation of an employee.
5. The right of an employee to exercise all the options vested in him at onceor at various points of time within the exercise period.
6. The procedure for making a fair and reasonable adjustment to the numberof options and to the exercise price in case of rights issue, bonus issues andother corporate actions.
7. The grant, vest and exercise of option in case of employees who are on longleave.
8. The procedure for cashless exercise of options, if any.
The Compensation Committee comprises Shri R. Narayanan, Shri K.Raghavendra Rao and Shri Subramanian Andi and the Committee met once
during the year 2008-09 on April 26, 2008 to discuss and revise the exerciseperiod of options granted from two to three years under Employee Stock OptionSchemes 1999 and 2005.
6. Allotment CommitteeThe Allotment Committee of the Board was constituted in 2001. The purpose
of this committee is to consider allotment of equity shares whenever the need
arises. The Committee comprises Shri R. Narayanan, Shri K. Raghavendra Rao,
Dr C. Bhaktavatsala Rao, Dr M. R. Girinath and Dr I. Seetharam Naidu. The
Committee met four times during the year from April 01, 2008 to March 31,
2009, on April 26, May 29, August 13 and August 29 in 2008 to discuss and
consider the allotment of equity shares under Employee Stock Option 1999
and 2005 Schemes and to discuss and consider the allotment of equity shares
on conversion of warrants issued to promoters.
7. Share Transfer and Investor’s Grievance CommitteeThe Company’s shares are compulsorily traded in dematerialised form. During
the year 2008-09, the Committee met 12 times to consider the transfers in the
physical segment.
Name(s) of Director(s) Number of meetings
Held Attended
Shri R. Narayanan, Chairman 12 12
Shri K. Raghavendra Rao 12 12
Dr C. Bhaktavatsala Rao 12 11
The Board has designated Smt. Bhoomijha Murali, Company Secretary as the
Compliance Officer.
The following table shows the nature of complaints received from shareholders
during 2008-09 and 2007-08, all of which were responded within one month.
Sl. Nature of complaints Received and answered
no. 2008-09 2007-08
1. Non-receipt of share certificates sent 9 13
for transfer/bonus shares
2. Non-receipt of dividend warrants 25 20
3. Complaints from SEBI, Stock exchanges 6 3
and Government departments
Total 40 36
Year AGM / EGM Location Special resolutions passed Date Time
2007 AGM Kamaraj Memorial Hall 1. Reappointment of Managing Director July 19, 2007 10.30 AM
New No.492 2. Revision in the salary of Deputy Managing Director
Old No.573, 574-A 3. Alteration of Articles of Association
Anna Salai 4. ORCHID ESOP 99 Scheme – Variation in terms by revising the price
Chennai – 600 006 5. Employee stock option scheme – 2007
2007 EGM Kamaraj Memorial Hall 1. Issue of warrants convertible into equity February 14, 2007 10.00 AM
New No.492
Old No.573, 574-A,
Anna Salai
Chennai – 600 006
2006 AGM Kamaraj Memorial Hall 1. Raising of long term funds June 02, 2006 10.00 AM
New No.492 2. Alteration of Memorandum of Association
Old No.573, 574-A 3. Alteration of Articles of Association
Anna Salai
Chennai – 600 006
All the resolutions including the special resolutions set out in the respective notices were passed by the shareholders unanimously.
None of the resolutions passed at the above meetings were required to be passed through postal ballot.
Postal ballotThe Board of directors at their meeting held on January 28, 2009 proposed to conduct postal ballot for obtaining the approval of the shareholders under Section
293 (1)(a) & (d) with respect to the increase in the borrowing powers and the power to create mortgage in favour of the lending institutions.
Ms. S. Lalitha, MA, BGL, FCS, practising Company Secretary, acted as Scrutiniser for conducting the postal ballot process in a fair and transparent manner. Both
the resolutions were approved by the members as ordinary resolutions and the postal ballot result in respect of the same was declared by the Chairman on March
07, 2009, in terms of the rules. Following was the voting pattern in respect of the above resolutions :
Particulars Resolution number 1 Resolution number 2
Total number of postal ballot forms received 1370 1370
Total number of votes polled 26066749 26066749
Number of invalid votes 8557 8557
Number of valid votes 26058192 26058192
Votes and percentage in favour of the resolution 25753220 (98.83%) 25747117 (98.81%)
Votes and percentage against the resolution 304972 (1.17%) 311075 (1.19%)
9. Disclosures- No transaction of material nature conflicting with the Company’s interest
was entered into by the Company with related parties i.e. Company’s
subsidiaries, Directors or management or relatives.
- Transactions with the related parties are disclosed in Note 16 of Schedule “Q”
to the financial statements in the Annual Report.
- There were no instances of non-compliance by the Company on any matter
related to capital markets during the preceding three years. Hence, there were
no penalties, strictures imposed by SEBI / Stock Exchanges or any other
statutory authorities against the Company.
- Presently the Company does not have a whistleblower policy. No employee
has been denied access to approach the Audit Committee to report any serious
concerns.
- No differential treatment from the accounting standards was followed in
preparation of the financial statements of the Company.
- The Company complies with all mandatory requirements and also adopted
some of the non-mandatory requirements as detailed below.
10. Means of communication- Financial results are published by the Company in Business Standard,
Dinamani, Financial Express and Makkal Kural.
- Results are also displayed in URL www.orchidpharma.com. Official news
releases are also updated in the site.
1616 Orchid Chemicals & Pharmaceuticals Ltd.
- Presentations made during the year are available on the Company’s website
www.orchidpharma.com.
- The Company has an internal news magazine called ECHO.
- Key developments are communicated to the Stock Exchanges and media as
and when they occur.
11. General shareholder information and Management’sdiscussion and analysis Appended to this Report.
12. CEO / CFO certificationAs required under Clause 49 of the Listing Agreement, a certificate duly signed
by CEO, Shri K. Raghavendra Rao and CFO, Shri S. Krishnan was placed at the
meeting of the Board of Directors held on June 29, 2009.
13. Auditors certificate on compliance of conditions ofCorporate GovernanceCertificate from the Auditors is enclosed along with this Report.
Non-mandatory requirements1. Chairman’s officeThe Company maintains an office for the Chairman at its registered office at
‘Orchid Towers’, 313, Valluvarkottam High Road, Nungambakkam, Chennai –
600 034, Tamil Nadu, India and also reimburses the expenses incurred in
performance of his duties.
2. Remuneration CommitteeThe Company constituted a Remuneration Committee. The terms of reference
of the Committee are described at Serial No.4 herein above.
3. Compensation CommitteeThe Company constituted a Compensation Committee. The terms of reference
of the Committee are described at Serial No.5 herein above.
4. Allotment CommitteeThe Company constituted an Allotment Committee. The terms of reference of
the Committee are described at Serial No.6 herein above.
5. Shareholders’ rightsThe quarterly financial results are published in the newspapers as mentioned
in Serial No.10 above. The results are also displayed on the Company’s website.
The Board of Orchid Chemicals & Pharmaceuticals Limited laid down a code of conduct for all Board members and senior management. The code of conduct has
been posted in the Company’s website www.orchidpharma.com. All the Board members and the senior management affirmed compliance to the code for the year
2008-09.
Place: Chennai K. Raghavendra RaoDate: June 29, 2009 Managing Director
17
CODE OF CONDUCT CERTIFICATION
17Annual Report 2008-09
To
The Members of
ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
We have examined the compliance of conditions of Corporate Governance by
Orchid Chemicals & Pharmaceuticals Limited (the Company), for the year ended
on March 31, 2009, as stipulated in Clause 49 of the Listing Agreement of the
said Company with the stock exchanges.
The compliance of conditions of Corporate Governance is the responsibility of
the management. Our examination was limited to procedures and
implementation thereof, adopted by the Company to ensure compliance with
the conditions of the Corporate Governance. It is neither an audit nor an
expression of opinion on the financial statements of the Company.
In our opinion and to the best of our information and according to the
explanations given to us, we certify that the Company has complied with the
conditions of Corporate Governance as stipulated in Clause 49 of the above-
mentioned Listing Agreement.
We further state that such compliance is neither an assurance as to the future
viability of the Company nor the efficiency or effectiveness with which the
management has conducted the affairs of the Company.
For SNB ASSOCIATESChartered Accountants
Place: Chennai (B. Mahalingam)Date: June 29, 2009 Partner
Membership No. 210408
AUDITORS’ CERTIFICATE ON CORPORATE GOVERNANCE
ANNEXURE V TO DIRECTORS' REPORT DETAILS OF OPTIONS GRANTED TO EMPLOYEES UNDER ORCHID – ESOP 1999 &ESOP 2005 SCHEME.
1818 Orchid Chemicals & Pharmaceuticals Ltd.
Options granted ORCHID – ESOP 1999 Scheme
During 2006-2007, 300,000 options were granted
In the year 2005-2006, 292,075 options were granted
In the year 2003-2004, 307,925 options were granted
In the year 1999-2000, 600,000 options were granted
ORCHID – ESOP 2005 Scheme During 2006-2007, 610,000 options were granted
The above Options are convertible into equity shares of Rs. 10/- each.
The pricing formula The price being the closing price of shares of Orchid on the date on which the options were grantedby the Compensation Committee of the Board of Directors.
ORCHID – ESOP 1999 Scheme
2006-2007 - Rs. 339.25 *
2005-2006 - Rs. 300.65
2003-2004 - Rs. 252.00
1999-2000 - Rs. 243.35
Subsequent to the Bonus Issue, the number of options outstanding and the price were adjusted by
the Board. Accordingly, the revised price applicable for the options allotted during various years prior
to bonus issue were revised as follows:
2005-2006 – Rs. 200.44
2003-2004 – Rs. 168.00
1999-2000 – Rs. 162.24
* For the options granted during April 2006 at a price of Rs. 339.25, the Compensation Committee
has revised the price of the options from Rs. 339.25 to Rs. 193.25 (as per the closing price of Orchid’s
scrip on August 11, 2006, being the date of Compensation Committee Meeting in which repricing was
considered), and the same was approved by the shareholders at the Annual General Meeting held on
July 19, 2007.
ORCHID – ESOP 2005 Scheme2006-2007 – Rs. 193.25
Options Vested during the year Nil under 1999 Scheme
Nil under 2005 Scheme
Options exercised during the year 31,300 options (including the adjusted options that were exercised by the employees,
subsequent to the Bonus issue)
Total no. of shares arising out of Exercise of options 31,300 shares
Options lapsed 1,416,226 options (748,910 options have lapsed out of the original 1,500,000 options granted and
147,241 options have lapsed out of the options arising out of the adjustment due to bonus issue,
under Orchid ESOP 1999 Scheme. 520,075 options have lapsed under Orchid ESOP 2005 Scheme.)
1919Annual Report 2008-09
Variations of terms of Options ORCHID ESOP 1999 Scheme
An adjustment in share price/the number of options outstanding was made by the Company in respect
of the Employee Stock Options granted but not exercised by the Employees due to the issue of bonus
shares during October 2005. Accordingly, the total numbers of options outstanding (so as to be
multiplied by 3/2) as well as the price at which each option may be exercised (so as to be multiplied
by 2/3) were adjusted.
For the 300,000 options granted during April 2006 at a price of Rs. 339.25, the Compensation
Committee of the Board of Directors revised the price of the options in the interest of the employees,
due to the fall in the price of the shares of the Company and accordingly approved a repricing of the
options from Rs. 339.25 to Rs. 193.25 as per the closing price of Orchid at National Stock Exchange
on August 11, 2006, and the same was approved by the shareholders at the Annual General Meeting
held on July 19, 2007.
Total no. of options in force 1,010,478 options are in force.
Employee wise details of options granted to
i) Senior Managerial Personnel No options were granted to Senior Managerial Personnel during the year.
ii) Employees holding 5% or more of the total number of options granted during the year NIL
iii) Employees who were issued shares equal to or exceeding 1% of the issued capital NIL
Consideration received against the no. of shares issued during the year Rs. 62.40 lakh
Earnings per share (Diluted) Rs. (7.61)
Where the Company has calculated the employee The Company has granted the options to the employees on the closing price of shares of Orchid on
compensation cost using the intrinsic value of the November 22, 1999, January 20, 2004, April 27, 2005 & April 28, 2006 under ORCHID ESOP-1999
stock options, the difference between the employee Scheme and on August 11, 2006 under ORCHID ESOP-2005 Scheme and not on the intrinsic value.
compensation so computed and the employee Hence, the difference between the employee compensation and the employee compensation cost
compensation cost that shall have been recognized that shall have been recognized if it had used the fair value of the options, may not be applicable.
if it had used the fair value of the options, shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed.
Weighted – average exercise price The weighted average exercise price (26 weeks preceding the date of grant) was Rs. 183.42 for the
options granted on November 22, 1999, Rs. 199.31 for the options granted on January 20, 2004,
Rs. 299.30 for the options granted on April 27, 2005 and Rs. 282.14 for the options granted on April
28, 2006 under ORCHID ESOP-1999 Scheme and Rs. 267.89 for the options granted on August 11,
2006 under ORCHID ESOP-2005 Scheme.
1 Registered Office 'Orchid Towers', 313, Valluvar Kottam High Road, Nungambakkam,
Chennai - 600 034, Tamil Nadu, India.
2 Date, time and venue of 17th Annual General Meeting (AGM) Wednesday, September 30, 2009, 10.00 am at Kalaignar Arangam, “Anna
Arivalayam”, 367-369, Anna Salai, Teynampet, Chennai-600018
3 Dividend Payment Date for fiscal 2009 Second Week of October 2009 subject to approval of shareholders.
4 Dates of book closure September 19, 2009 to September 30, 2009 (both days inclusive)
5 Financial CalendarFinancial reporting for
Quarter ending June 30, 2009 Last week of July 2009
Quarter ending September 30, 2009 Last week of October 2009
Quarter ending December 31, 2009 Last week of January 2010
Year ending March 31, 2010 Last week of May 2010
6 The equity shares of Rs. 10/- each are listed at Madras Stock Exchange LimitedExchange Building, Post Box No.183
New No.30 (Old No. 11), Second Line Beach
Chennai - 600 001, Tamil Nadu, India
Tel : 91-44-25228951, Fax : 91-44-25244897
National Stock Exchange of India LimitedRegd Office : "Exchange Plaza", Bandra-Kurla Complex
Bandra (East), Mumbai - 400 051, Maharashtra, India
Tel : 91-22-26598100, 66418100, Fax : 91-22-26598120
Bombay Stock Exchange LimitedFloor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Fort
Mumbai - 400 001, Maharashtra, India
Tel : 91-22-22721233, 22721234, Fax : 91-22-22721919
7 Foreign Currency Convertible Bonds (FCCBs) Aggregating to US$ 42.5 million issued in Luxembourg Stock ExchangeNovember 2005 and due November 2010 are Bourse de Luxembourg
listed at Siège social, 11, avenue de la Porte-Neuve L-2227 Luxembourg
Tel : +352 47 79 36-1; Telefax : +352 47 32 98
Aggregating to US$ 175 million issued in February Singapore Exchange Limited2007 and due February 2012 are listed at 2 Shenton Way #19-00 SGX Centre 1, Singapore 068804
Tel : (65) 62368888, Fax : (65) 65356994
8 Listing Fees Listing Fees have been paid for all the above Stock Exchanges
for 2008-2009 and 2009-2010
2020 Orchid Chemicals & Pharmaceuticals Ltd.
ANNEXURE VI TO DIRECTORS' REPORT GENERAL SHAREHOLDERS' INFORMATION
2121Annual Report 2008-09
9 Stock Market dataa) Monthly high and low quotations along with the volume of shares traded at NSE and BSE for 2008-2009 are:
Month NSE NSE S&P BSE
High Low Volume of CNX 500 High Low Volume of BSE 500(Rs.) (Rs.) Shares (Nos) INDEX (Avg) (Rs.) (Rs.) Shares (Nos) INDEX (Avg)
Apr-08 343.35 156.20 368083842 3976 330.00 156.00 208944476 6458
May-08 292.80 234.25 66716711 4100 286.40 234.00 36994161 6729
Jun-08 264.70 201.00 35077763 3590 265.00 215.10 19079391 5879
Jul-08 270.00 201.00 19629582 3283 268.90 219.00 10432978 5281
Aug-08 267.85 235.00 4163769 3540 267.25 239.00 1838865 5693
Sep-08 255.50 197.55 2680838 3329 255.10 198.15 992197 5355
Oct-08 224.00 81.15 6596097 2483 218.90 93.25 2869177 3948
Nov-08 134.50 67.15 7361362 2196 134.80 66.85 3245232 3483
Dec-08 104.80 75.00 5251674 2223 104.30 76.00 2115947 3490
Jan-09 109.35 70.60 5708865 2214 108.80 70.10 2314911 3458
Feb-09 76.00 65.00 3410464 2165 75.80 64.95 1452742 3344
Mar-09 84.00 56.25 9427080 2133 84.20 56.50 4062826 3260
TOTAL 534108047 294342903
b) Graphical representation of Volume of Shares traded of Orchid during April 2008 - March 2009
c) Comparison of broad based indices with share price of Orchid
2222 Orchid Chemicals & Pharmaceuticals Ltd.
10 Stock Exchange Security Code and other related information
Madras Stock Exchange Limited OCL
Bombay Stock Exchange Limited 524372
National Stock Exchange of India Limited ORCHIDCHEM
Luxembourg Stock Exchange US68572Y2090
Singapore Exchange Limited XS0287742653
Depository ISIN No. INE191A01019
Corporate Identification Number (CIN) L24222TN1992PLC022994
2323Annual Report 2008-09
11 Distribution of Shareholding as on
No of equity 31st March 2009 31st March 2008
shares held No. of No. of % of No. of No. of % of shares Shareholders Shareholders shares Shareholders Shareholders
1-500 5528064 54947 94.33 7254530 63186 92.19
501-1000 1437197 1874 3.22 2268877 2881 4.20
1001-2000 1125866 779 1.34 1819890 1223 1.78
2001-3000 502953 197 0.34 1006622 391 0.57
3001-4000 304109 86 0.15 597083 166 0.24
4001-5000 413920 90 0.15 809778 173 0.25
5001-10000 778362 103 0.18 1674258 230 0.34
10001 & above 60351605 167 0.29 50419738 292 0.43
TOTAL 70442076 58243 100.00 65850776 68542 100.00
12 Dematerialization of SharesThe shares of the Company are in compulsory demat segment and are available for trading in both the depository systems, namely, National Securities Depository
Limited and Central Depository Services (India) Limited. Shares dematerialised upto March 31, 2009 are :
No. of Shares % of Shares No. of Shareholders % of Shareholders
69973680 99.34 55814 95.83
13 a) Shareholding Pattern as on March 31, 2009
Category No of Shares Held Percentage of Shareholding
A Promoter Holding1 Promoters
a) Indian Promoters 14916172 21.18
b) Foreign Promoters Nil Nil
2 Persons acting in concert Nil Nil
Sub-Total (1+2) 14916172 21.18
B Non-Promoter Holding3 Institutional Investors
a) Mutual Funds 2814108 3.99
b) Banks, Financial Institutions, Insurance Companies 7577386 10.76
(Central / State Govt. Institutions / Non-government Institutions)
c) Foreign Institutional Investors (FIIs) 3916213 5.56
Sub-Total (3) 14307707 20.31
4 Othersa) Private Corporate Bodies 22473235 31.90
b) Indian Public (Resident Individuals) 14339678 20.36
c) Non Resident Indians / Overseas Corporate Bodies 342705 0.49
d) Foreign Companies 4062579 5.76
Sub-Total (4) 41218197 58.51
Grand Total (1+2+3+4) 70442076 100.00
15 Legal ProceedingsThere are a few pending cases relating to the disputes on the title of the
shares. The Company has been made a party to the disputes but these, however,
are not material in nature.
16 Share Transfer System M/s Integrated Enterprises (India) Limited are the Registrar and Share
Transfer Agents for servicing activities relating to both Physical and Electronic
segments. The share transfer committee met 12 times during the year
2008-2009.
17 Unclaimed DividendsPursuant to Section 205 A of the Companies Act, 1956, the unclaimed dividend
for the financial year 2000-2001 was transferred to the Investor Education
and Protection Fund (IEPF) in September 2008.
Dividend for the financial year 2001-2002 is due for transfer to IEPF in
September 2009.
The dividends for the years from 2001-2002 onwards, which remain unclaimed
for seven years will be transferred to Investor Education and Protection Fund
established by the Central Government under Section 205 C of the Companies
Act, 1956 as and when due. Shareholders who have not encashed their
dividends for these periods are requested to contact the Company immediately.
18 ECS MandateTo service its investors better, the Company requests all shareholders who hold
shares in electronic form to update their bank particulars with their respective
depository participants immediately. Shareholders holding shares in physical
form may kindly forward the bank particulars to the Company's Registrar and
Share Transfer Agent.
19 Plant Locationsa) Active Pharmaceutical Ingredient Facilitiesi) Alathur WorksPlot Nos.85-87, 98-100, 126-131, 138-151 and 159-164
SIDCO Industrial Estate, Alathur, Kancheepuram Dist, Pin 603 110
Tamil Nadu, India
b) Shareholding Pattern Chart
2424 Orchid Chemicals & Pharmaceuticals Ltd.
Foreign Companies,
FIIs, NRIs and others
11.81%
Resident Individuals
20.36%
Institutional Investors
14.75%
Promoters
21.18%
Bodies Corporate
31.90%
14 Outstanding FCCBs and conversion dates Name of the Instrument Total Converted as on Bought Back as on Outstanding as on Likely Conversion
Issued March 31, 2009 March 31, 2009 March 31, 2009 Date
a) Foreign Currency Convertible Bonds USD 4,25,00,000 * USD 2,27,90,000 * USD 22,50,000 * USD 1,74,60,000 * On or before
(FCCBs) (issued during 2005-06) November 03, 2010
b) Foreign Currency Convertible Bonds USD 17,50,00,000 * NIL USD 3,78,00,000 * USD 13,72,00,000 * On or before
(FCCBs) (issued during 2006-07) February 28, 2012
* FCCBs are represented in value till the time they are converted into equity shares.
ii) Aurangabad WorksL-8 & L-9, MIDC Industrial Area
Waluj, Aurangabad Dist., Pin 431 136
Maharashtra, India
b) Formulations (Finished Dosage Form) Facilitiesi) A10/A11, SIDCO Industrial Estate
Alathur, Kancheepuram Dist., Pin 603 110
Tamil Nadu, India
ii) Plot Nos.B3–B6, B11–B14 and B15–B18
SIPCOT Industrial Park, Irungattukottai, Sriperumbudur (Tk.), Pin 602 105
Tamil Nadu, India
iii) B-77, SIDCO Industrial Estate
Alathur, Kancheepuram Dist., Pin 603 110
Tamil Nadu, India
20 Research and Development Centresa) Plot No.476/14, Old Mahabalipuram Road, Sholinganallur
Chennai 600 119, Tamil Nadu, India
b) Plot Nos.B21–B23 & B31–B33, SIPCOT Industrial Park, Irungattukottai
Sriperumbudur (Tk.), Pin 602 105, Kancheepuram Dist
Tamil Nadu, India
21 Investor Contactsa) Corporate Communications & Investor Relations
Mr Ch.RamHead, Corporate Communications & Investor Relations
Phone : 91-44-28244908; Fax: 91-44-28211002
E-mail : [email protected]
b) Investor Correspondence / Compliance Officer
Mrs Bhoomijha MuraliGeneral Manager - Legal & Company Secretary
Phone : 91-44-28284232; Fax : 91-44-28275960
E-mail : [email protected]
c) Registrar and Share Transfer AgentIntegrated Enterprises (India) Limited
2nd Floor, Kences Towers, No.1 Ramakrishna Street,
North Usman Road
T.Nagar, Chennai - 600 017, Tamil Nadu, India
Tel : 91-44-28140801 - 03, Fax : 91-44-28142479
E-mail : [email protected]
2525Annual Report 2008-09
2626 Orchid Chemicals & Pharmaceuticals Ltd.
MANAGEMENT DISCUSSION AND ANALYSIS
Global pharmaceutical industry The global pharmaceutical sales reached US$ 773 billion in 2008; however,the growth rate moderated from 6.6% in 2007 to 4.8% in 2008. Thepharmaceuticals market had to contend with a number of forces includingdecline in new product approvals and the global economic recession, markedin particular by a sharp downturn in the world’s largest economies of USA andEU. However, the pharmaceutical market scenario was also characterized by agrowth in the emerging markets. The table below tracks the growth of thepharmaceutical sector over the last 5 years.
Global pharmaceuticals sales (US$ bn)
[Source: IMS Health Market Prognosis (includes IMS Audited and Unaudited markets)]
Global pharmaceutical sales are expected to grow at around 5% p.a to exceed$810 billion in 2009. The shift towards pharmaceuticals for lifestyle diseasesis expected to continue. The top five therapeutic segments in 2008 werecholesterol and triglyceride regulators, anti-ulcerants, anti-depressants, anti-psychotics and anti-epileptics. These therapies are growing in emergingmarkets as well although these markets are still dominated by acute therapiessuch as anti-infective and gastro-intestinal categories.
The table below highlights regional distribution of sales and growth rates.
(US$ bn)
Countries 2008 2007 Growth (%)
North America 225.2 220.8 2.0
Europe (top five) 114.3 112.1 2.0
Japan 68.6 66.6 3.0
Latin America (top three) 24.2 22.0 10.0
Australia/New Zealand 7.8 7.1 9.9
Selected countries 440.1 428.6 2.7
[Source: IMS Data, December 2008, data for year ending December]
US marketThe US pharmaceutical market which constitutes around 47% of the globalmarket, grew only marginally - from US$ 206.5 bn in 2007 to US$ 208.6 bn in2008. The US pharmaceutical industry is expected to grow modestly in 2009owing to the plateau in new product approvals, lower demand for the newlyintroduced products and the adverse change in the economic climate.Notwithstanding this, a large number of blockbuster drugs going off patent inthe coming years will continue to open up opportunities for genericpharmaceutical companies. The new US government has outlined healthcare
reforms in 2010 budget plan which are expected to benefit the genericsindustry.
European markets The five major European pharmaceutical markets (Germany, France, Italy, UKand Spain) grew by 2% - from US$ 112.1 bn in 2007 to US$ 114.3 bn in 2008.The aggregate demand of the top five European Union countries is projectedto grow by 3 to 4% in the coming year backed by the increase in the ageingpopulation and rising demand for preventive care. Large governmental tendersand government policies on pricing and reimbursement are influencing thecompetitive intensity in the European pharmaceuticals market.
Japan Japan is the second single largest pharmaceutical market after US and thesecond highest spender in the world for healthcare. The pharmaceutical salesin the Japanese market increased by 3% from US$ 66.6 bn in 2007 to US$68.6 bn in 2008. Generic drugs currently have a low share of the totalpharmaceutical market in Japan. The market is expected to grow to over US$86 bn in 2012, supported by a high promotion of generic drugs, liberalizationof over-the-counter (OTC) drug sales as well as the government’s efforts toimprove launch conditions for novel products. The opening up of the genericssector by the government has been attracting foreign generic companies intothe country.
Emerging markets The emerging markets of China, Brazil, India, Mexico, Turkey and Russia, tomention a few, are forecast to grow faster at a combined 14 to 15% pace toreach US$ 105 to 115 billion in 2009. Along with the new-found focus of theinnovator companies on generics, greater government spending on healthcare,and broader public and private healthcare funding will drive greater access to,and demand for, innovative as well as generic medicines in these markets.
Global generics market The generics market thus remains a major growth segment of the globalpharmaceuticals market in both developed and emerging markets. The growthwill continue to be driven by greater availability of quality generic medicineson one hand and by healthcare spending by the governments on the other.While the emerging markets have traditionally been generics oriented,regulated markets such as US, EU and Japan would witness a continuinggrowth in the generics markets, opening up a large market space for genericsplayers.
CRAMSGiven the current plateauing in new product approvals, pressures from genericsubstitution and the raising regulatory bar on new drug approvals, innovatorcompanies are seeking to improve R&D productivity by outsourcing R&D workand also in-licensing new drug candidates for pipeline expansion. There is alsoan increasing trend to outsource the requirements of pre-clinical and clinicalquantities of new chemical entities (NCEs).
The global opportunity for Custom Research and Manufacturing Services(CRAMS), which is essentially innovation driven, is estimated at around $40billion and is expected to register a healthy growth rate of 15%. Skilledmanpower, diversity of services and cost-competitiveness are enabling India toemerge as a favoured destination for contract research in the world. Indiawould also become a major player in bioequivalence studies for generic drugs
27
and human clinical studies for innovator drugs. Clinical trials in India costsignificantly less than the costs in the advanced countries. India also offersthe advantage of a vast drug-naïve patient pool.
Indian pharmaceutical industry
The Indian pharmaceutical market is estimated at US$ 10.76 bn in 2008,growing at a robust pace. Presently the Indian industry ranks 4th in volumeterms and 13th in value terms globally.
The Indian pharmaceutical industry caters to both domestic demand andoverseas demand in terms of finished dosage forms as well as activepharmaceutical ingredients (APIs). The overseas market further comprisescontract research and manufacturing services (CRAMS) as well as collaborativeand proprietary drug licensing opportunities.
The Indian pharmaceutical exports surged by 22% from US$ 6.9 bn in the firstnine months of 2007-08 to US$ 8.44 bn in the first nine months of 2008-09.US, Russia, Austria, Germany and the UK are the top five export destinationsfor India’s pharmaceuticals, which cater to over 75 countries. The spurt inoverseas demand is largely due to the high level of regulatory filings and costcompetitiveness of the Indian generics. The Indian generic product exports areexpected to grow at an even higher clip over the next few years, given thenumber of drugs going off patent in the coming years.
Indian companies continue to be increasingly active in the US market. From anaverage of 25 ANDA approvals in the early 2007, the number of ANDAapprovals spurted to around 50, reaching 134 in 2008. In the first quarter of2009, Indian companies achieved 50 ANDA approvals, reflecting the continuedpace of ANDA filings and approvals. This regulatory thrust will lead to greateravailability of generic medicines and will result in increased competitivepressures.
Stronger GDP growth, higher emphasis on healthcare and a global costadvantage would result in the continued growth of the Indian pharmaceuticalindustry. The industry is likely to grow to around US$ 50 bn in 2015-16 witha CAGR of around 14%. Exports, driven by generics and contract research, areexpected to grow at a CAGR of 16.2% while the domestic market is expectedto grow by 12.5%, India would also emerge as a favoured destination forCRAMS. [Source: Indian Pharmaceutical industry - Vision - 2015].
Orchid’s initiatives in 2008-09
Orchid’s strategy, which is based on the twin drivers of generics and innovationbusinesses is geared to cater to the diversified global pharmaceutical canvas.
Given the competition in the generics space, Orchid has focused on nicheantibiotic products and complex non-antibiotic products for more exclusivepositioning in the market space. Orchid also established world-classdevelopment and manufacturing facilities in the cephalosporin, penicillin andcarbapenem areas, as well as non-penicillin, non-cephalosporin areas, coveringboth APIs and dosage forms and also catering to oral and sterile products asapplicable. To support the innovation strategy, Orchid has also establishedstate-of-the-art drug discovery and development facilities which meet theneeds of proprietary and collaborative drug discovery.
During the year under review, Orchid continued several strategic initiatives tostrengthen its position in the global pharmaceutical space. Some of theseinitiatives are:
Consolidated its presence in US generics market with cephalosporininjectable and dosage forms which contributed significantly to the revenuebasket.
Launched Piperacillin-Tazobactam a premium, life saving antibiotic in theCanadian and Australian markets. Orchid has been the first generic companyto launch the product in Canada and Australia.
Received progressively multiple MA (Marketing Authorisation) approvals forPiperacillin-Tazobactam in the EU market.
Received MA approvals for cephalosporin products licensed to thedistribution partner in EU.
Forayed into the non-penicillin, non-cephalosporin (NPNC) space with thelaunch of Granisetron in the US market, with other approvals on the anvil.
Orchid’s business development canvas and growth initiatives are supported bya large pipeline of global regulatory filings and robust infrastructuralcapabilities. During the year under review, Orchid achieved several regulatorymilestones.
Cumulative ANDA filings count reached 58 in US, of which 29 were inCephalosporins, 5 in Penicillins, 3 in Carbapenems and 21 in the NPNC segment(of which 7 are Para IV FTFs).
Marketing Authorisation filings in EU reached 29, of which 23 were in thecephalosporin segment, 1 in Penicillins, 2 in Carbapenems and 3 in the NPNCsegment.
DMF filings in the API segment peaked to 72 which include 26 in thecephalosporin segment and 33 in NPNC segment, 2 in Penicillins segment and11 in the carbapenems segment.
Increased DMFs filed in Japan to 3, all of which in the cephalosporin field.
On the infrastructural front, Orchid continued to add selectively to itscapabilities to augment capacity, expand product range and cater to morediversified demand. Completion of the Carbapenem dosage forms facility andcreation of a second line for cephalosporin products for certain innovativeproducts were some of the key accomplishments.
In the area of drug discovery and development, some of the key initiativesincluded:
Acquired a significant stake in the US based drug discovery and developmentcompany, Diakron Pharmaceuticals to develop a novel investigational oralanticoagulant drug, in-licensed by Diakron from Merck & Co., Inc., post-PhaseI. The target will be to develop the compound as a novel oral anticoagulantwith a new formulation and position it uniquely.
Entered into a strategic research collaboration and license agreement withMerck & Co Inc to discover, develop and commercialize novel agents for thetreatment of bacterial and fungal infections. Orchid will undertake discoveryand candidate development through Phase IIa human clinical trials, after whichMerck will assure responsibility for further development and commerciallaunch.
Accelerated Orchid’s proprietary drug discovery business by developingseveral additional hits and leads in the therapeutic areas of inflammation,oncology, diabetes and anti-infectives.
27Annual Report 2008-09
2828 Orchid Chemicals & Pharmaceuticals Ltd.
Financial review
Revenues
Orchid’s total revenue for the fiscal under review (excluding excise duty &exchange rate gain on FCCB), stood at Rs. 121,429 lakh in 2008-09 comparedto Rs. 124,016 lakh in 2007-08. Delay in approval by US FDA of Piperacillin-Tazobactam injection has contributed to the plateau in sales relative to thegrowth expectations. Several initiatives are, however, culminating well andwill lead to a robust growth pattern going forward. During the year underreview, Orchid forayed into the Penicillin injections segment by securing theapproval for Tazobactam-Piperacillin in the Canadian, ANZ and Europeanmarkets. This is the 3rd product segment for Orchid after Cephalosporins andNon-antibiotics. This would lead to an increased utilisation of the Company’sasset base resulting in greater unlocking of value.
Steady market penetration of Cefepime, an injectable product, for which Orchidwas the sole generic player and Cefdinir capsules, an oral product, supportedgenerics revenue growth. Other sterile products such as Cefazolin, Cefoxitinand Ceftriaxone injections and oral solid dosage forms such as Cefadroxylcapsules and oral suspension products also supported the sales performance inthe US generics market in 2008-09.
With the increased competition in the generics business and delay in approvalsfor its premium products, the share of formulations business in the totalbusiness was 54%, as compared to 58% in previous fiscal. However, API salesmoved upto 46% of the total revenue in fiscal 2009, compared to 42% in theprevious fiscal.
Expenses
The Company’s expense component comprised material costs, staff costs andwelfare expenses, power and fuel costs, other manufacturing, selling and otherexpenses, R&D, interest and depreciation expenses. The following tableprovides the break-up for the various expense components as a % of totalrevenues
Figures in %
Fiscal years 2008 2009
Operating expenses:
Material costs 35.0 42.0
Staff costs and welfare expenses 8.1 10.1
Power and fuel 5.6 6.0
Other manufacturing selling and Other expenses 19.7 23.1
Sub total 68.5 81.2
R&D expenses 3.6 3.8
Interest and finance charges 6.5 12.8
Depreciation and miscellaneous Expenses written off 7.9 10.7
Taxes:
Provision for current/fringe benefit tax 2.5 0.1
Provision for deferred tax 1.9 1.1
While with increasing scale of operations and general inflationary trends,escalation in operational costs were inevitable during the year, a series of costcontainment measures ensured prudent cost management. Even thoughoperations had to be geared up for higher levels of development andmanufacturing activity in the months to come, the cost profile of theoperations continues to be competitive.
Operating expensesImported raw materials, Pen-G, 7-ACA and intermediates used in themanufacture of relevant Orchid products, principally constituted theCompany’s material costs. Staff costs and welfare expenses comprised wages,salaries, bonus and other expenses for our employees, employee provident fund,medical and other funds. Power and fuel expenses involved the cost ofelectricity, diesel and furnace oil for our manufacturing facilities. The principalcomponents of other manufacturing, selling and other expenses comprisedselling commission, insurance charges, factory maintenance expenses,consumption of stores, spares and chemicals and travelling expenses.
The Company’s R&D expenses included regular operating expenses, projectcosts and expenses for research and infrastructure programs. While R&Drevenue expenditures were expensed when incurred, R&D capital expenditureswere added to assets and depreciated. Interest and finance charges comprisedinterest on long-term and working capital borrowings, bill discounting andother bank charges. Depreciation and miscellaneous charges comprised a majorportion of our operating expenses.
Material costs: Due to new operational facilities, higher production volumes,increased batches to support growing global filings and an increase in theaverage price of certain key inputs contributed to the increase in material costto Rs. 51,031 lakh for fiscal ended 2009 compared to Rs. 43,465 lakh for thefiscal ended 2008. As a percentage of total revenue, the material costs grewfrom 35% to 42%.
Staff costs and welfare expenses: With the expanding scale of operations andnew units coming on stream, the demand for technical and quality man-powerhas pushed the manpower cost upwards for the fiscal ended 2009. Theemployee cost during fiscal 2009 increasing to Rs. 12,227 compared with Rs. 9,990 lakh in 2007-08. As a percentage of total revenue, the staff andwelfare costs increased from 8.1% to 10.1%.
Power and fuel costs: Increased oil and gas prices and higher powerconsumption to support growing production volumes impacted power and fuelcosts, which increased by 5.6% from Rs. 6,958 lakh in 2008 to Rs. 7,345 lakhin 2009. As a percentage of total revenue, the power and fuel costs increasedmarginally from 5.6% to 6.0%.
Other manufacturing, selling and other expenses: Increased scale of operationsand geographic expansion, increased other manufacturing, selling and otherexpenses by 14.8% from Rs. 24,477 lakh in 2007-08 to Rs. 28,092 lakh in2008-09. As a percentage of total revenue, the share was 23.1 %, comparedwith 19.7 % in 2007-08.
R&D costs: An increased trend of all other cost components like employee cost,maintenance and other operating costs was also seen at the research anddevelopment side. As a result the R&D costs increased by 2.5% from Rs. 4,519lakh for fiscal 2008 to Rs. 4,633 for fiscal 2009. As a percentage of totalrevenue, R&D costs were higher at 3.8 %, compared to 3.6 % in 2007-08.
EBIDTA: Delay in launch of envisaged new products coupled with a significantchange in the generic landscapes of certain key products and pressure onselling prices of select generics in the regulated markets saw the direct impact
on EBIDTA which decreased by 40.5% from Rs. 41,734 lakh in 2007-08 to Rs. 24,831 lakh in 2008-09. EBIDTA margin as percentage of total revenuedecreased from 33.7 % in fiscal 2008 to 20.4% in fiscal 2009.
Interest: The interest costs grew by 91.3% at Rs. 15,519 lakh in 2008-09compared with Rs. 8,113 lakh in 2007-08. As a percentage of total revenue,interest costs in 2008-09 were higher at 12.8 %, compared to 6.5% in 2007-08. Higher borrowings were required to complete the projects on hand andsupport extended working capital cycles in a recessionary environment.
Depreciation and amortization expenses: An increase in operations and anadded asset base led to a 33.1% increase in depreciation from Rs. 9,767 lakhin fiscal 2008 to Rs. 12,997 lakh in fiscal 2009. As a percentage of totalrevenue, depreciation was higher at 10.7 % in 2008-09, compared to 7.9 % in2007-08.
Profit before taxation and exceptional items: The Company’s profit beforetaxation and exceptional items de-grew by 162.3% from Rs. 16,727 lakh forfiscal 2008 to -Rs. 10,415 lakh for fiscal 2009. Provision for taxation stood atRs. 1,533 lakh in fiscal 2009 compared with Rs. 5,401 lakh in fiscal 2008.Exceptional items accounted for the notional foreign exchange gains theCompany experienced due to rupee appreciation. Gains on exceptional itemsin fiscal 2009 was Rs. 5,162 lakh net of tax compared with Rs. 6,377 lakh infiscal 2008.
Profit after tax: Profit after tax (PAT) reduced to Rs. 5,217 lakh for fiscal 2009as against Rs. 18,454 lakh for fiscal 2008. The PAT margin, as a percentage oftotal revenue, decreased from 14.9% in 2007-08 to a negative -4.3% in 2008-09, as a carryover effect of the factors discussed above.
Cash Profit after tax : Exclusive of the notional book entries of deferred taxprovision and depreciation the revised cash profit for fiscal 2009 was Rs. 9,151lakh as compared to Rs. 30,562 lakh in 2008. Though there was a de-growthin profitability, operating costs and a decrease in turnover growth, severalmeasures for cost constraint and revenue growth that have been fructifyingtowards the end of fiscal 2009 would have a positive impact during the currentyear.
Internal control and adequacyThe internal control systems and procedures were designed to assist in theidentification and management of risks, the procedure-led verification of allcompliance as well as an enhanced control consciousness.
The Company’s internal control system provides for adequate documentationof policies, guidelines, authorities and approval procedures covering all theimportant functions at the Company. It has a proper and adequate system ofinternal control commensurate with the size and nature of its business. Thedeployment of an ERP covers most of its operations supported by a definedon-line authorization protocol.
The Company has introduced operating procedures (SOPs) across all functions,covering the daily operations of the business. Many SOPs were designed tomeet the GMP, FDA, ISO, management and other statutory requirements. TheCompany continuously monitors with procedures and has been intruding newsystems from time to time.
The highlights of the internal control weaknesses and internal audit reportsare placed before each Audit Committee meeting along with therecommendations and responses of the management. The members of theBoard deliberate and advise the management on improvements/compliance.Besides, statutory auditors also present their suggestions to the members forimprovements or developments.
Human resourcesOrchid’s 4040 employees (as of March 31, 2009) represent a huge motivatedforce, which works tirelessly to drive corporate performance.
The Company’s significant HR initiatives in 2008-09 comprised:
Sourcing talent for critical positions in India and overseas, includingscientific professionals returning from the US inducted into the R&D team atsenior levels
Creating new roles and functions to meet emerging business needs, viz.,NDDS (Novel Drug Delivery Systems), Medical Affairs, Orchid Japan team andBusiness Development team
Restructuring the HR function to align with business units andadding/modifying the corporate HR structure to sharpen HR focus
Launching knowledge sharing forums to encourage informal learning amongemployees
Initiating a forum for senior executives (Leadership Excellence throughPerformance or LEAP) to discuss and resolve common organizational issues
Theme-based employee development programmes to suit various levels ofemployees
Information technologyInformation Technology plays a key role in enabling business to be moreeffective and responsive. They key areas of focus this year have beenautomation of process flows reinforcing collaborative working among variousdepartments, enabling aggressive cost reductions and enhancing service levelsto users. Some of the key interventions are as below.
Product Development: The entire Business process for approval of newproduct introduction for specific geographies was automated through a work-flow solution spanning across various key functions involved. Right from theinitiator to the final approver, the documents travel electronically step-by-stepthrough departments with provision for adding data and comments. This hasreplaced the paper based process completely and more than 150 products havebeen processed in a short time after implementation.
eTeam Rooms: In our pursuit to continually improve collaboration amongvarious functions we have launched electronic team-rooms. Notable ones arefor eTeam rooms for senior management interactions, corporate safety andproduction planning. These teams share documents and work on themcollaboratively in a centralized manner through the facilities available in theteam room like document repository, blogging, adding comments on a post,calendaring etc.
ESG (FDA) Integration: Closely on the heels of going live on a world-classeCTD package in the previous year, Orchid has integrated with FDA-ESG(Electronic Submission Gateway). By this, our electronic dossiers are directlyuploaded onto FDA’s server with digital signatures and other authentications.We are one of the early movers in India to utilize this facility.
IT Service Desk Automation: A package was implemented so that users canregister their calls for IT services online and get them resolved faster andeffectively. User calls once entered, are assigned to service personnelelectronically and monitored throughout their life cycle. Performance againstSLA’s are measured, escalations are automated and information on progresscontinuously made available to end users.
Policy Enforcement: Quite a lot of IT policies in the areas like energyconservation, data integrity, uniform desktop environment, etc. have beenautomated this year leading to less manual intervention on enforcement.
Office Communication Server (OCS): In line with emerging unified
2929Annual Report 2008-09
communication trends, OCS was implemented for key personnel. They can havecalls within our network on one-on-one basis or on conference mode. It alsohas features like instant messaging, presence awareness, document sharingfacility etc. Considerable cost reduction has been achieved in travel andcommunication besides the key aspect of improved collaborative working.
Cost Management: Numerous measures have been taken this year towardsreducing the IT cost through measures like introduction of ‘Pay-per-use’ modelin printing, enhanced outsourcing, aggressive win-win agreements with ITvendors, cost-effective software alternatives etc.
Customer Satisfa ction Index: A process has been instituted to measureinternal user satisfaction on various IT services through appropriate services inregular intervals and to work on measures to improve them continuously basedon end-user feedback. Orchid will continue to focus on the latest trends in IT and adopt theappropriate ones for leveraging its competitive advantage.
Risk managementLike all businesses, the pharmaceutical industry has its risks. The risks that theCompany faces may be classified as risks relating to the business, the currencyand capital markets and the operations. The Company has appropriate policiesand strategies to manage the risks. Some of the key risks and mitigationstrategies are detailed herein.
Product-market factors
The Company currently derives a significant portion of its revenue fromcephalosporins and a smaller portion from penicillins and non-penicillin, non-cephalosporins. The Company currently also derives a significant portion of itsrevenues from regulated markets. Envisaged product diversification andincreases in such revenues arising from newer product groups, includingcarbapenems are tied to regulatory approvals and patent expiries, especially inregulated markets. Any material adverse developments in such product-marketstrategies and regulatory approvals could therefore have an adverse materialeffect on the revenues and profitability. An increase in the intensity ofcompetition in any of its products and markets and any constraints faced bycustomers in making timely payments could also have a material adverseimpact on the performance of the Company. The Company has implementedstrategies to diversify its product range and ramp up sales in non-cephalosporintherapeutic areas to address such concerns. The company accords considerableimportance to the implementation of its well-integrated and well-diversifiedproduct development plans and launch strategies to mitigate the product-market risks.
Supply factors
The Company depends on its suppliers for its key raw materials, intermediatesand other packaging materials. For the regulated markets, some of these inputsare sourced from US FDA approved suppliers. While the Company hascontractual arrangements in places with the existing suppliers and also hasalternative suppliers to cater to supply deficiencies, the possibility of any supplyconstraints affecting the Company’s performance cannot be ruled out. TheCompany conducts a continuous review of its supply and outsourcingoperations to ensure adequate and timely supplies.
Safety factors
Pharmaceutical operations involve handling of hazardous raw materials andprocesses. Any untoward accident can disrupt operations and business. Orchidhas worked with DuPont, the world leader in industrial safety, to implementseveral initiatives for achieving excellence in safety. Utmost importance is givento the behavioural and scientific aspect of safety management. A CentralSafety Committee, supported by several sub-committees coordinates andmonitors safety management in the Company.
Financial factors
As the Company implemented an aggressive and time-bound multi-therapeuticproduct strategy expanding its manufacturing base from cephalosporins toinclude penicillins, carbapenems and NPNCs, a significant portion of theinvestment had to be financed out of debt. The high level of debt, and theconsequent interest burden would constitute a risk in the event of marketdownturn. The Company’s product-market diversification is intended tostrengthen revenue and profitability base to counter the pressures of highleverage.
Exports constitute a dominant share of the Company’s business. Some of thefinancial products (FCCBs and derivative instruments) are exchange rate linked.Risks of exchange rate fluctuation could have profit implications as peraccounting standards. The exchange rate risk is hedged to a significant extentby imports. The Company has been exploring options to reduce the level ofdebt and has during the year under review bought back FCCBs at a significantdiscount and cancelled a portion of FCCB debt. The Company would continueto adopt risk mitigation policies in aspects related to exchange rate risk,including maintenance of appropriate systems and procedures.
Intellectual property
The Company’s regulated market strategy is based on introducing genericversions after the products go off patent, based on non-infringing processes.Some of the products are Paragraph IV, First-to-File ANDA applications, whichinvolve legal challenges. The Company also files and seeks to obtain patents fornew drugs and novel drug delivery systems under development. Patents andlitigation in select cases, are therefore significant to the Company. The successof the Company depends, in part, on its ability to protect and defend itsproprietary and intellectual property information and obtain patents andoperate without infringing on the proprietary rights of others.
The Company takes all reasonable steps to ensure that its products, includingthe generic products manufactured and sold by it, do not infringe valid third-party intellectual property rights. The Company also takes due care indefending its litigation in respect of legal challenges. The Company relies onthe diligence and opinions as well as services of internal scientific staff andexternal attorneys to ensure that intellectual property matters are wellmanaged and well defended.
The Company accords utmost importance to retention of employees byproviding a conducive work environment and implementing appropriate talentmanagement policies. The Company has also in place confidentialityagreements with its employees to protect confidentiality of proprietaryinformation.
3030 Orchid Chemicals & Pharmaceuticals Ltd.
AUDITORS’ REPORT
1. We have audited the attached Balance Sheet of Orchid Chemicals &
Pharmaceuticals Limited (the Company) as at March 31, 2009 and also
the Profit and Loss Account of the Company for the year ended on that
date annexed thereto and the Cash Flow Statement for the year ended on
that date. These financial statements are the responsibility of the
Company’s management. Our responsibility is to express an opinion on
these financial statements based on our audit.
2. We conducted our audit in accordance with auditing standards generally
accepted in India. Those Standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing
the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation. We believe that our audit provides a reasonable basis for our
opinion.
3. As required by the Companies (Auditor’s Report) Order, 2003 issued by the
Central Government of India in terms of sub-section (4A) of Section 227
of the Companies Act, 1956, we annexe hereto a statement on the matters
specified in paragraphs 4 and 5 of the said Order.
4. Further to our comments in the Annexure referred to above, we report
that:
a. We have obtained all the information and explanations, which to the
best of our knowledge and belief were necessary for the purposes of
our audit;
b. In our opinion, proper books of account as required by law have been
kept by the Company so far as appears from our examination of those
books;
c. The Balance Sheet, Profit and Loss Account and Cash flow statement
dealt with by this report are in agreement with the books of account;
d. In our opinion, the Balance Sheet, Profit and Loss Account and Cash
Flow Statement dealt with by this report comply with the accounting
standards as referred to in sub-section (3C) of Section 211 of the
Companies Act, 1956;
e. On the basis of written representations received from the directors,
as on March 31, 2009, and taken on record by the Board of Directors,
we report that none of the directors is disqualified as on March 31,
2009 from being appointed as a director in terms of clause (g) of sub-
section (1) of Section 274 of the Companies Act, 1956;
5. a. The company has made an application to the Central Government for
approval of the remuneration amounting to Rs.343.45 lakhs paid to
the Managing Director and whole time Director as the minimum
remuneration payable in case of inadequacy of profit and the approval
of the same is still awaited.
b. Debtors are subject to confirmation. Refer Note No. 30 of Schedule
‘Q’.
6. In our opinion and to the best of our information and according to the
explanations given to us, subject to Para 5(a) & (b) above, the said
accounts read with notes thereon, specifically Note No.2 (i) (4) regarding
adoption of amended Accounting Standard (AS-11) and the impact of the
same on the loss for the year of the company, give the information
required by the Companies Act, 1956, in the manner so required and give
a true and fair view in conformity with the accounting principles generally
accepted in India:
i. In the case of the Balance Sheet, of the State of affairs of the
Company as at 31st March 2009;
ii. In the case of the Profit and Loss Account, of the Loss for the year
ended on that date; and
iii. In the case of Cash Flow Statement, of the cash flows for the year
ended on that date.
For SNB Associates
Chartered Accountants
B. Mahalingam
Place: Chennai Partner
Date: June 29, 2009 Membership No. 210408
Report of the Auditors to the Members
3131Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
ANNEXURE TO AUDITORS’ REPORT
1. The Company has maintained proper records showing full particulars
including quantitative details and situation of its fixed assets. According
to the information and explanations given to us, most of the fixed assets
have been physically verified by the Management during the year. In our
opinion, the frequency of such physical verification is reasonable having
regard to the size of the Company and the nature of its assets. No material
discrepancies were noticed on such verification as compared to the
available records. There was no substantial disposal of fixed assets during
the year.
2. Physical verification of Inventory has been conducted by the Management
at reasonable intervals. The procedures for physical verification of stocks
followed by the Management are reasonable and adequate in relation to
the size of the Company and nature of its business. The Company is
maintaining proper records of inventory and no material discrepancies
were noticed on physical verification.
3. a. The Company has not taken any loans, secured or unsecured from
companies, firms or other parties covered in the register maintained
under Section 301 of the Companies Act, 1956.
b. As informed to us, the Company any loans, secured or unsecured from
companies, firms or other parties for which entries are required to be
made under Section 301 of the Companies Act, 1956.
4. In our opinion and according to the information and explanation given to
us, there is adequate internal control system commensurate with the size
of the Company and the nature of its business for the purchase of
inventory and fixed assets and for the sale of goods and services. During
the course of our audit, no major weakness has been noticed in the
internal control system.
5. In our opinion and according to the information and explanation given to
us, the particulars of contracts or arrangements referred to in Section 301
of the Companies Act, 1956 have been entered in the register required to
be maintained under that section.
The transactions made in pursuance of such contracts or arrangements
have been made at prices which are reasonable having regard to the
prevailing market prices / Joint venture agreements at the relevant time.
6. The Company has not accepted any deposits from the public.
7. In our opinion, the Company has an internal audit system commensurate
with the size and nature of its business.
8. We have broadly reviewed the books of account maintained by the
Company, pursuant to the rules made by the Central Government for the
maintenance of the Cost Records under Section 209(1)(d) of the
Companies Act, 1956 and are of the opinion that prima facie the
prescribed accounts and records have been made and maintained.
9. The Company is generally regular in depositing undisputed Statutory Dues
including Provident fund, Investor Education and Protection Fund,
Employees’ State Insurance, Income-Tax, Sales-Tax, Wealth-Tax, Service-
Tax, Custom duty, Excise duty, Cess and any other statutory dues applicable
to it with the appropriate authorities.
10 According to the information and explanations given to us, no undisputed
amounts payable in respect of sales-tax, Income-Tax, Wealth Tax, Service
Tax, Custom duty, Excise duty and Cess were outstanding at the year end
for a period of more than six months from the date they became payable.
11. According to the records of the Company, there are no disputed amounts
that have not been deposited with appropriate authorities on account of
Income Tax, Sales-Tax, Wealth Tax, Service-Tax, Custom duty, Excise duty
and Cess except the following:
Referred to in Paragraph 3 of our Report of even date:
32 Orchid Chemicals & Pharmaceuticals Ltd.
PROFIT AND LOSS ACCOUNT for the year ended March 31, 2009
Annexure to Auditors’ Report
12. The Company has no accumulated losses at the end of the financial yearand it has not incurred any cash losses in the current and in theimmediately preceding financial year.
13. Based on our audit procedures and on the information and explanationsgiven by the management, the Company has defaulted in certainrepayments of principal and interest to banks as per details given in NoteNo. 29 of Schedule ’Q’. The Company does not have any borrowings byway of debentures.
14. The Company has not granted any loans and advances on the basis ofsecurity by way of pledge of shares, debentures and other securities.
15. In our opinion and according to the information and explanations givento us, the nature of activities of the Company does not attract any specialstatute applicable to chit fund and nidhi / mutual benefit fund/societies.
16. Based on our examination of records and the information andexplanations given to us, the Company has not dealt / traded in any shares,securities, debentures and other investments during the year.
17. According to the information and explanations given to us, the Companyhas not given any guarantee for loans taken by others from banks orfinancial institutions.
18. The term loans obtained by the Company were applied only for thepurposes for which the loans were obtained.
19. According to the Cash Flow Statement and other records examined by usand the information and explanations given to us on an over all basis, the
funds raised on short-term basis, prima facie, have not been used duringthe year for long-term investment other than temporary deploymentpending application.
20. The Company has made preferential allotment of 4965000 warrants, topromoters covered in the register maintained under Section 301 of theCompanies Act, 1956, each warrant convertible into one equity share ofRs.10 each within 18 months from the date of issue. The above issue ofwarrant is in accordance with SEBI guidelines.
21. The Company did not have any outstanding debentures / bonds during theyear for which creation of securities is required.
22. The Company has not raised any money through public issue during theyear. The end use of the money raised through Foreign CurrencyConvertible Bonds in the earlier years has been disclosed and verified.
23. Based on the audit procedures performed and information andexplanations given by the management, we report that no fraud on or bythe Company has been noticed or reported during the course of our audit.
For SNB AssociatesChartered Accountants
B. MahalingamPlace: Chennai PartnerDate: June 29, 2009 Membership No. 210408
33Annual Report 2008-09
Name of the Statute Nature of Period to which the Amount Forum where the dispute is pendingDues amount relates Rs in Lacs
Central Excise Act1944, Excise Duty 1999-00 to 2000-01 111.95 Customs, Excise and Service Tax Appellate Tribunal Chennai
2000-01 &2001-02 37.12 Customs, Excise and Service Tax Appellate Tribunal Chennai2004-05 124.77 Commission of Central Excise, Chennai2004-05 0.55 Customs, Excise and Service Tax Appellate Tribunal Chennai2005-06 0.59 Customs, Excise and Service Tax Appellate Tribunal Chennai2005-06 91.53 Commissioner of Central Excise Chennai2005-06 11.57 Joint Commissioner of Central Excise, Chennai2006-07 9.36 Joint Commissioner of Central Excise, Chennai2006-07 1.92 Customs, Excise and Service Tax Appellate Tribunal Chennai2006-07 223.18 Commissioner of Central Excise, Chennai2006-07 243.41 Commissioner of Central Excise, Aurangabad2007-08 1.64 Commissioner of Central Excise (Appeals), Chennai2007-08 3.92 Commissioner of Central Excise, Chennai2007-08 12.21 Commissioner of Central Excise, Chennai2007-08 274.77 Commissioner of Central Excise, Aurangabad2007-08 32.19 Additional Commissioner of Central Excise, Aurangabad2008-09 1.75 Assistant Commissioner of Central Excise, Chennai
Finance Act, 1994 Service - Tax June 1997 to 2001-02 42.26 Assistant Commissioner of Central Excise, Chennai(Chapter V) 2006-07 4.74 Commissioner of Central Excise (Appeals), Chennai
2006-07 9.24 Additional Commissioner of Central Excise, Chennai2007-08 13.15 Commissioner of Central Excise (Appeals), Chennai2007-08 10.95 Additional Commissioner of Central Excise, Chennai2007-08 14.78 Assistant Commissioner of Central Excise, Chennai2008-09 8.04 Assistant Commissioner of Central Excise, Chennai
Income Tax Act, 1961 Income tax AY 1997-98 53.82 Income tax Appellate Tribunal- ChennaiAY 1997-98 & 98-99 68.88 Commisioner of Income tax, ChennaiAY 2005-06 45.12 Commisioner of Income tax, Chennai
Orchid Chemicals & Pharmaceuticals Ltd.
BALANCE SHEET as at March 31, 2009
Schedule 31.03.2009 31.03.2008
I SOURCES OF FUNDS
A. Shareholders’ Funds
Share Capital A 7044.21 6585.08
Reserves and Surplus B 59977.30 62224.45
B. Loan Funds
Secured Loans C 169500.96 96246.14
Unsecured Loans
From Banks 11004.01 21000.00
Foreign Currency Convertible Bonds ( Refer Note 6 ) 79170.45 78098.18
C. Deferred Tax Liability (Refer Note 19(a) of Schedule Q) 12949.20 11577.55
Total 339646.13 275731.40
II. APPLICATION OF FUNDS
D. Fixed Assets D
Gross Block 253559.21 196056.58
Less : Depreciation 66924.52 54675.91
Net Block 186634.69 141380.67
Capital Work in Progress 38815.97 38052.58
Advance for capital items 15762.66 23580.03
241213.32 203013.28
E. Investments E 12236.81 11382.00
F. Foreign currency Monetary item Translation difference Account 8357.94 –
G. Current Assets, Loans And Advances
Inventories F 74368.79 63318.64
Sundry Debtors G 65903.57 52256.38
Cash and Bank Balances H 4152.04 2284.84
Other Current Assets I – 13.18
Loans and advances J 15958.68 14642.67
160383.08 132515.71
H. Less Current Liabilities and Provisions K 82545.02 71179.59
77838.06 61336.12
Total 339646.13 275731.40
Notes on accounts Q
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
(Rs. lakh)
34 Orchid Chemicals & Pharmaceuticals Ltd.
PROFIT AND LOSS ACCOUNT for the year ended March 31, 2009
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
Schedule 31.03.2009 31.03.2008
I. INCOME
Sales & Operating Income L 120321.43 125018.14
Less : Excise Duty 1177.39 119144.04 1126.52 123891.62
Other Income M 9015.41 7250.87
128159.45 131142.49
II. EXPENDITURE
Material Cost N 51030.99 43464.90
Manufacturing, Selling & Other Expenses O 52297.47 45944.05
Interest and Finance charges P 15518.60 8112.63
Depreciation / Amortisation 12997.21 9766.78
131844.27 107288.36
III. PROFIT /(LOSS)
Profit/(Loss) for the year before tax (3684.82) 23854.13
Less : Provision for tax
Current Taxes – 2908.97
Fringe Benefit Tax 161.00 150.00
Deferred Taxes (Refer Note 19(a)) 1371.65 1532.65 2341.55 5400.52
Profit/(Loss) for the year after tax (5217.47) 18453.61
Balance brought forward 8157.47 4010.17
Balance Available for Appropriation 2940.00 22463.78
IV. APPROPRIATIONS
Excess provision of dividend & tax thereon of earlier year written back (963.71) (1129.82)
Proposed Dividend 915.84 2936.99
Tax on proposed dividend 155.65 1071.49 499.14 3436.13
Transfer to General Reserve – 12000.00
Balance carried to Balance Sheet 2832.22 8157.47
V. EARNINGS PER SHARE (Face value of Rs. 10/-each)
Basic (Rs.) (7.61) 28.03
Diluted (Rs.) (7.61) 18.85
Notes on Accounts Q
(Rs. lakh)
35Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008
Authorized10,00,00,000 (Previous year 10,00,00,000) Equity Shares of Rs. 10/- each 10000.00 10000.00Issued, Subscribed and Paid-up7,04,42,076 (Previous year - 6, 58,50,776) equity Shares of Rs.10/- each fully paid. 7044.21 6585.08Of the above:
1,73,76,940 Equity shares of Rs.10/- each were allotted as fully paid
bonus shares by capitalisation of reserves.
Schedule “A” SHARE CAPITAL
(Rs. lakh)
All Rupee Term Loans and Foreign Currency Term Loans from Banks/Financial Institutions are secured by Pari Passu charge by way of joint mortgage on immovable
and movable assets situated at Factory premises at SIDCO Industrial Area, Alathur, MIDC Industrial Area, Aurangabad,SIPCOT Industrial Park, Irungattukottai and
R&D premises at Sholinganallur and current assets, subject to prior charges created/ to be created on current assets in favour of bankers and financial institutions
for securing working capital borrowings. Total term loans aggregating Rs. 82,927 lakh are additionally secured by personal guarantee of Shri K.Raghavendra Rao,
Managing Director of the Company.
Packing Credit and Advances against bills from Banks and Working Capital Loans from Banks are secured by first charge on all current assets namely, Stocks
of Raw materials, Semi-finished & Finished Goods, Stores and Spares not relating to Plant & Machinery (Consumable Stores and Spares), Bills Receivable, Book
Capital Reserve– Opening Balance 805.54 805.54
– Additions during the year 89.14 894.68 – 805.54
Securities Premium Account– Opening Balance 24780.45 21635.37
– Additions during the year* (Refer Note 6 (c) of Schedule Q) 8336.90 3145.08
33117.35 24780.45
Deductions during the year– Provision for premium on redemption of FCCB – –
– GDR/FCCB issue expenses adjustment – 33117.35 – 24780.45
General Reserve– Opening Balance 28480.99 17091.49
– Less : Adjustment for Retirement Benefits** – (610.50)
– Less : Adjustment for AS11 (5347.94)
– Add : Transfers during the year – 23133.05 12000.00 28480.99
**(Refer Note.1(h) of Schedule Q)
Surplus in Profit & Loss Account 2832.22 8157.47
59977.30 62224.45
(* includes Exchange rate gain/(loss) on provision for premium on redemption of FCCB Rs. (7414.30) lakh (Previous year Rs. 3079.69 lakh))
Schedule “B” RESERVES & SURPLUS
From Banks
– Rupee Term Loans 92064.85 36115.13
– Foreign Currency Term Loans 24261.25 13,646.40
– Rupee & Foreign Currency Packing Credit/Cash credit & Advance against Bills 53021.00 46298.51
169347.10 96060.04
Hire Purchase Finance 153.86 186.10
169500.96 96246.14
Schedule “C” SECURED LOANS
36 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS as at March 31, 2009
Debts & all other movable property both present and future excluding such movables as may be permitted by the banks/ financial institutions from time to time
and by second charge on immovable properties after charges created/ to be created on immovable assets in favour of Financial Institutions/Banks for securing
Term Loans. The borrowings from banks are additionally secured by personal guarantee of Shri. K. Raghavendra Rao, Managing Director of the Company.
Hire purchase Loans are secured by the assets acquired through such loans.
Schedule “D” FIXED ASSETS
Gross Block (At Cost) Depreciation/Amortization Written Down Value
SL Asset Description As at Additions Deletions As at Up to For On Up to As at As at
No. 1.4.2008 during during 31.3.2009 31.3.2008 the year Deletions 31.3.2009 31.3.2009 31.3.2008
the year the year
1. Freehold Land &
Site Development@ 3180.04 – – 3180.04 – – – – 3180.04 3180.04
2. Leasehold Land@ 2581.52 11.59 – 2593.11 46.84 9.24 – 56.08 2537.03 2534.68
3. Buildings 23612.67 16078.90 – 39691.57 2948.77 851.03 – 3799.80 35891.77 20663.90
4. Plant & Machinery 143027.24 38315.28 731.51 180611.01 43544.17 10751.86 521.21 53774.82 126836.19 99483.07
5. Factory Equipment 1454.93 263.62 0.88 1717.67 660.83 142.34 0.54 802.63 915.04 794.10
6. Laboratory Equipment 8505.49 3180.25 18.04 11667.70 1757.37 468.91 9.21 2217.07 9450.63 6748.12
7. Office Equipment 2009.49 494.97 163.29 2341.17 1092.33 200.82 132.84 1160.31 1180.86 917.16
8. Furniture & Fittings 1597.58 188.33 11.87 1774.04 526.79 97.80 6.49 618.10 1155.94 1070.79
9. Vehicles 720.65 84.69 189.41 615.93 199.78 57.99 78.32 179.45 436.48 520.87
10 Intangible Assets
Acquired
Brands & Trademarks * 2778.16 – – 2778.16 2335.38 115.63 – 2451.01 327.15 442.78
Internally Generated
DMF & ANDA ** 6588.81 – – 6588.81 1563.65 301.60 – 1865.25 4723.56 5025.16
Total 196056.58 58617.63 1115.00 253559.21 54675.91 12997.22 748.61 66924.52 186634.69 141380.67
Previous Year's Figures 143181.65 52974.33 99.40 196056.58 44940.05 9766.78 30.92 54675.91 141380.67
As at As at 31.3.2009 31.3.2008
Rs. lakh Rs. lakh@ Assets acquired pending for registration in favour of the Company.
Freehold Land 59.09 59.09
Leasehold Land – 1756.54
Fixed Assets include assets on Hire Purchase (Gross Block) 306.10 294.74
* Represents value of registrations and value of applications filed Pending registration
** Refer Note 1 (b) (iv) of Schedule Q
(Rs. lakh)
37Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008Nos. Rs. lakh Nos. Rs. lakh
(at cost)
LONG TERM
Trade, UnQuoted
Subsidiary Companies
Orchid Europe Limited, UK
Common stock of GBP 1 each fully paid up 10000 6.42 10000 6.42
Less : Provision for diminution in value (6.42) (6.42)
– –
Ogna Farma, Brazil@
Common stock – 134.42
Less : Provision for diminution in value – (134.42)
– –
Orchid Pharma Japan KK
Common stock JPY 50000 each fully paid up 600 122.49 –
Orchid Pharmaceuticals Inc., USA
Common stock of US$ 1 each fully paid up 200000 85.07 200000 85.07
Less : Provision for diminution in value (40.21) (40.21)
44.86 44.86
Bexel Pharmaceutical Inc.**
9,999,990 Series A & 48,93,750 Series B Convertible Preferred Stock 23894830 8883.24 23894830 8883.24
par value USD 0.001 per share and 9,001,090 Common
stock of par value USD 0.001 per share
Orchid Pharmaceuticals SA(Proprietary)Limited.South Africa 230033 13.11 139965 8.48
10000 shares each fully paid up
Orchid Research Laboratories Ltd.
Fully paid up equity shares of Rs. 10 each 14876600 1487.66 14876600 1487.66
Less : Provision for diminution in value (1487.66) (1487.66)
– –
9063.70 8936.58
Joint Venture Companies
Diakron Pharmaceuticals, Inc. USA
Series A Preferred stock and common stock representing 40% interest 3229859 727.69 –
NCPC Orchid Pharmaceuticals Company Ltd, China 2364.24 2364.24
Common stock representing 50% interest in the Company
3091.93 2364.24
Schedule “E” INVESTMENTS
38 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008Nos. Rs. lakh Nos. Rs. lakh
Others
– Trade, Unquoted
Sai Regency Power Corporation Pvt. Ltd.
Fully paid up equity shares of Rs. 10/- each 450000 45.00 450000 45.00
– Non-Trade, Unquoted
Madras Stock Exchange
Fully paid up equity shares of Re. 1/– each 911430 23.98 47970 23.98
MSE Financial Services Ltd.
Fully paid up equity shares of Rs. 10/- each 31936 3.83 31936 3.83
Non - Trade, Quoted
Bank of India -
Fully paid up equity shares of Rs. 10/- each 18600 8.37 18600 8.37
81.18 81.18
Total Value of Investments 12236.81 11382.00
Market Value for quoted investment is Rs. 40.81 Lakhs. (Previous year Rs. 47.04 Lakhs)
Aggregate value of unquoted investment is Rs. 12228.44 lakh (Previous year Rs. 11373.63 lakh)
Units bought and sold during the year:
Chola Mutual Fund 10000000 units valued at Rs. 1000 lakh
** Each Series A & B Preferred stock is convertible into One Common stock, at any time, at the option of the Company and will have voting rights
equal to one common stock and has the same value as common stock.
@ deleted as the Company is wound up
Schedule “E” INVESTMENTS (Contd.)
31.03.2009 31.03.2008
Raw Materials 15997.28 11221.29
Stores and Spare parts 2532.80 2877.69
Chemicals and Consumables 1001.40 1084.68
Packing Materials 1515.77 1551.83
Intermediates & WIP 42669.70 36420.24
Finished Goods 9842.02 9613.16
Traded Goods 809.82 549.75
74368.79 63318.64
Schedule “F” INVENTORIES (Refer Note 1(f), Schedule “Q”)
(Rs. lakh)
Debts more than 6 months (Unsecured)
Considered Good 48017.26 21300.17
Considered Doubtful 1615.11 1615.11
Other Debts (Considered Good)
Secured 217.94 233.81
Unsecured 17668.37 30722.40
67518.68 53871.49
Less: Provision for Doubtful Debts 1615.11 1615.11
65903.57 52256.38
Schedule “G” SUNDRY DEBTORS
39Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008
Cash In Hand 9.79 9.25
Balances With Scheduled Banks OnCurrent account 1317.26 871.34
Term Deposit account 2100.82 713.52
Margin money deposit 645.80 604.08
Share Application money and Dividend account 55.21 52.61
Balances with other Banks on :Current account (Ref Note 12 of Schedule Q) 23.16 34.04
4152.04 2284.84
Schedule “H” CASH AND BANK BALANCES
(Rs. lakh)
Interest accrued on deposits and advances * 21.07 34.25
21.07 34.25
Less: Provision for Doubtful Interest accrued 21.07 21.07
*Includes dues from subsidiary Rs. 21.07 lakh (Previous Year 21.07 lakh) – 13.18
Schedule “I” OTHER CURRENT ASSETS
Considered GoodAdvances recoverable in cash or kind or for value to be received 6320.57 6258.71 Advance Payment of Tax 4100.88 3987.29 Loans to Subsidiaries 4405.33 3382.36 Deposits– With Government authorities 508.78 342.24 – Others 623.12 672.07 Considered Doubtful– Loan to Subsidiary 3211.59 1710.25 - Others 205.33 2039.06
19375.60 18391.98 Less: Provision for Doubtful Advances/Loans to Subsidiaries 3416.92 3749.31
15958.68 14642.67
Schedule “J” LOANS AND ADVANCES (Unsecured)
Acceptances 73.78 1389.02 Sundry creditors (other than Micro, Small & Medium Scale Enterprises) for– Capital Items 5669.71 4346.70 – Other supplies 21621.85 18228.10 – Expenses [Includes due to Directors - Rs. 21 lakh (Previous year - Rs. 400 lakh)] 9288.97 3685.15 Investor Education and Protection Fund shall be credited by the following amounts namely :*– Unclaimed Dividend 55.21 52.61 – Share Application Money Refundable 5.42 5.42 Premium payable on redemption of FCCBs (Ref Note 6(c)) 34254.36 33750.35 Other liabilities [Refer Note 18. (b) of Schedule Q] 1918.43 1888.22 Provisions For– Retirement Benefits 1231.37 1043.47 – Rebates/Discounts 4000.00 –– Taxation 3354.43 3354.42 – Proposed Dividend 915.84 2936.99 – Tax on Proposed Dividend 155.65 499.14 * Represents balances in those accounts as of 31st March. Actual amount to be transferred to the Investor Education and Protection Fund will be determined on due dates. 82545.02 71179.59
Schedule “K” CURRENT LIABILITIES AND PROVISIONS
40 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS for the year ended March 31, 2009
31.03.2009 31.03.2008
Sales 116835.64 120287.72
Less : Excise Duty 1158.68 115676.96 1123.64 119164.08
Operating Income
Income from services rendered
Technical & Consultancy Fees (TDS - Rs. Nil (Previous year - Rs. Nil)) 30.58 2.88
Contract Research & Development 149.58 239.40
Sale of Other Materials 472.93 321.50
Less : Excise Duty 18.71 454.22 2.88 318.62
Development Fee 1938.09 3206.67
Licence Fee 713.23 860.82
Other Operating Income 181.38 99.15
119144.04 123891.62
Schedule “L” SALES & OPERATING INCOME
(Rs. lakh)
Income from Investments
Dividend (Refer Note 8 of Schedule Q) 301.85 1.80
Exchange Rate Gain on FCCBs – 7126.67
Gain on cancellation of FCCBs–net 6730.53 –
Provision for doubtful debts written back 1833.73 –
Profit on sale of fixed assets 2.92 1.90
Miscellaneous Income 146.38 120.50
9015.41 7250.87
Schedule “M” OTHER INCOME
Raw Materials Consumed 50407.82 39049.41
Cost of Traded Goods 3367.60 53775.42 2610.12 41659.53
Less: (Accretion to) / Depletion in Stocks
Closing Stock of Intermediates, WIP & Finished Goods 52511.72 46033.40
Opening Stock of Intermediates, WIP & Finished Goods 46033.40 (6478.32) 44099.62 (1933.78)
Consumption of Packing Materials 3733.89 3739.15
51030.99 43464.90
Schedule “N” MATERIALS COST
Power and Fuel 7344.64 6957.85
Conversion Charges 1760.00 2100.82
Consumption of Stores, Spares & Chemicals 2547.67 3480.19
Factory Maintenance 2281.65 1972.41
Salaries and Wages 10250.63 8173.83
Contribution to Provident & other funds 1002.08 723.93
Staff Welfare 1035.71 1092.00
Rent 18.98 18.06
Rates & Taxes 160.14 127.63
Insurance 1201.17 1355.14
Postage, Telephone & Telex 151.26 154.66
Printing & Stationery 233.58 241.99
Vehicle Maintenance 57.54 68.47
Research & Development Expenses (Refer Note 25) 4633.46 4519.07
Schedule “O” MANUFACTURING, SELLING AND OTHER EXPENSES
41Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS for the year ended March 31, 2009
31.03.2009 31.03.2008
Schedule “O” MANUFACTURING, SELLING AND OTHER EXPENSES (CONTD.)
(Rs. lakh)
Advertisement 17.92 28.63
Recruitment expenses 155.41 259.25
Auditors' Remuneration
Statutory Auditors [Refer Note 7 of Schedule Q] 67.00 66.00
Cost Auditors 11.24 11.06
Travelling and Conveyance 1383.77 1151.12
Directors' Remuneration & perquisites (Refer Note 9) 343.44 707.75
Directors' travelling
Inland 13.53 11.28
Overseas 29.62 62.04
Directors' sitting fees 14.20 15.20
Loss on sale of fixed asset/written off 214.05 13.97
Freight outward 2364.24 2097.42
Commission on Sales 950.34 1253.70
Business Promotion and Selling Expenses 1367.14 1177.15
Consultancy & Professional Fees 3119.87 2457.91
Exchange Rate Loss/ (Gain) 1568.35 749.97
Provision for Rebates/Discounts 4000.00 –
Provision for Diminution in value of Investments – 134.42
Provision for Losses of subsidiary companies 1501.34 1822.66
Provision for doubtful advances – 1547.96
Miscellaneous expenses 2497.50 1390.51
52297.47 45944.05
Interest on Term Loans 5122.19 1801.17
Other Interest & Finance Charges 10396.41 6311.46
15518.60 8112.63
Schedule “P” INTEREST AND FINANCE CHARGES (Refer Note 10)
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
42 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS
43Annual Report 2008-09
1. Significant Accounting Policiesa) Accounting Convention
The Financial Statements are prepared under historical cost convention. Revenues are recognised and expenses are accounted on their accrual with
necessary provisions for all known liabilities and losses.
b) Fixed Assetsi) Fixed Assets are stated at the original cost inclusive of inward freight, incidental expenses related to acquisition and related pre-operational
expenses and technical knowhow fees where applicable.
ii) Machinery spares which can be used only in connection with specific fixed assets and the use of which are irregular, are charged over the period
of the life of such fixed asset, in accordance with Accounting Standard (AS 10 ).
iii) Brands represent brands acquired by the Company and includes IPR & Licences purchased for a consolidated consideration.The cost of brands,
patents and trademarks are amortised over a period of 60 months from the month of acquisition.
iv) INTERNALLY GENERATED INTANGIBLE ASSETS - DMF & ANDA
DMF and ANDA costs represent expenses incurred on development of processes and compliance with regulatory procedures of the US FDA, in
filing Drug Master Files("DMF") and Abbreviated New Drug Applications("ANDA"), in respect of products for which commercial value has been
established by virtue of third party agreements/arrangements. This is in accordance with the requirements of Accounting Standard 26.
The cost of each DMF/ANDA is amortised to the extent of recovery of developmental costs applicable as per terms of agreement or over a period
of five years from the date on which the product covered by DMF/ANDA is commercially marketed, whichever is earlier.
v) Assets are depreciated on straight line basis at the rates specified in Schedule XI of the Companies Act, except in respect of the following assets,
where the useful lives reckoned in computing the depreciation for the year are different from those derived from the rates specified in Schedule
XI of the Companies Act, 1956. The revised useful life of the assets have been determined by the Management based on technical assessment.
Asset Categories Useful lifeReactors, Pipes, Pipe fittings, Valves, Motors, Pumps, Nitrogen Plant, Gear Boxes, 9 years
Cables and Centrifuges Evaporator (indigenous), Jet aeration system (indigenous),
Ventilation & Exhaust system, HCL column, ETP (indigenous), scrubber, incinerator (indigenous)
& Instrumentation items.
Depreciation is provided at rate arrived based on useful life or Schedule XI rates whichever is higher.
vi) Leasehold assets cost is amortised over the period of the Lease.
vii) Depreciation on assets added/disposed off during the year is provided on pro-rata basis from the month of addition or up to the month of disposal,
as applicable.
viii) Impairment of assets:
Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired. An impairment
occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the assets and its
eventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net sales
price or present value as determined above.
c) Borrowing CostsInterest cost on qualifying asset being an asset that necessarily takes a substantial period of time to get ready for its intended use or sale, is capitalised
at the weighted average rate of the funds borrowed and utilised for acquisition of such assets.
d) Treatment of expenditure during construction period.Expenditure during construction period is included under capital work-in-progress and the same is allocated to the respective fixed assets on the
completion of construction.
e) InvestmentsInvestments considered long term are shown at cost. Diminution in the value of investments other than temporary are provided for. Current investments
are valued at lower of cost and market value.
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
As at 31.03.2009 As at 31.03.20083. Estimated amounts of contracts remaining to be executed on capital account
(net of advances) and not provided for. 10712.57 13063.43
4. a. Other monies for which company is contingently liable :
– Bills Discounted 21402.71 21395.61
– Unexpired Letters of Credit 13295.03 15217.56
– Bank Guarantees outstanding 518.89 946.82
– Claims against the Company not acknowledged as debts
Excise demands under dispute pending before Excise authorities 1182.43 861.50
Service Tax dispute pending before High Court of Chennai 103.16 56.03
b. Provision and contigencies in accordance with AS 29 :
Opening Balance – –
Additions during the year 4000.00 –
Closing Balance 4000.00 –
(Rs. lakh)
f) Inventoriesi) Stores & Spares – At weighted average cost.
ii) Raw Materials – At annual weighted average cost
iii) Finished Goods @ – At Lower of cost & net realisable value
iv) Work in Progress & Intermediates @ – At Lower of cost & net realisable value
@ After adjustment of unrealised profits on inter division transfer.
g) Revenue RecognitionSales are recognised on despatch of goods from the factory/ warehouse and price differentials are accounted for at the end of each quarter as per the
terms of marketing arrangement. Sales are net of returns, discounts and inter-division transfers. Service income is recognised as per contractual terms.
In respect of composite contracts involving development and other activities, income is recognised on the basis of contractual terms after considering
the quantum of work completed.
h) Retirement BenefitsRetirement Benefits are accounted on acturial valuation carried out at the end of the year. The Company's liability towards the gratuity of employees is
covered by a group gratuity policy with LIC and ICICI Prudential Life Insurance Company Ltd and the contribution to the fund is based on actuarial
valuation carried out yearly as at 31st March as per the revised AS15. Provision for Leave Encashment has been made based on actuarial valuation as at
the year end as per revised AS15.
i) Translation of Foreign Currency items1) Non - Monetary foreign currency items are carried at cost.
2) All inter-related transactions are recognised at common rates.
3) Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction.
4) Monetary items denominated in foreign currencies at the year end are restated at year end rates. In case of items which are covered by forward
exchange contracts, the difference between the year end rate and the rate on the date of the contract is recognised as exchange difference
and the premium paid on forward contracts is recognised over the life of the contract.
The Company has exercised the option provided under the amendment to the Companies (Accounting Standards) Amendment Rules, 2006 dated
March 31, 2009, AS 11. The exercise of the above option has resulted in (a) Rs. 5347.94 lakh relating to previous year adjusted in General Reserve
(b) amount remaining unamortised in the financial statements as on March 31, 2009 is Rs. 8357.94 lakh (c) The value of fixed assets adjusted
for exchange loss is Rs. 2994.32 lakh resulting in depreciation amount being more by Rs. 33.73 lakh (d) loss for the year is lower by
Rs. 16666.46 lakh.
j) Subsidy on Fixed AssetsSubsidy received on fixed assets is credited to the cost of respective fixed assets.
2. Sales tax recoverable has been recorded on the basis of the claims submitted or in the process of being submitted, as per rules relating to EOU and which in
the opinion of the Company are recoverable.
44 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
5. The Company has filed an appeal against the demand made by the Income Tax department amounting to Rs. 98.94 lakh-(Previous year Rs. 53.82 lakh). No
provision has been made as the Company is confident of winning the appeal. No provision has also been made for demand of interest amounting to Rs. 68.88
lakh (Previous year Rs. 68.88 lakh) as petition has already been filed for waiver of interest.
6. Foreign Currency Convertible Bonds (FCCBs) :a) The Company raised FCCBs during 2006-07 aggregating to USD 175 million (Rs. 77358.75 lakh) with an option to the investor to convert the FCCBs into
equity shares of the Company at an initial conversion price of Rs. 348.335 per share at a fixed rate of exchange on conversion Rs. 43.93 = USD 1, at any
time after April 9, 2007 and prior to February 18, 2012. Further the Company has an option of early redemption of these FCCBs in whole at any time on
or after February 28, 2010 and prior to February 21, 2012, subject to certain conditions. Unless previously converted, redeemed or repurchased and
cancelled, the FCCBs will be redeemed on February 28, 2012 at 142.77% of their principal amount.
During the year 2008-09, the Company bought FCCBs and cancelled to the extent of USD 37.80 million and the outstanding FCCBs as at March 31, 2009
is USD 137.20 million.
b) The Company raised FCCBs during the year 2005-06 aggregating to USD 42.50 million (Rs. 19284.50 lakh) including a green shoe option of USD 5 million
(Rs. 2289.50 lakh) with an option to the investor to convert the FCCBs into equity shares or global depository receipts at an initial conversion price of
Rs. 243.80 per share at a fixed rate of exchange on conversion Rs. 44.94 = USD 1. Out of the above, FCCBs amounting to USD 22.79 million (Rs. 10241.82
lakh) have been so far converted.
Further, the Company has an option of early redemption of these FCCBs at any time after November 03,2006 subject to certain conditions. Unless
previously converted, redeemed or repurchased and cancelled, the FCCBs will be redeemed on November 03, 2010 at 147.1688% of their principal
amount.
During the year 2008-09, the Company bought FCCBs to the extent of USD 2.25 million and the outstanding FCCBs as at March 31, 2009 is USD 17.46
million.
The current status of above FCCBs conversion into equity is as follows:
c) Provision has already been made for the entire premium payable on redemption of FCCBs amounting to Rs. 36830.08 lakh by debiting the Securities
Premium Account (SPA). In the event that the conversion option is exercised by the holder of FCCBs in the future, the amount of premium charged to
SPA will be suitably adjusted in the respective years.
The debit to share premium account for premium on FCCBs and for issue expenses have been made on the gross value without adjusting any tax impact.
Tax benefits accruing to the Company on account of claiming such expenses will be credited to the SPA account in the year in which the benefit is enjoyed
by the Company.
The provision for premium on redemption of FCCBs debited to SPA is being restated at the exchange rate prevailing at the year end and the gain/(loss)
of (Rs. 7414.30 lakh) on account of such restatement is adjusted to the security premium account.
d) Even though the Company has provided for the premium on redemption of FCCBs as per note [c] above, the Company also makes provision for dividend
in the books of account on the equity shares to be allotted upon conversion of FCCBs outstanding as at respective year end. Since the Company is
obliged, as per SEBI guidelines, to pay dividend to those FCCBs holders who convert their FCCBs into equity after adoption of the financial statements
and upto the book closure date.
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
Particulars FCCBs Value Number of Increase in Increase in Security
Shares Equity Premium
US$ million in lakh Rs. lakh Rs. lakh
Conversion effected up to March 31, 2009 22.79 42.00 420.09 9821.71
22.79 42.00 420.09 9821.71
45Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
As at 31.03.2009 As at 31.03.2008e) Usage of funds raised through FCCBs
Opening Balance 6.85 10,117.21
Funds received – –
Add: Interest received – –
Less: Expenses of Issue/Exchange fluctuations (0.96) 168.24
7.81 9,948.97
Repayment of Loans – –
Capital Expenditure/ Advances/ ANDA filings – 9,942.12
Balance 7.81 6.85
(Rs. lakh)
Year ended Year ended31.03.2009 31.03.2008
7. Auditors' remuneration include the following:
Audit fee 50.00 50.00
Tax Audit fee 7.50 7.50
For certification & other matters 9.50 8.5067.00 66.00
8. Dividend includes the followingTrade 297.84 –
Non-trade 4.00 1.80
301.84 1.80 9. Directors' Remuneration (including Managing Director's Remuneration)
– Salaries 228.00 204.00
– Contribution to funds 55.08 48.60
– Other Perquisites 60.36 55.15
– Commission – 400.00
343.44 707.75 Net Profit for Computation of Managing Director's CommissionProfit /(Loss) for the year before taxation as per Profit & Loss Account (3684.82) 23854.13
Add : Directors' Remuneration 343.44 707.75
Loss on sale of Investments – –
Loss on sale of Fixed Assets 231.98 16.95
Exchange rate losses on FCCB 2839.17
Provision for Rebates/discounts 4000.00
Provision for Doubtful debts / Advances – 1547.96
Provision for Diminution in value of investment – 134.42
Losses of Subsidiary companies 1501.34 1822.66
5231.11 28083.87
Less : Profit on sale of Investments – –
Provision for Doubtful advances written back 1833.73
Exchange rate gain on FCCB – 7126.67
Gain on FCCB cancellation 6730.53
Profit on sale of Fixed Assets 2.92 1.90
8567.18 7128.57
Net Profit/(Loss) (3336.07) 20955.30
The Company has made an application to Central Government to approve the remuneration paid to the Managing Director and whole time director,as the
minimum remuneration payable in case of inadequacy of profit. Approval for the same is awaited and the above remuneration is subject to such approval.
(Rs. lakh)
46 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
Year ended Year ended31.03.2009 31.03.2008
10. a) Other Interest and Finance Charges is after crediting interest receipts 100.83 38.92 TDS on interest receipts 15.32 6.98
b) Amount of interest capitalised 4541.23 3979.13 11. a) Factory Maintenance includes
– Repairs & Maintenance - Plant & Machinery 732.40 516.94 – Repairs & Maintenance - Building 140.22 139.79
b) Consumption of Stores, Spares and Chemicals include Stores & Spares issued for maintenance 596.61 824.50
(Rs. lakh)
2008-09 2007-0812. Balance as at the end of the year and maximum amount outstanding at any time
during the year with banks other than Scheduled Banks.
Barclays Bank, London Balance as at March 31 1.39 –
Maximum amount outstanding 10127.00 –
Citibank NA, New York Balance as at March 31 5.38 4.96
amount outstanding 5.38 6.26
JSC Vneshtorgbank, Moscow Balance as at March 31 4.61 24.76
Maximum amount outstanding 69.88 52.60
Bank of India, New Jersey Balance as at March 31 2.41 1.88
Maximum amount outstanding 2.41 10110.95
Industrial Investment Bank, Ukraine Balance as at March 31 – 0.12
Maximum amount outstanding 27.84 33.83
Eco Bank, Ghana Balance as at March 31 6.60 0.30
Maximum amount outstanding 21.78 5.17
JS ATF Bank, Kazak Balance as at March 31 0.22 2.02
Maximum amount outstanding 18.41 23.72
Private Bank, Ukraine Balance as at March 31 2.54 –
Maximum amount outstanding 28.69 –
13. Amounts Due to Micro, Small and Medium EnterprisesThe Identification of Micro, Small and Medium Enterprises Suppliers as defined under "The Micro, Small and Medium Enterprises Development Act 2006" is
based on the Information available with the management. As certified by the Management, the amounts overdue as on March 31, 2009 to Micro, Small
and Medium Enterprises on account of principal amount together with interest, aggregate to Rs. Nil (Previous year Nil).
14. Derivative Instruments and Unhedged Foreign Currency Exposure:
a) Derivative instruments
b) The purpose for which the instruments have been acquired is for hedging the foreign currency exposures.
Sl No. Particulars As at As at 31.03.2009 31.03.2008
1. Currency Swap 17221.85 21649.40
(Rs. lakh)
47Annual Report 2008-09
48 Orchid Chemicals & Pharmaceuticals Ltd.
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
2008-09 2007-08Currency Foreign Rs. lakh Foreign Rs. lakh
Currency Currency
i) Receivables OutstandingUSD 123217942 52941.99 122525472 48572.06 EURO 448782 300.54 595724 286.42 AUD 161626 56.39 – –
ii) Payables Outstanding USD 18610098 9166.18 29694024 11934.03 EUR 706015 506.72 4063999 2584.70 JPY 1847128 7.95 28418597 114.73 Others – 27.37 – 48.41
iii) Advance Paid GBP 272591 229.34 707210 562.41 SGD 11280 3.29 11280 3.29 USD 5357900 2719.40 4670000 1845.58 EUR 10247544 7014.70 566045 352.87 CHF 130390 60.03 – –
iv) FCCBs USD 154660000 79170.45 194710000 78098.18 v) Loans USD 47394502 24261.25 62098487 24887.03
c) The Foreign Currency Exposures that are not hedged by a derivative instrument or otherwise
16. a) Related Party TransactionsIn accordance with Accounting Standard 18, the disclosure required is given below:
Nature of Transaction Subsidiary Joint venture Key Management Relatives of Key Personnel Management
Personnel/ Companiesin which they exercise
significant influence
Finance – Equity Contribution 127.12 727.69 – – (63.41) (–) (–) (–)
– Loans & Advances 2524.31 – – – (3647.11) (–) (–) (–)
– Shares allotted – – – 9166.75 (–) (–) (–) (–)
– Warrants allotted – – – – (–) (–) (–) (–)
– Forfeiture of advance on warrants – – – 89.14 (–) (–) (–) (–)
Sale of goods – 3232.39 – – (–) (4140.49) (–) (–)
Rendering of Services / Interest income/rent 120.67 354.14 – – (120.50) (–) (–) (–)
Transfer of IPR – – – – (–) (–) (–) (–)
Availment of Services/Rent 495.44 – – 425.64 (452.11) (–) (–) (136.41)
– Remuneration – – Ref Note 9 – Amounts due at the end of the year – Debit 7637.99 349.13 – 10.83
(5113.68) (124.06) (–) (111.10)Amounts due at the end of the year – Credit – – – –
(–) (–) (–) (–)
(Figures in brackets are for previous year)
(Rs. lakh)
The MTM loss amounting to Rs. 3934.46 lakh on the derivatives outstanding as on March 31, 2009 has been recognised in the accounts and included underexchange rates loss/(gain) account
15. Excise duty on finished goods has been accounted on removal of goods from factory,wherever applicable. Finished goods at factory have been valued at costexclusive of excise duty and no provision has been made for excise duty on such goods. The above treatment has no impact on Profit & Loss account.
49Annual Report 2008-09
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
Names of the related parties and description of relationship.
1. Subsidiary Orchid Europe Limited, UK
Orchid Pharmaceuticals Inc., USA
Orgenus Pharma, Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc., USA)
Orchid Research Laboratories Ltd., India
Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa
Bexel Pharmaceuticals, Inc., USA
Orchid Pharma Japan KK
2. Joint Venture NCPC Orchid Pharmaceuticals Company Limited, China
Diakron Pharmaceuticals, Inc., USA
3. Key Management Personnel Mr. K Raghavendra Rao, Managing Director
Dr. C Bhaktavatsala Rao, Deputy Managing Director
4. Relatives of Key Management Personnel Mrs. R Vijayalakshmi (wife of Mr. K Raghavendra Rao)
Ms R Divya and Ms R Sowmya (daughters of Mr.K.Raghavendra Rao)
5. Companies in which relatives of Key Spectrasoft Technologies Limited, India.
Management personnel exercise significant influence.
All whole time directors have been considered as Key Management Personnel as they are involved in planning, directing and controlling the activities of the
reporting enterprise.
b) Information on Loans & Advances as Balance Maximum amount
per Clause 32 of the Listing Agreement as on 31-03-2009 outstanding
during the year
Subsidiary – Orchid Europe Limited, UK 596.10 811.60
Orchid Pharmaceuticals, Inc., USA 64.15 64.15
Bexel Pharmaceuticals, Inc., USA 2655.25 2655.25
Orchid Research Laboratories Ltd., India 4244.30 4244.30
Joint Venture - NCPC Orchid Pharmaceuticals Company Ltd., China 349.13 349.13
(Rs. lakh)
17. In terms of the resolution passed by the Company at the EGM dated October 21,1999 Employee Stock Option Scheme was extended to the employees of the
Company. Accordingly options totalling 15,00,000 Nos were given to the employees as per the scheme formulated under “ORCHID-ESOP 99" scheme by the
Compensation committee of the Board of Directors. Each option is convertible into one equity share of Rs. 10/- each at a price of Rs. 243.35 including
premium for 6,00,000 Nos, Rs. 252 including premium for 3,07,925 Nos, Rs. 300.65 including premium for 2,92,075 Nos and Rs. 339.25 for 3,00,000 Nos.
No entries were passed in the books as the options were given at the market prices prevailing on the date of issuance of options.
A fair and reasonable adjustment in share price/ the number of options outstanding was made by the Company in respect of the Employee Stock Options
granted but not exercised by the Employees due to the corporate action of issue of bonus shares during October 2005. The total number of options outstanding
and the price was adjusted so that the total value and options available to each option holder remained the same.
Consequently the revised and adjusted prices per share are Rs. 162.24 (Rs. 243.35), Rs. 168.00 (Rs. 252.00) and Rs. 200.44 (Rs. 300.65) respectively for
6,00,000 Nos, 3,07,925 Nos and 2,92,075 Nos of options granted by the Company.
For the 3,00,000 options granted during April 2006 at a price of Rs. 339.25, the Compensation Committee of the Board of Directors considered repricing of
the options in the interest of the employees, due to the fall in the price of the shares of the Company and accordingly approved a repricing of the options
from Rs. 339.25 to Rs. 193.25 as per the closing price of Orchid at National Stock Exchange on August 11, 2006. The revision in the price has been approved
by the shareholders at the Annual General Meeting held on July 19, 2007.
Pursuant to the exercise of options by employees, the Allotment Committee of the Board at its meeting held on April 26, 2008, May 29, 2008 and August
13, 2008 allotted 7,525, 16,175, and 3,000 equity shares respectively to the employees under ORCHID ESOP 99 Scheme. 536,153 Options were outstanding
as at March 31, 2009 including the additional number of options adjusted, due to the bonus issue.
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
In terms of the resolution passed by the Company at the AGM dated July 18, 2005 the shareholders approved the scheme formulated under “ORCHID-ESOP
2005”for allotting 10,00,000 Nos. Accordingly 6,10,000 options were given to the eligible directors and employees by the compensation committee of the
Board of Directors at a meeting held on August 12, 2006. Each option is convertible into one equity share of Rs. 10/- each at a price of Rs. 193.25 per share
including premium.
Pursuant to the exercise of options by employees, the Allotment Committee of the Board at its meeting held on April 26, 2008, May 29, 2008, August 13,
2008 and August 29, 2008 allotted 1,900, 200, 1,000 and 1,500 equity shares respectively to the employees and 84,325 Options were outstanding as at March
31, 2009 under ORCHID ESOP 2005 Scheme.
18. a) In terms of the resolution passed by the Company on February 14, 2007, 50,00,000 warrants were allotted to the Promoter /Promoter Group(s), the
relative(s) of the Promoter on March 01, 2007. These warrants are eligible for conversion at the option of the Warrants holders, into equity shares of the
Company at a price of Rs. 202.58 per share within a period of 18 months of the date of allotment.
During the year, pursuant to the exercise of option by the warrant holders, the Allotment Committee of the Board at its meeting held on August 13, 2008
and August 29, 2008 have allotted 381,000 and 41,79,000 equity shares respectively. The balance 440,000 warrants were not exercised within the
stipulated period. Hence on September 01, 2008 the 10% advance paid by them amounting to Rs. 89.14 lakh on the unexercised warrants was forfeited
and credited to capital reserve.
b) Other liabilities include Rs. Nil (Previous year Rs. 1,012.90 lakh) being the amount received as advance against the warrants issued to the promoter
group, including Rs. Nil (Previous year Rs. 7.09 lakh) from a Director.
19. a) Provision for Deferred tax for the year Rs. 1371.65 lakh (Previous year Rs. 2341.55 lakh)
Deferred Tax liability represents the following:
As at 31.03.2009 As at 31.03.2008
Timing Difference on account of Depreciation 21655.01 18911.28
Timing Difference on account of Losses (8705.81) (7333.73)
In accordance with clause 29 of Accounting Standard (AS22) Deferred tax Assets and Deferred tax Liabilities have been set off.
20. Segmental ReportingThe Company was disclosing segment information classifying the business as Bulk drugs and Formulations till the financial year 2004-05. However in view
of integration of bulk actives and formulations business, with the commissioning of Generics formulation facilities from the financial year 2005-06, the
Company considers the business as one interrelated and integrated business of "Pharmaceutical products" and hence no separate segmental reporting is
provided.
(Rs. lakh)
21. Additional information pursuant to the provisions of Paragraph 3, 4C & 4D of Part II of Schedule VI of the Companies Act, 1956
A) Licensed & Installed Capacity (as certified by the management)
Class of Goods Regd/ Licensed Installed Regd/ Licensed Installed2008-09 2008-09 2007-08 2007-08
Bulk Drugs and Intermediates
Oral & Sterile MT 990 990 900 800
Dosage Forms
Vials Nos Millions 20 20 20 20
Tablets Nos Millions 576 576 576 576
Capsules Nos Millions 139 139 139 139
Dry syrups/Powders Nos Millions 13 13 13 13
Installed Capacities are calculated based on a typical product mix, and applicable shift operations.
50 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
B) Value of Raw Materials, Spare Parts and Components consumed during the year
Year ended 31.03.2009 Year ended 31.03.2008
Percentage Amount Percentage Amount
Rs. lakh Rs. lakh
Raw Materials
Imported 79.35% 39996.78 79.25% 30947.55
Indigenous 20.65% 10411.04 20.75% 8101.86
100.00% 50407.82 100.00% 39049.41
Spare Parts, Consumables & Packing Material
Imported 39.78% 2499.09 47.14% 3403.15
Indigenous 60.22% 3782.47 52.86% 3816.19
100.00% 6281.56 100.00% 7219.34
2008-09 2007-08C) Earnings In Foreign Exchange during the year
F.O.B. Value of Exports 93202.59 100855.60
Export of Services including royalty/ knowhow (net of withholding tax) 2714.89 4123.10
D) C.I.F Value of Imports (on cash basis)Raw Materials 28214.51 19598.04
Capital Goods 8175.49 7064.07
Spare Parts, Components, Consumables & Packing materials 5953.24 4174.66
E) Expenditure in Foreign Currency (on cash basis)Travelling Expenses 256.23 139.12
Interest & Bank Charges 2071.04 783.07
Professional/Consultancy Fees 1899.67 1431.43
Royalty/Technical knowhow 103.93 201.50
Others 3277.12 3130.60
F) Dividend Remittances in Foreign Currency during the yearYear to which dividend relates 2007-08 Final 2006-07 Final No of Non Resident Share Holders 2 3
No of Shares held by Non Resident Share Holders 3515000 14189367
Gross Dividend (Rs. lakh)* 105.45 425.68
Net Dividend (Rs. lakh)* 105.45 425.68
* represents only shares in respect of which dividend is remitted in foreign currency by the Company
(Rs. lakh)
22. Reconciliation of Basic and Diluted shares used in computing Earnings Per Share (Equity shares of Rs.10/- each fully paid-up)
Year ended Year ended31.03.2009 31.03.2008
Profit After Tax Rs. (5217.47) 18453.61
No of Shares Outstanding Nos. 70442076 65850776
Weighted Average Number of shares Nos. 68579472 65832234
Earning per Share - Basic Rs. (7.61) 28.03
No of warrants & options allotted Nos. 21141785 32048733
Total No of Equity shares to compute diluted EPS Nos. 89721257 97880967
Earning per Share - Diluted Rs. (7.61) 18.85
51Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
23. Disclosure as per requirements of Accounting Standard 26
As at As at31.03.2009 31.03.2008
ACQUIRED– Brands & Trademarks Useful life 5 Years 5 Years
Gross Carrying Amount (Rs. in lakh) Opening 442.78 888.41
Additions – –
Amortisation 115.63 445.63
Closing 327.15 442.78
INTERNALLY GENERATED- DMF & ANDA(Refer Note 1(b)(iv) of Schedule Q)Useful life 5 Years 5 Years
Gross Carrying Amount (Rs. in lakh) Opening 5025.16 4465.97
Additions - 868.87
Amortisation 301.60 309.68
Closing 4723.57 5025.16
24. a) Details of Group Companies
Name of Subsidiary/Joint Venture Country Type of Percentage Nature of Nature of holding of Holding Relationships Business
Orchid Europe Limited UK Equity 100% Subsidiary Marketing NCPC Orchid Pharmaceuticals Company Limited China Equity 50% Joint Venture Manufacturing Bexel Pharmaceuticals Inc.* USA Convertible @68.48% Subsidiary Research
Preferred stock with equal voting rights as Common stock and Common stock
Orchid Pharmaceuticals Inc. USA Common stock 100% Subsidiary ServicesOrgenus Pharma Inc. USA Subsidiary of Services
OrchidPharmaceuticalsInc.,
Orchid Research Laboratories Ltd. India Equity 100% Subsidiary Research Orchid Pharmaceuticals SA (proprietary) Limited South Africa Equity 100% Subsidiary Marketing
Orchid Pharma Japan KK Japan Equity 100% Subsidiary Marketing
Diakron Pharmaceuticals Inc. USA Convertible 40% Joint Venture ResearchPreferred stockand Common stock
* Preferred stock has been considered as common stock for the purpose of calculating the percentage of holding since Preferred stock has the same voting rights as common stock.
@ excluding 31.52% held through a wholly owned subsidiary
52 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
b) The Company's share of interest in Assets, Liabilities, Income and Expenses of Joint Venture companies
As at 31.03.2009 As at 31.03.2008
Fixed Assets 4014.20 2889.25
Current Assets 6229.88 4452.57
Current Liabilities 3955.62 3005.36
Loans 1910.00 1710.00
Income 11941.72 8244.30
Expenses 11026.84 7707.81
(Rs. lakh)
25. Expenditure on Research and Development
Year ended Year ended31.03.2009 31.03.2008
Capital expenditure 812.15 2564.00
Revenue expenditure charged to the Profit & Loss account 4633.46 4519.07
5445.61 7083.07
Such Capital expenditure for the year 2006-07, 2005-06 & 2004-05 are
Rs. 3934.25 lakh, Rs. 3474.14 lakh & Rs. 3262.56 lakh and revenue expenditures
for the year 2006-07, 2005-06 & 2004-05 are Rs. 3963.13 lakh, Rs. 2662.10 lakh &
Rs.1958.12 lakh respectively.The above information has been provided as required by
Department of Scientific and Industrial Research.
Revenue Research and Development Expenses include :
Power and Fuel 211.27 208.64
Conversion Charges 1.32 –
Consumption of Stores, Spares & Chemicals 945.15 1234.01
Salaries, Wages and Bonus 1841.17 1243.98
Contribution to Provident & other funds 137.43 142.67
Staff Welfare 157.31 121.01
Rates & Taxes 2.30 13.77
Insurance 13.98 20.95
Postage, Telephone & Telex 11.61 27.23
Printing & Stationery 29.76 29.73
Vehicle Maintenance 5.60 3.92
Recruitment expenses 18.22 23.48
Travelling and Conveyance 32.04 54.50
Loss on Sale of Asset 17.94 2.98
Testing Charges 564.65 895.81
Consultancy & Professional Fees 305.41 52.46
Others 338.29 443.93
4633.46 4519.07
53Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
26. A. Defined Contribution Plan
i) The Company contributes 12% of the salary for all eligible employees towards provident fund managed by the Central Government.
ii) The Company also contributes a certain percentage of salary for all eligible employees in managerial cadre towards Superannuation Funds
managed by Life Insurance Corporation of India
B. Defined Benefit Plan
As at As at As at As at31.03.2009 31.03.2008 31.03.2009 31.03.2008
Gratuity Leave Encashment(funded) (unfunded)
1) Reconciliation of opening and closing balances
of Defined Benefit obligationDefined Benefit Obligation at the
beginning of the year 819 813 734 538
Current Service Cost 132 168 101 106
Interest Cost 62 65 52 39
Acturial (gain)/ loss (260) (212) (147) 154
Benefits paid (93) (14) (169) (102)
Defined Benefit Obligation at the year end 660 819 571 734
2) Reconciliation of opening and closing balances of fair value of plan assetsFair Value of plan assets at the beginning of the year 344 406
Expected return on plan assets 38 41
Acturial gain / (loss) 54 (113)
Employer contribution 155 25
Benefits paid (93) (14)
Fair value of plan assets at year end 497 344
Actual return on plan assets (91) (72)
3) Reconciliation of fair value of assets and obligationsFair value of plan assets 497 344 – –
Present value of obligation 660 819 571 734
Amount recognised in Balance Sheet 163 475 571 734
4) Expense recognised during the year Current Service Cost 132 168 101 106
Interest Cost 62 65 52 39
Expected return on plan assets (38) (41) – –
Acturial (gain) / loss (313) (99) (147) 154
Net Cost (157) 92 6 299
5) Investment Details % Invested Funds Managed by Insurer 100% 100%
6) Acturial assumptionsDiscount rate (per annum) 8% 8% 8% 8%
Expected rate of return on plan assets (per annum) 10% 10% – –
Rate of escalation in salary (per annum) 5% 10% 5% 10%
The estimates of rate of escalation in salary considered in actuarial valuation, take into account inflation, seniority, promotion and other relevant
factors including supply and demand in the employment market. The above information is certified by the actuary.
(Rs. lakh)
54 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE ACCOUNTS
Schedule “Q” NOTES ON ACCOUNTS (Contd.)
27. On completion of winding up process of Joint Venture/Subsidiary company the value of investments amounting to Rs.134.42 lakhs (Previous year Rs.112.13lakhs) written off has been adjusted against the provision already made in earlier year amounting to Rs.134.42 lakhs (Previous year Rs.112.13 lakhs).
28. The Central Government by an order under Section 211(4) of the Companies Act,1956 dt. 23.04.2009 has exempted the Company from the disclosure ofquantitative details in compliance of para 3(i)(a), 3(ii)(a), 3(ii)(b) and 3(ii)(d) of Part II of Schedule VI of the Companies Act, 1956 for the financial year ending31-03-2009.
31. Previous year's figures have been re-grouped wherever necessary to conform to current year's classification.
(Rs. lakh)
On behalf of the BoardAs per our report of even dateFor SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
29. There have been certain delays in repayment of principal and interest to the banks as below :
Bank Principal Interest Due Date Date PaidFederal Bank 383.78 13-Aug-08 4-Sep-08
22.84 31-Oct-08 26-Feb-09451.40 13-Nov-08 25-Feb-09
24.48 30-Nov-08 26-Feb-09467.84 13-Feb-09 26-Mar-09
South Indian Bank 785.89 31-Mar-09 2-Jun-09Allahabad Bank 2500.00 31-Jul-08 27-Aug-08
2500.00 31-Aug-08 10-Oct-08250.00 13-Sep-08 10-Oct-08250.00 27-Sep-08 10-Oct-08
2500.00 30-Sep-08 10-Oct-08250.00 13-Dec-08 25-Feb-09250.00 27-Dec-08 26-Mar-09250.00 13-Mar-09 26-Mar-09
Bank of Baroda 500.00 30-Sep-08 19-Jan-09500.00 31-Dec-08 28-Jan-09500.00 31-Mar-09 30-May-09
Federal Bank 28.47 30-Sep-08 29-Nov-08767.05 30-Sep-08 31-Dec-08
30.14 31-Oct-08 28-Jan-0929.50 30-Nov-08 26-Feb-0930.52 30-Nov-08 26-Feb-09
767.05 30-Nov-08 26-Mar-09767.05 31-Mar-09 30-May-09
IDBI Bank 417.00 30-Sep-08 31-Dec-08417.00 31-Dec-08 26-Mar-09417.00 31-Mar-09 30-May-09
Indian Bank 250.00 30-Sep-08 4-Oct-08250.00 31-Dec-08 26-Mar-09250.00 31-Mar-09 2-Jun-09
Punjab and Sind Bank 88.06 31-Dec-08 24-Feb-09Syndicate Bank 250.00 31-Dec-08 26-Mar-09
250.00 31-Mar-09 30-May-09IDBI Bank 97.89 30-Nov-08 25-Feb-09
55Annual Report 2008-09
30. Sundry Debtors shown in the Balance sheet are subject to confirmations. The Company has sent confirmation letters to all the debtors. In view of therecessionary trend, some of the debtors have been requesting for discounts and the Company is in the process of negotiations with such customers. TheCompany has made adequate provisions for such estimated claims under the head “Provision for Rebates / Discounts”.
Orchid Chemicals & Pharmaceuticals Ltd.
BALANCE SHEET ABSTRACT AND COMPANY’S GENERAL BUSINESS PROFILE
Public Issue
Bonus Issue
3 1 0 3
Registration No.
Balance Sheet Date
I. Registration Details
II. Capital Raised during the year (Amount in Rs. Thousands)
Total Liabilities
III. Position of Mobilization and Deployment of Funds (Amount in Rs. Thousands)
2 0 0 9
Date Month Year
Private Placement
Paid-up Capital
Sources of Funds
Total Assets
Reserves & Surplus
IV. Performance of Company (Amount in Rs. Thousands)
Item Code No. (ITC Code) Product DescriptionV. Generic Names of Three Principal Products/Services of Company (as per monetary terms)
Net Fixed Assets Investments
Turnover Total Expenditure
Application of Funds
3 3 9 6 4 6 1 3
2 9 4 1 . 1 0 B U L K C E P H A L O S P O R I N S
3 0 0 4 . 1 0 P H A R M A P R O D U C T S
2 9 4 2 . 0 0 O T H E R B U L K D R U G S
2 2 9 9 4
7 0 4 4 2 1
1 1 9 1 4 4 0 4
Other Income 9 0 1 5 4 1
Profit/Loss before Tax – 3 6 8 4 8 2 Profit/Loss after Tax – 5 2 1 7 4 7
1 3 1 8 4 4 2 7
Earnings Per Share in Rs. Dividend– 7 . 6 1 1 0 %
2 4 1 2 1 3 2 1 2 2 3 6 8 1
Net Current Assets Misc. Expenditure7 7 8 3 8 0 6 N I L
Accumulated Losses N I L
4 5 6 0 0
Rights Issue N I L
State Code 1 8
N I L
3 1 3
3 3 9 6 4 6 1 3
5 9 9 7 7 3 0
Secured Loans Unsecured Loans1 6 9 5 0 0 9 6 9 0 1 7 4 4 6
Deferred Tax Liability 1 2 9 4 9 2 0
On behalf of the Board
K. Raghavendra RaoManaging Director
Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduDeputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
56 Orchid Chemicals & Pharmaceuticals Ltd.
CASH FLOW STATEMENT for the year ended March 31, 2009
31.03.2009 31.03.2008A. CASH FLOW FROM OPERATING ACTIVITIES
Net Profit before taxation and extraordinary item (3684.82) 23854.13
Adjustment for
Depreciation 12997.21 9766.78
Dividend Income (301.85) (1.80)
Provision for doubtful advances written back (1833.73) –
Provision for diminution in value of investments – 325.03
Provision for discounts/Rebates 4000.00 –
Gain on cancellation of FCCBs-net (6730.53) –
Loss of subsidiary companies 1501.34 1632.06
Loss / (profit) on sale of Fixed Assets 229.06 15.05
Foreign Exchange Rate Fluctuations - Unrealised (3469.02) (5474.73)
Interest Expense 15518.60 8112.63
Provision for doubtful debts – 1547.96
Operating Profit before Working Capital Changes 18226.26 39777.11
Adjustments for:
Trade and other Receivables (6631.13) (18929.19)
Inventories (11050.15) (3091.41)
Trade Payables 3209.40 7101.03
Cash generated from Operations 3754.38 24857.54
Income Taxes Paid (274.59) (3218.98)
Net Cash from Operating Activities 3479.79 21638.56
B. CASH FLOW FROM INVESTING ACTIVITIES
Purchase of Fixed Assets (46210.84) (55287.70)
Proceeds from Sale / Deletion of Fixed Assets 137.32 53.44
Investments in Subsidiaries (854.81) (136.22)
Dividends received 301.85 1.80
Net cash used in Investing Activities (46626.48) (55368.68)
(Rs. lakh)
57Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
CASH FLOW STATEMENT (Contd.) for the year ended March 31, 2009
31.03.2009 31.03.2008C. CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of Share Capital (net of expenses) 10951.54 67.88
Proceeds from /(Repayment)Working Capital Borrowings 6722.49 16433.04
Proceeds from Long Term Borrowings 92250.93 43868.13
Repayment of Long Term Borrowings (29422.58) (33143.14)
Proceeds /cancellation of FCCBs (net of expenses) (5632.39) –
Proceeds from / (Repayment of) Short Term Borrowings (9995.99) 12000.00
Proceeds from /(Repayment of) HP Finance (29.23) (20.95)
Interest paid (19503.59) (12091.76)
Dividend paid including dividend distribution tax (2472.41) (2310.46)
Net cash from Financing Activities 42868.77 24802.74
D. NET INCREASE IN CASH AND CASH EQUIVALENTS (277.92) (8927.38)
Cash and Cash equivalents at the beginning of period 1628.15 10555.53
Cash and Cash equivalents at the end of period 1350.21 1628.15
Reconciliation Statement
Cash and bank Balances as per Balance sheet 4152.04 2284.84
Less : Margin Money Deposit 2746.62 604.08
Unclaimed Dividend 55.21 52.61
Cash and cash Equivalents as per cash flow 1350.21 1628.15
(Rs. lakh)
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
58 Orchid Chemicals & Pharmaceuticals Ltd.
CONSOLIDATED AUDITORS’ REPORT
1. We have audited the attached Consolidated Balance Sheet of OrchidChemicals & Pharmaceuticals (the “Company”) and its subsidiaries andjoint ventures (together the “Group”), as at March 31, 2009 and theConsolidated Profit and Loss Account and the Consolidated Cash Flowstatement for the year then ended. These financial statements are theresponsibility of the Company’s management. Our responsibility is toexpress an opinion on these consolidated financial statements basedon our audit.
2. We conducted our audit in accordance with the generally acceptedauditing standards in India. These standards require that we plan andperform the audit to obtain reasonable assurance about whether thefinancial statements are prepared, in all material respects, inaccordance with an identified financial reporting framework and arefree of material misstatements. An audit includes, examining on a testbasis, evidence supporting the amounts and disclosures in the financialstatements. An audit also includes assessing the accounting principlesused and significant estimate made by management, as well asevaluating the overall financial statements presentation. We believethat our audit provides a reasonable basis for our opinion.
3. a) The financial statements of a subsidiary which represents as atMarch 31, 2009, total liabilities (net) of Rs. 585.80 lakh (Previousyear Rs. 422.07 lakh) and total revenue for the year ended of Rs. 151.97 lakh (Previous year Rs. 447.18 lakh) has been audited byother auditors and we have relied upon such audited financialstatements for the purpose of our audit of the ConsolidatedFinancial Statements and our opinion, insofar as it relates to theamounts included in respect of such subsidiary is based solely onthe report of the other auditors.
b) The audited financial statements for the year ended March 31, 2009were not available in respect of four subsidiaries and two jointventures of the Company. Consequently, such subsidiaries and jointventures have been accounted for in the Consolidated FinancialStatements, on the basis of unaudited financial statementsprovided by the management of such subsidiaries and jointventures. The total assets (net) of Rs. 1994.51 lakh as at March 31,2009 (Previous year Rs. 699.78 lakh) and total revenue for the yearthen ended of Rs. 12307.83 lakh (Previous year Rs. 8244.30 lakh)in respect of such subsidiaries and share of joint ventures areincluded in the Consolidated Financial Statements.
Our opinion, in so far as it relates to the amounts included inrespect of such subsidiaries and joint ventures, is based solely onthe accounts as approved by the management of such subsidiariesand joint ventures.
4. The company has made an application to Central Government forapproval of the remuneration amounting to Rs.343.45 lakhs paid to theManaging Director and whole time Director as the minimumremuneration payable in case of inadequacy of profit and the approval
of the same is still awaited.
5. Debtors are subject to confirmation. Refer Note No. 23 of Schedule ‘P’to the Consolidated Financial Statements.
6. Subject to our remark in Para 3 (b) and 5 above:
a. We report that the consolidated financial statements have been prepared by the company in accordance with the requirements of Accounting standards –
AS – 21 - Consolidated financial statements
AS – 27 - Financial Reporting of Interests in Joint ventures, on thebasis of the separate audited financial statements of OrchidChemicals & Pharmaceuticals Limited and a subsidiary and theaudited/unaudited financial statements of subsidiary companiesand joint venture companies as mentioned above, considered inthe consolidated financial statements.
b. In our opinion, on the basis stated in paragraph (2) above, and onthe consideration of separate audit reports on and managementapproved accounts of individual financial statements of thecompany, its aforesaid subsidiaries and joint ventures, theconsolidated financial statements give a true and fair view inconformity with the accounting principles generally accepted inIndia:
i. In the case of the Consolidated Balance Sheet, oftheconsolidated state of affairs of the Group as at 31st March2009;
ii. In the case of the Consolidated Profit and Loss Account, of theconsolidated results of operations of the Group for the yearended on that date; and
iii. In the case of the Consolidated Cash Flow Statement, of theconsolidated cash flows of the Group for the year ended onthat date.
7. a. Attention is drawn to the remarks of the Auditors of a subsidiarycompany given in the Note No. 7 of Schedule ‘P’ to theConsolidated Financial Statements.
b. Attention is drawn to Note No. 2 (J) (4) of Schedule P to theConsolidated Financial Statements regarding adoption of amendedAccounting Standard (AS-11) and the impact on the same on theloss for the year of the company.
For SNB Associates
Chartered Accountants
B. Mahalingam
Place: Chennai Partner
Date: June 29, 2009 Membership No. 210408
To The Board of DirectorsOrchid Chemicals & Pharmaceuticals Limited
Auditors’ Report on Consolidated Financial Statements of Orchid Chemicals & Pharmaceuticals Limited and its Subsidiaries, and JointVentures
59Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
CONSOLIDATED BALANCE SHEET as at March 31, 2009
Schedule 31.03.2009 31.03.2008
I. SOURCES OF FUNDS
A. Shareholders’ Funds
Share Capital A 7044.21 6585.08
Reserves and Surplus B 56335.59 59912.92
B. Loan Funds
Secured Loans C 171410.97 97956.15
Unsecured Loans – –
From Banks 11004.01 21000.00
Foreign Currency Convertible Bonds (Refer Note 8) 79170.45 78098.18
C. Deferred Tax Liability (Refer Note 16 (a) of Schedule P) 12846.91 11490.53
Total 337812.14 275042.86
II. APPLICATION OF FUNDS
D. Fixed Assets D
Gross Block 269566.33 209812.30
LESS Depreciation 68815.62 55816.98
Net block 200750.71 153995.32
Capital Work in Progress 38907.09 38354.91
Advance for capital items 15762.66 255420.51 23657.04 216007.27
E. Investments 81.19 81.19
F. Foreign currency Monetary item Translation difference Account 8357.94 –
G. Current Assets, Loans And Advances
Inventories E 76825.38 64915.45
Sundry Debtors F 67254.12 53793.57
Cash and Bank Balances G 5250.68 3103.90
Other Current Assets H – 13.18
Loans and advances I 10205.71 10508.39
159535.89 132334.49
H. Less Current Liabilities and Provision J 85583.39 73380.09
73952.50 58954.40
Total 337812.14 275042.86
Notes on accounts P
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
(Rs. lakh)
60 Orchid Chemicals & Pharmaceuticals Ltd.
CONSOLIDATED PROFIT AND LOSS ACCOUNT for the year ended March 31, 2009
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
Schedule 31.03.2009 31.03.2008
I. INCOME
Sales & Operating Income K 130862.28 131222.91
Less : Excise Duty 1177.39 129684.89 1126.52 130096.39
Other Income L 8605.40 7130.37
138290.29 137226.76
II. EXPENDITURE
Material Cost M 58561.90 47931.81
Manufacturing, Selling & Other Expenses N 54065.78 48170.56
Interest and Finance charges O 15645.01 8200.05
Depreciation / Amortisation 13399.25 10067.84
141671.94 114370.26
III. PROFIT/(LOSS)
Profit/(Loss) for the year before tax (3381.65) 22856.50
Less : Provision for tax
Current Taxes 0.69 2908.98
Fringe Benefit Tax 167.25 159.00
Deferred Taxes (Refer Note 16 (a) of Schedule P) 1349.40 1517.34 2254.53 5322.51
Profit/(Loss) for the year after tax (4898.99) 17533.99
Balance brought forward 1126.98 (2100.70)
Balance Available for Appropriation (3772.01) 15433.29
IV. APPROPRIATIONS
Excess provision of dividend & tax thereon of earlier year written back (963.71) (1129.82)
Proposed Dividend 915.84 2936.99
Tax on proposed dividend 155.65 1071.49 499.14 3436.13
Transfer to General Reserve – 12000.00
Balance carried to Balance Sheet (3879.79) 1126.98
V. EARNINGS PER SHARE (Face value of Rs. 10/-each)
Basic (7.14) 26.93
Diluted (7.14) 17.91
Notes on Accounts P
(Rs. lakh)
61Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008
Authorized10,00,00,000(Previous year 10,00,00,000) Equity Shares of Rs. 10/- each 10000.00 10000.00Issued, Subscribed and Paid-up7,04,42,076(Previous year - 6,58,50,776) equity Shares of Rs. 10/- each fully paid. 7044.21 6585.08Of the above:
1,73,76,940 Equity shares of Rs. 10/- each were allotted as fully paid
bonus shares by capitalisation of reserves.
Schedule “A” SHARE CAPITAL
(Rs. lakh)
All Rupee Term Loans and Foreign Currency Term Loans from Banks & Financial Institutions are secured by Pari Passu charge by way of joint mortgage on immovable
and movable assets situated at Factory premises at SIDCO Industrial Area, Alathur, MIDC Industrial Area, Aurangabad, SIPCOT Industrial Park, Irungattukottai and
Capital Reserve– Opening Balance 805.54 805.54
– Additions during the year 89.14 894.68 – 805.54
Securities Premium Account– Opening Balance 24780.46 21635.38
– Additions during the year* (Ref Note 8 (c) of Schedule P) 8336.90 3145.08
33117.36 24780.46 Deductions during the year– Provision for premium on redemption of FCCBs – –
– GDR/FCCB issue expenses adjustment – 33117.36 – 24780.46
General Reserve– Opening Balance 28060.01 16670.51
– Less : Adjustment for Retirement Benefits** – (610.50)
– Less : Adjustment for AS11 (5347.94) –
– Add : Transfers during the year **(Refer Note.2(i) of Schedule P) – 22712.07 12000.00 28060.01
Foreign Currency Fluctuation Reserve– Opening Balance (69.86) (128.88)
Adjustments 719.64 649.78 59.02 (69.86)
Surplus in Profit & Loss Account (3879.79) 1126.98
Adjustment on consolidation 2841.49 (1038.30) 5209.79 6336.77
(* includes Exchange rate gain/(loss) on provision for premium on redemption of
FCCB Rs. (7414.30) lakh (Previous year Rs. 3079.69 lakh)) 56335.59 59912.92
Schedule “B” RESERVES & SURPLUS
From Banks
– Rupee Term Loans 92064.85 36115.13
– Foreign Currency Term Loans 24261.25 13,646.40
– Rupee & Foreign Currency Packing Credit/Cash credit & Advance against Bills 53021.00 46298.51
169347.10 96060.04
From Financial Institutions
Foreign Currency
– Term Loans 1910.00 1710.00
– Working Capital Loans – 1910.00 – 1710.00
Hire Purchase Finance 153.87 186.11
171410.97 97956.15
Schedule “C” SECURED LOANS
62 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS as at March 31, 2009
R&D premises at Sholinganallur and current assets, subject to prior charges created/ to be created on current assets in favour of bankers and financial institutions
for securing working capital borrowings. Total term loans aggregating Rs. 82,927 lakh are additionally secured by personal guarantee of Shri K. Raghavendra Rao,
Managing Director of the Company.
Packing Credit and Advances against bills from Banks and Working Capital Loans from Banks and financial institutions are secured by first charge on all current
assets namely, Stocks of Raw materials, Semi-finished & Finished Goods, Stores and Spares not relating to Plant & Machinery (Consumable Stores and Spares),
Bills Receivable, Book Debts & all other movable property both present and future excluding such movables as may be permitted by the banks/ financial institutions
from time to time and by second charge on immovable properties after charges created/ to be created on immovable assets in favour of Financial Institutions/Banks
for securing Term Loans. The borrowings from banks are additionally secured by personal guarantee of Shri. K. Raghavendra Rao, Managing Director of the
Company.
Hirepurchase Loans are secured by the assets acquired through such loans.
Schedule “D” FIXED ASSETS
Gross Block (At Cost) Depreciation/Amortization Written Down ValueSL Asset Description As at Additions Deletions As at Up to For On Up to As at As atNo. 1.4.2008 during during 31.3.2009 31.3.2008 the year Deletions 31.3.2009 31.3.2009 31.3.2008
the year the year
1. Goodwill On Consolidation* 9482.32 – – 9482.32 – – – – 9482.32 9482.32
2. Freehold Land &
Site Development@ 3180.04 – – 3180.04 – – – – 3180.04 3180.04
3. Leasehold Land@ 2581.52 11.59 – 2593.11 46.84 9.24 – 56.08 2537.03 2534.68
4. Buildings 24166.41 16162.91 – 40329.32 3027.54 881.64 – 3909.18 36420.14 21138.87
5. Plant & Machinery 145966.30 39486.31 731.51 184721.10 44402.52 10997.90 227.49 55172.93 129548.17 101563.78
6. Factory Equipment 1454.93 263.62 0.88 1717.67 660.83 142.34 0.55 802.62 915.05 794.10
7. Laboratory Equipment 9079.09 3608.88 18.04 12669.93 1883.20 551.81 17.41 2417.60 10252.33 7195.89
8. Office Equipment 2067.53 524.18 163.29 2428.42 1131.54 219.23 131.93 1218.84 1209.58 935.99
9. Furniture & Fittings 1717.31 289.18 21.53 1984.96 563.63 149.28 8.84 704.07 1280.89 1153.68
10. Vehicles 749.88 99.12 189.41 659.59 201.85 62.47 78.32 186.00 473.59 548.03
11. Intangible Assets
Acquired
Brands & Trademarks ** 2778.16 – – 2778.16 2335.38 115.63 – 2451.01 327.15 442.78
Patents & Registrations – 432.90 – 432.90 – 32.04 – 32.04 400.86 –
Internally Generated
DMF & ANDA *** 6588.81 – – 6588.81 1563.65 301.60 – 1865.25 4723.56 5025.16
Total 209812.30 60878.69 1124.66 269566.33 55816.98 13463.18 464.54 68815.62 200750.71 153995.32
Previous Year Figures 156337.91 53629.07 154.68 209812.30 45797.56 10067.84 48.42 55816.98 153995.32
As at As at 31.3.2009 31.3.2008
Rs. lakh Rs. lakh@ Assets acquired pending for registration in favour of the Company.
Freehold Land 59.09 59.09
Leasehold Land – 1,756.54
Fixed Assets include assets on Hire Purchase (Gross Block) 306.10 294.74
* Refer Note 2 (e) of Schedule - P
** Represents value of registrations and value of applications filed Pending registration
*** Refer Note 2 (b) (v) of Schedule - P
(Rs. lakh)
63Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
Debts more than 6 months (Unsecured)
Considered Good 48017.26 21284.68
Considered Doubtful 1615.11 1666.24
Other Debts (Considered Good)
Secured 217.94 233.81
Unsecured 19018.92 32275.08
68869.23 55459.81
Less: Provision for Doubtful Debts 1615.11 1666.24
67254.12 53793.57
Schedule “F” SUNDRY DEBTORS
Cash In Hand 10.27 9.69
Balances With Scheduled Banks On:Current account 1330.83 891.66
Term Deposit account 2100.82 713.52
Margin money deposit 645.80 604.08
Share Application money and Dividend account 55.21 52.61
Balances With Other Banks On:Current account 23.16 34.04
Others 1084.59 798.30
5250.68 3103.90
Schedule “G” CASH AND BANK BALANCES
Interest accrued on deposits and advances – 13.18
– 13.18
Schedule “H” OTHER CURRENT ASSETS
SCHEDULES TO THE CONSOLIDATED ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008
Raw materials 16436.06 11669.64
Stores and Spare parts 2558.15 2898.26
Chemicals and Consumables 1129.30 1115.90
Packing Materials 1515.77 1551.85
Intermediates & WIP 43721.48 36748.99
Finished Goods 10654.80 10381.06
Traded Goods 809.82 549.75
76825.38 64915.45
Schedule “E” INVENTORIES (Refer Note 2 (g), Schedule "P")
(Rs. lakh)
64 Orchid Chemicals & Pharmaceuticals Ltd.
31.03.2009 31.03.2008
Acceptances 541.34 2028.26
Sundry creditors (other than Micro, Small & Medium Scale Enterprises) for
– Capital Items 5949.06 4423.44
– Other supplies 24583.97 21015.20
– Expenses [Includes due to Directors - Rs. 21 lakh (Previous year - Rs. 400 lakh)] 7935.31 2156.58
Investor Education and Protection Fund shall be credited
by the following amounts namely: *
– Unclaimed Dividend 55.21 52.61
– Share Application Money Refundable 5.42 5.42
Premium payable on redemption of FCCBs (Ref Note 8 c) 34254.36 33750.35
Other liabilities [Refer Note 15 (b)] 2600.74 2114.20
PROVISIONS FOR
– Retirement Benefit 1231.37 1043.47
– Rebates/Discounts 4000.00 –
– Taxation 3355.12 3354.43
– Proposed Dividend 915.84 2936.99
– Tax on Proposed Dividend 155.65 499.14
85583.39 73380.09
* Represents balances in those accounts as of 31st March, Actual amount to be transferred to the Investor Education and Protection Fund will be determined
on due dates.
Schedule “J” CURRENT LIABILITIES AND PROVISIONS
(Rs. lakh)
SCHEDULES TO THE CONSOLIDATED ACCOUNTS as at March 31, 2009
31.03.2009 31.03.2008
Considered Good
Advances recoverable in cash or kind or for value to be received 4972.24 5506.74
Advance Payment of Tax 4100.88 3987.29
Deposits
– With Government authorities 508.83 342.29
– Others 623.76 672.07
Considered Doubtful
– Others 205.33 2039.06
10411.04 12547.45
Less: Provision for Doubtful Advances 205.33 2039.06
10205.71 10508.39
Schedule “I” LOANS AND ADVANCES (Unsecured)
(Rs. lakh)
65Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS for the year ended March 31, 2009
31.03.2009 31.03.2008
Sales 127161.16 126461.78
Less : Excise Duty 1158.68 126002.48 1123.64 125338.14
Operating Income
Income from services rendered
– Technical & Consultancy Fees (TDS - Rs. Nil (Previous year - Rs. NiI)) 30.58 2.88
Contract Research & Development 393.05 272.79
Sale of Other Materials 472.93 321.51
Less : Excise Duty 18.71 454.22 2.88 318.63
Development Fee 1938.09 3206.67
Licence Fee 713.23 860.82
Other Operating Income 153.24 96.46
129684.89 130096.39
Schedule “K” SALES & OPERATING INCOME
(Rs. lakh)
Income from Investments
Dividend (Refer Note 10 of Schedule P) 4.00 1.80
Exchange Rate Loss/ (Gain) on FCCB – 7126.67
Gain on cancellation of FCCBs-net 6730.53 –
Provision for doubtful debts written back 1833.73 –
Profit on sale of fixed assets 2.92 1.90
Miscellaneous Income 34.22 –
8605.40 7130.37
Schedule “L” OTHER INCOME
Raw Materials Consumed 58623.82 44055.58
Cost of Traded Goods 3367.60 61991.42 2610.12 46665.70
Less: (Accretion) / Depletion to Stocks
Closing Stock of Intermediates, WIP & Finished Goods 54376.28 47130.05
Opening Stock of Intermediates, WIP & Finished Goods 47130.05 (7246.23) 44599.57 (2530.48)
Consumption of Packing Materials 3816.71 3796.59
58561.90 47931.81
Schedule “M” MATERIALS COST
66 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS for the year ended March 31, 2009
31.03.2009 31.03.2008
Power and Fuel 7755.35 7290.17
Conversion Charges 1760.00 2100.82
Consumption of Stores, Spares & Chemicals 2806.81 3902.74
Factory Maintenance 2594.74 2184.19
Salaries and Wages 11499.63 9727.16
Contribution to Provident & other funds 1083.49 795.09
Staff Welfare 1162.94 1191.93
Rent 194.85 112.68
Rates & Taxes 177.98 153.20
Insurance 1216.48 1403.17
Postage, Telephone & Telex 168.10 174.16
Printing & Stationery 252.69 261.67
Vehicle Maintenance 64.98 75.19
Research & Development (Refer Note 20 of Schedule P) 4647.76 4877.53
Advertisement 36.49 41.33
Recruitment expenses 160.47 313.97
Auditors' Remuneration
Statutory Auditors [Refer Note 9 of Schedule P] 85.34 98.08
For certification & other matters 0.28 –
Cost Auditors 11.24 11.06
Travelling and Conveyance 1429.81 1258.30
Directors' Remuneration & perquisites 343.44 707.75
Directors' travelling
Inland 13.53 11.28
Overseas 29.62 62.04
Directors' sitting fees 14.20 15.20
Loss on sale of fixed asset 214.05 13.98
Freight outward 2400.74 2122.77
Commission on Sales 1049.00 1304.82
Business Promotion and Selling Expenses 1585.02 1587.66
Consultancy & Professional Fees 2721.09 2205.96
Exchange Rate Loss/(Gain) 1592.69 770.94
Provision for Rebates/Discounts 4000.00 –
Provision for doubtful debts & advances – 1552.39
Bad debts and advances written off – –
Miscellaneous expenses 2992.97 1843.32
54065.78 48170.56
Schedule “N” MANUFACTURING, SELLING AND OTHER EXPENSES
(Rs. lakh)
Interest on Term Loans 5245.90 1887.57
Other Interest & Finance Charges 10399.11 6312.48
15645.01 8200.05
Schedule “O” INTEREST AND FINANCE CHARGES (Refe Note 11)
67Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
1. a) The Company and description of businessOrchid Chemicals & Pharmaceuticals Limited was incorporated in India in July 1992 and started commercial production in February 1994. The Company
manufactures and sells active pharmaceuticals ingredients and finished dosage forms (formulations) as applicable under 100% export oriented unit
scheme(s) in export and domestic markets. The Company also has full fledged R & D facilities. The Company has invested in the following companies :
a) Orchid Europe Limited, a company formed in the United Kingdom initially to market neutraceuticals through mail order/ direct marketing in the
United Kingdom and Europe, and now to support the Company’s generics foray in UK and Europe.
b) NCPC Orchid Pharmaceuticals Company Limited incorporated in China, engaged in the business of manufacture and sale of bulk drugs.
c) Bexel Pharmaceuticals, Inc., USA engaged in pharmaceutical research and development.
d) Orchid Pharmaceuticals, Inc., USA to provide services in USA. It has a wholly owned subsidiary "Orgenus Pharma Inc, USA" which provides services
in USA.
e) Orchid Research Laboratories Limited, India engaged in pharmaceutical research and development.
f) Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa to register and market formulations in South Africa
g) Orchid Pharma Japan KK, to support marketing of bulk drugs and formulations in Japan
h) Diakron Pharmaceuticals Inc., USA engaged in Pharmaceutical research and development
The Company, its Subsidiaries and its Joint Ventures are collectively referred as "the Group".
b) ConsolidationThe Company's consolidated financial statement has been prepared on the following basis.
c) Convenience TranslationThe accounts of the subsidiary companies and Joint Venture companies have been prepared in their respective currencies.. For the purpose of
convenience the balances are translated into Indian currency, being the reporting currency in the consolidated financial statements, at the closing
rate as at March 31.
Schedule “P” NOTES ON ACCOUNTS
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Name of Subsidiary/ Joint venture Country Type of Percentage Nature of Accounting
Holding of holding relationship standard adopted
for consolidation
of accounts
Orchid Europe Limited U.K Equity 100% Subsidiary A S 21*
Orchid Pharmaceuticals, Inc. USA Common stock 100% Subsidiary A S 21*
Orgenus Pharma Inc. USA Subsidiary of Orchid
Pharmaceuticals Inc.
Orchid Research Laboratories Ltd. $ India Equity 100% Subsidiary A S 21*
Orchid Pharmaceuticals SA (Proprietary) Limited South Africa Equity 100% Subsidiary A S 21**
NCPC Orchid Pharmaceuticals Company Limited China Equity 50% Joint Venture A S 27**
Bexel Pharmaceuticals, Inc.*** $ USA Convertible Preferred $68.48% Subsidiary A S 21**
stock with equal voting
rights as Common stock
and Common stock
Orchid Pharma Japan KK Japan Equity 100% Subsidiary A S 21*
Diakron Pharmaceuticals, Inc. USA Convertible Preferred 40% Joint Venture A S 27**
stock and Common stock
* based on the Audited accounts
** based on the Management approved accounts
*** Preferred stock has been considered as common stock for the purpose of calculating the percentage of holding since Preferred stock has the same voting rights as commonstock.
$ Excluding 31.52% held through a wholly owned subsidiary.
68 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
2. Group Significant Accounting Policiesa) Accounting Convention
The Financial Statements are prepared under historical cost convention. Revenues are recognised and expenses are accounted on their accrual withnecessary provisions for all known liabilities and losses.
b) Fixed Assetsi) Fixed Assets are stated at the original cost inclusive of inward freight, incidental expenses related to acquisition and related pre-operational
expenses and technical knowhow fees where applicable.
ii) Machinery spares which can be used only in connection with specific fixed assets and the use of which are irregular, are charged over the periodof the life of such fixed asset, in accordance with Accounting Standard (AS 10).
iii) Brands represent brands acquired by the Company and includes IPR & Licences purchased for a consolidated consideration. The cost of brands,patents and trademarks are amortised over a period of 60 months from the month of acquisition.
iv) The cost of patents / registrations acquired by subsidiaries / joint venture are amortised over their useful life after they are put to use.
v) INTERNALLY GENERATED INTANGIBLE ASSETS - DMF & ANDADMF and ANDA costs represents expenses incurred on development of processes and compliance with regulatory procedures of the US FDA, in filingDrug Master Files("DMF") and Abbreviated New Drug Applications("ANDA"), in respect of products for which commercial value has been establishedby virtue of third party agreements/arrangements. This is in accordance with the requirements of Accounting Standard 26. The cost of eachDMF/ANDA is amortised to the extent of recovery of developmental costs as applicable per terms of agreement or over a period of five years fromthe date on which the product covered by DMF/ANDA is commercially marketed, whichever is earlier.
vi) Assets are depreciated on straight line basis at the rates specified in Schedule XI of the Companies Act, except in respect of the following assets,where the useful lives reckoned in computing the depreciation for the year are different from those derived from the rates specified in ScheduleXI of the Companies Act, 1956. The revised useful life of the assets have been determined by the Management based on technical assessment.Depreciation in the books of Subsidiaries/Joint Ventures have not been restated, since the differences are not material.
Asset Categories Useful lifeReactors, Pipes, Pipe fittings, Valves, Motors, Pumps, Nitrogen Plant, Gear Boxes, Cables and Centrifuges 9 yearsEvaporator(Indigenous), Jet aeration system(indigenous), Ventilation & Exhaust system, HCL column,ETP(indegenous), scrubber, incinerator (indigenous) & Instrumentation items.
Depreciation is provided at rate arrived based on useful life or Schedule XI rates whichever is higher.
vii) Leasehold assets cost is amortised over the period of the Lease.
viii) Depreciation on assets added/disposed off during the year is provided on pro-rata basis from the month of addition or up to the month of disposal,as applicable.
ix) Impairment of assets:Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired. An impairmentoccurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the assets and itseventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net salesprice or present value as determined above.
c) Borrowing CostsInterest cost on qualifying asset being an asset that necessarily takes a substantial period of time to get ready for its intended use or sale, is capitalisedat the weighted average rate of the funds borrowed and utilised for acquisition of such assets.
d) Treatment of expenditure during construction period.Expenditure during construction period is included under capital work-in-progress and the same is allocated to the respective fixed assets on thecompletion of construction.
e) The excess of cost to the Company of its interest in subsidiaries / joint ventures over its share of net assets of such subsidiaries / joint ventures at thedate of acquisition of interest is recognised as goodwill on consolidation.Goodwill arising on consolidation is not amortised.
Schedule “P” NOTES ON ACCOUNTS (Contd.)
69Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
f) InvestmentsInvestments considered long term are shown at cost. Diminution in the value of investments other than temporary are provided for. Current investmentsare valued at lower of cost and market value.
g) Inventoriesi) Stores & Spares – At weighted average cost.ii) Raw Materials – At annual weighted average costiii) Finished Goods @ – At Lower of cost & net realisable valueiv) Work in Progress & Intermediates @ – At Lower of cost & net realisable value
@ After adjustment of unrealised profits on inter division transfer.
h) Revenue RecognitionSales are recognised on despatch of goods from the factory/ warehouse and price differentials are accounted for at the end of each quarter as per theterms of marketing arrangements. Sales are net of returns, discounts and inter-division transfers. Service income is recognised as per contractual terms.In respect of composite contracts involving development and other activities, income is recognised on the basis of contractual terms after consideringthe quantum of work completed.
i) Retirement BenefitsRetirement Benefits are accounted on acturial valuation carried out at the end of the year. The Company's liability towards the gratuity of employees iscovered by a group gratuity policy with LIC and ICICI Prudential Life Insurance Company Ltd and the contribution to the fund is based on actuarialvaluation carried out yearly as at 31st March as per the revised AS15. Provision for Leave Encashment has been made based on actuarial valuation as atthe year end as per revised AS15.
j) Translation of Foreign Currency items1) Non - Monetary foreign currency items are carried at cost2) All inter-related transactions are recognised at common rates.3) Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction.4) Monetary items denominated in foreign currencies at the year end are restated at year end rates. In case of items which are covered by forward
exchange contracts, the difference between the year end rate and the rate on the date of the contract is recognised as exchange difference andthe premium paid on forward contracts is recognised over the life of the contract.
The Company has exercised the option provided under the amendment to the Companies (Accounting Standards) Amendment Rules, 2006 dated March31, 2009 AS 11. The exercise of the above option has resulted in (a) Rs. 5347.94 lakh relating to previous year adjusted in General Reserve (b) amountremaining unamortised in the financial statements as on March 31, 2009 is Rs. 8357.94 lakh (c) The value of fixed assets adjusted for exchange loss isRs. 2994.32 lakh resulting in depreciation amount being more by Rs. 33.73 lakh (d) loss for the year is lower by Rs. 16666.46 lakh.
k) Subsidy on Fixed AssetsSubsidy received on fixed assets is credited to the cost of respective fixed assets.
3. Sales tax recoverable have been recorded on the basis of the claims submitted or in the process of being submitted, as per rules relating to EOU and whichin the opinion of the Company are recoverable.
Schedule “P” NOTES ON ACCOUNTS (Contd.)
As at 31.03.2009 As at 31.03.20084. Estimated amounts of contracts remaining to be executed on 10712.57 13063.43
capital account (net of advances) and not provided for.5. a. Other monies for which company is contingently liable :
– Bills Discounted 21402.71 21395.61 – Unexpired Letters of Credit 13295.03 15217.56 – Bank Guarantees outstanding 518.89 946.82 – Claims against the Company not acknowledged as debts – – Excise demands under dispute pending before Excise authorities 1182.43 861.50 Service Tax dispute pending before High Court of Chennai 103.16 56.03
b. Provision and contigencies in accordance with AS 29 :Opening Balance – – Additions during the year 4000.00 – Closing Balance 4000.00 –
(Rs. lakh)
70 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
Particulars FCCBs Value Number of Increase in Increase in Security
Shares Equity Premium
US$ million in lakh Rs. lakh Rs. lakh
Conversion effected up to March 31, 2009 22.79 42.00 420.09 9821.71
22.79 42.00 420.09 9821.71
71Annual Report 2008-09
6. The Company has filed an appeal against the demand made by the Income Tax department amounting to Rs. 98.94 lakh (Previous year Rs. 53.82 lakh). No
provision has been made as the Company is confident of winning the appeal. No provision has also been made for demand of interest amounting to Rs. 68.88
lakh (Previous year Rs. 68.88 lakhs) as petition has already been filed for waiver of interest.
7. In the financial statements for the year ended December 31, 2008 of Bexel, prepared as a Development Stage Enterprise, the auditors of the Company have
referred to Note 2 to the financial statements and expressed an opinion that the successful completion of the Company's development program and ultimately
the attainment of profitable operations is dependant upon future events, including maintaining adequate financing to fulfil its development activities and
achieving a level of revenues adequate to support the Company's cost structure. The text of Note 2 referred to is reproduced below.
"The financial statements of the Company have been prepared in conformity with Statement of Financial Accounting Standards (“SFAS”) No. 7, Accounting
and Reporting by Development Stage Enterprises, and assume the Company will continue as a going concern. As a development stage company, with no
commercial operating history, the Company is subject to all of the risks and expenses inherent in the establishment of a new business enterprise. To address
these risks and expenses, the Company must, among other things, respond to competitive developments, attract, retain and motivate qualified personnel and
support the expense of marketing new products based on innovative technology. To date, the Company has incurred expenses in research and development
activities without generating sufficient revenues to offset those expenses. As a result the Company has incurred losses and negative cash flow from operating
activities, and as of December 31, 2008, the Company had accumulated net losses of USD 22,246,475. There can be no assurance that management will achieve
the intended results".
8. Foreign Currency Convertible Bonds (FCCBs):a) The Company raised FCCBs during the year 2006-07 aggregating to USD 175 million (Rs. 77358.75 lakh) with an option to the investor to convert the
FCCBs into equity shares of the Company at an initial conversion price of Rs. 348.34 per share at a fixed rate of exchange on conversion Rs. 43.93 = USD
1, at any time after April 9, 2007 and prior to February 18, 2012. Further the Company has an option of early redemption of these FCCBs in whole at any
time on or after February 28, 2010 and prior to February 21,2012, subject to certain conditions. Unless previously converted, redeemed or repurchased
and cancelled, the FCCBs will be redeemed on February 28, 2012 at 142.77 % of their principal amount.
During the year 2008-09, the Company bought FCCBs to the extent of USD 37.80 million and the outstanding FCCBs as at March 31, 2009 is USD 137.20
million.
b) The Company raised FCCBs during the year 2005-06 aggregating to USD 42.50 million (Rs. 19284.50 lakh) including a green shoe option of USD 5 million
(Rs. 2289.50 lakh) with an option to the investor to convert the FCCBs into equity shares or global depository receipts at an initial conversion price of
Rs. 243.80 per share at a fixed rate of exchange on conversion Rs. 44.94 = USD 1. Out of the above, FCCBs amounting to USD 22.79 million (Rs. 10241.82
lakh) have been so far converted.
Further, the Company has an option of early redemption of these FCCBs at any time after November 03,2006 subject to certain conditions. Unless
previously converted, redeemed or repurchased and cancelled, the FCCBs will be redeemed on November 03,2010 at 147.1688% of their principal amount.
During the year 2008-09, the Company bought FCCBs to the extent of USD 2.25 million and the outstanding FCCBs as at March 31, 2009 is USD 17.46
million.
The current status of above FCCBs conversion into equity is as follows:
c) Provision has already been made for the entire premium payable on redemption of FCCBs amounting to Rs. 36830.08 lakh by debiting the Securities
Premium Account (SPA). In the event that the conversion option is exercised by the holder of FCCBs in the future, the amount of premium charged to
SPA will be suitably adjusted in the respective years.
The debit to share premium account for premium on FCCBs and for issue expenses have been made on the gross value without adjusting any tax impact.
Tax benefits accruing to the Company on account of claiming such expenses will be credited to the SPA account in the year in which the benefit is enjoyed
by the Company.
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
As at 31.03.2009 As at 31.03.2008
e) Usage of funds raised through FCCBs
Opening Balance 6.85 10117.21
Funds received – –
Add: Interest received – –
Less: Expenses of Issue/Exchange fluctuations (0.96) 168.24
7.81 9948.97
Repayment of Loans – –
Capital Expenditure/ Advances/ ANDA filings – 9942.12
Balance 7.81 6.85
(Rs. lakh)
Year ended Year ended31.03.2009 31.03.2008
9. Auditors' remuneration include the following:
Statutory – Audit fee 50.00 50.00
– Tax Audit fee 7.50 7.50
For certification & other matters 9.50 8.50
Others 18.34 32.08
85.34 98.08
10. Dividend includes the following
Non-trade 4.00 1.80
4.00 1.80
11. a) Other Interest and Finance Charges is after crediting interest receipts 100.83 38.92
TDS on interest receipts 15.32 6.98
b) Amount of interest capitalised 4541.23 3979.13
12. Excise duty on finished goods has been accounted on removal of goods from factory, wherever applicable. Finished goods at factory have been valued at
cost exclusive of excise duty and no provision has been made for excise duty on such goods. The above treatment has no impact on Profit & Loss account.
(Rs. lakh)
The provision for premium on redemption of FCCBs debited to SPA is being restated at the exchange rate prevailing at the year end and the gain/(loss)
of (Rs. 7414.30) lakh on account of such restatement is adjusted to the security premium account.
d) Even though the Company has provided for the premium on redemption of FCCBs as per note [c] above, the Company also makes provision for dividend
in the books of account on the equity shares to be allotted upon conversion of FCCBs outstanding as at respective year end. since the Company is obliged,
as per SEBI guidelines, to pay dividend to those FCCBs holders who convert their FCCBs into equity after adoption of the financial statements and upto
the book closure date.
72 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
13. Related Party TransactionsIn accordance with Accounting Standard 18, the disclosure required is given below:
Nature of Transaction Subsidiary Joint venture Key Management Relatives of Key Personnel Management
Personnel/ Companiesin which they exercise
significant influence
– Share Application money pending allotment – – – – (–) (–) (–) (–)
– Loans (Including Interest accrued) – – – – (–) (–) (–) (–)
– Shares allotted – – – 9166.75 (–) (–) (–) (–)
– Warrants allotted – – – – (–) (–) (–) (–)
– Forfeiture of advance on warrants – – – 89.14 (–) (–) (–) (–)
Sale of goods – 1616.19 – – (–) (2070.25) (–) (–)
Rendering of Services / Royalty / Interest income – – – – (–) (–) (–) (–)
Services Received / Rent Paid – – – 425.64 (–) (–) (–) (136.41)
Remuneration – – 343.44 – (–) (–) (707.75) (–)
Availment of services – – – – (–) (–) (–) (–)
Amounts Due at the end of the year – Debit – 63.17 – 10.83 (–) (63.17) (–) (111.10)
Amounts Due at the end of the year – Credit – – – – (–) (–) (–) (–)
Figures in brackets are for previous year
(Rs. lakh)
Names of the related parties and description of relationship.
1. Subsidiary Orchid Europe Limited, UK
Orchid Pharmaceuticals, Inc., USA
Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc., USA.)
Orchid Research Laboratories Ltd., India
Orchid Pharma Japan KK
Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa
Bexel Pharmaceuticals, Inc., USA
2. Joint Venture NCPC Orchid Pharmaceuticals Company Limited, China
Diakron Pharmaceuticals, Inc., USA
3. Key Management Personnel Mr. K Raghavendra Rao, Managing Director
Dr. C Bhaktavatsala Rao, Deputy Managing Director
4. Relatives of Key Management Personnel Mrs. R Vijayalakshmi (wife of Mr. K Raghavendra Rao)
Ms R Divya and Ms R Sowmya (daughters of Mr. K. Raghavendra Rao)
5. Companies in which relatives of Key Spectrasoft Technologies Limited, India.
Management Personnel exercise significant influence.
All whole time directors have been considered as Key Management Personnel as they are involved in planning, directing and controlling the activities of the
reporting enterprise.
73Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
b) Information on Loans & Advances as Balance Maximum amountper clause 32 of the Listing Agreement as on 31-03-2009 outstanding
during the year
Joint Venture - NCPC Orchid Pharmaceuticals Company Ltd. 174.57 174.57
(Rs. lakh)
14. In terms of the resolution passed by the Company at the EGM dated October 21,1999 Employee Stock Option Scheme was extended to the employees of theCompany. Accordingly options totalling 15,00,000 Nos were given to the employees as per the scheme formulated under “ORCHID-ESOP 99" scheme by theCompensation committee of the Board of Directors. Each option is convertible into one equity share of Rs. 10/- each at a price of Rs. 243.35 includingpremium for 6,00,000 Nos, Rs. 252 including premium for 3,07,925 Nos, Rs. 300.65 including premium for 2,92,075 Nos and Rs. 339.25 for 3,00,000 Nos. Noentries were passed in the books as the options were given at the market prices prevailing on the date of issuance of options.
A fair and reasonable adjustment in share price/ the number of options outstanding was made by the Company in respect of the Employee Stock Optionsgranted but not exercised by the Employees due to the corporate action of issue of bonus shares during October 2005. The total number of options outstandingand the price was adjusted so that the total value and options available to each option holder remained the same.
Consequently the revised and adjusted prices per share are Rs. 162.24 (Rs. 243.35), Rs. 168.00 (Rs. 252.00) and Rs. 200.44 (Rs. 300.65) respectively for 600000Nos, 307925 Nos and 292075 Nos of options granted by the Company.
For the 300,000 options granted during April 2006 at a price of Rs. 339.25, the Compensation Committee of the Board of Directors considered repricing ofthe options in the interest of the employees, due to the fall in the price of the shares of the Company and accordingly approved a repricing of the optionsfrom Rs. 339.25 to Rs. 193.25 as per the closing price of Orchid at National Stock Exchange on August 11, 2006. The revision in the price has been approvedby the shareholders at the Annual General Meeting held on July 19, 2007.
Pursuant to the exercise of options by employees, the Allotment Committee of the Board at its meeting held on April 26, 2008, May 29, 2008 and August13, 2008 allotted 7,525, 16,175, and 3,000 equity shares respectively to the employees under ORCHID ESOP 99 Scheme. 536,153 Options were outstandingas at March 31, 2009 including the additional number of options adjusted, due to the bonus issue.
In terms of the resolution passed by the Company at the AGM dated July 18, 2005 the shareholders approved the scheme formulated under “ORCHID-ESOP2005”for allotting 10,00,000 Nos. Accordingly 610,000 options were given to the eligible directors and employees by the compensation committee of the Boardof Directors at a meeting held on August 12, 2006. Each option is convertible into one equity share of Rs. 10/- each at a price of Rs. 193.25 per shareincluding premium.
Pursuant to the exercise of options by employees, the Allotment Committee of the Board at its meeting held on April 26, 2008, May 29, 2008, August 13,2008 and August 29, 2008 allotted 1,900, 200, 1,000 and 1,500 equity shares respectively to the employees and 84,325 Options were outstanding as at March31, 2009 under ORCHID ESOP 2005 Scheme.
15. a) In terms of the resolution passed by the Company on February 14, 2007, 50,00,000 warrants were allotted to the Promoter /Promoter Group(s), therelative(s) of the Promoter on March 01, 2007. These warrants are eligible for conversion at the option of the Warrants holders, into equity shares of theCompany at a price of Rs. 202.58 per share within a period of 18 months of the date of allotment.
During the year, pursuant to the exercise of option by the warrant holders, the Allotment Committee of the Board at its meeting held on August 13, 2008and August 29, 2008 have allotted 381,000 and 41,79,000 equity shares respectively. The balance 440,000 warrants were not exercised within thestipulated period. Hence on September 01, 2008 the 10% advance paid by them amounting to Rs. 89.14 lakh on the unexercised warrants was forfeitedand credited to capital reserve.
b). Other liabilities include Rs. Nil (Previous year Rs. 1,012.90 lakh) being the amount received as advance against the warrants issued to the promotergroup, including Rs. Nil (Previous year Rs. 7.09 lakh) from a Director.
16. a) Provision for Deferred tax for the year Rs. 1349.4 lakh (Previous year Rs. 2254.53 lakh)
Deferred Tax liability represents the following:
As at 31.03.2009 As at 31.03.2008
Timing Difference on account of Depreciation 21655.01 18911.28
Timing Difference on account of Losses (8815.09) (7420.75)
In accordance with clause 29 of Accounting Standard (AS22) Deferred tax Assets and Deferred tax Liabilities have been set off.
(Rs. lakh)
74 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
17. Segmental ReportingThe Company was disclosing segment information classifying the business as Bulk drugs and Formulations till the financial year 2004-05. However in view
of integration of bulk actives and formulations business, with the commissioning of Generics formulation facilities from the financial year 2005-06, the
Company considers the business as one interrelated and integrated business of "Pharmaceutical products" and hence no separate segmental reporting is
provided.
18. Reconciliation of Basic and Diluted shares used in computing Earnings Per Share (Equity shares of Rs. 10/- each fully paid-up)
Year ended Year ended31.03.2009 31.03.2008
Profit After Tax Rs. In lakh (4898.99) 17534.01
No of Shares Outstanding Nos. 70442076 65850776
Weighted Average Number of shares Nos. 68579472 65832234
Earning per Share - Basic Rs. (7.14) 26.63
No of warrants & options allotted Nos. 21141785 32048733
Total No of Equity shares to compute diluted EPS Nos. 89721257 97880967
Earning per Share - Diluted Rs. (7.14) 17.91
19. Disclosure as per requirements of Accounting Standard 26
As at As at31.03.2009 31.03.2008
ACQUIRED– Brands & Trademarks Useful life 5 Years 5 Years
Gross Carrying Amount (Rs. in lakh) Opening 442.78 895.31
Additions/Adjustments 432.90 (6.90)
Amortisation 147.68 445.63
Closing 728.00 442.78
INTERNALLY GENERATED– DMF & ANDA(Refer Note 2(b)(iv) of Schedule P)Useful life 5 Years 5 Years
Gross Carrying Amount (Rs. in lakh) Opening 5025.16 4465.97
Additions – 868.87
Amortisation 301.60 309.68
Closing 4723.57 5025.16
75Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
20. Expenditure on Research and Development
Year ended Year ended31.03.2009 31.03.2008
Capital expenditure 812.15 2564.00
Revenue expenditure charged to the Profit & Loss account 4647.75 4877.53
5459.90 7441.53
Such Capital expenditure for the year 2006-07, 2005-06 & 2004-05 are Rs. 3934.25 lakh,
Rs. 3474.14 lakh & Rs. 3262.56 lakh and revenue expenditures for the year 2006-07,
2005-06 & 2004-05 are Rs. 3963.13 lakh, Rs. 2662.10 lakh & Rs. 1958.12 lakh
respectively.The above information has been provided as required by
Department of Scientific and Industrial Research.
Revenue Research and Development Expenses include :
Power and Fuel 211.27 208.64
Conversion Charges 1.32 –
Consumption of Stores, Spares & Chemicals 945.15 1234.01
Salaries, Wages and Bonus 1841.17 1243.98
Contribution to Provident & other funds 137.43 142.67
Staff Welfare 157.31 121.01
Rates & Taxes 2.30 13.77
Insurance 13.98 20.95
Postage, Telephone & Telex 11.61 27.23
Printing & Stationery 29.76 29.73
Vehicle Maintenance 5.60 3.92
Recruitment expenses 18.22 23.48
Travelling and Conveyance 32.04 54.50
Loss on Sale of Asset 17.94 2.98
Testing Charges 578.95 1254.27
Consultancy & Professional Fees 305.41 52.46
Others 338.29 443.93
4647.75 4877.53
21. Derivative Instruments and unhedged Foreign currency Exposure : a) Derivative instruments
Sl. No. As at As at31.03.2009 31.03.2008
1. Currency Swap 17221.85 21649.40
76 Orchid Chemicals & Pharmaceuticals Ltd.
SCHEDULES TO THE CONSOLIDATED ACCOUNTS
Schedule “P” NOTES ON ACCOUNTS (Contd.)
2008-09 2007-08Currency Foreign Rs. Foreign Rs.
Currency Currency
i) Receivables OutstandingUSD 123217942 52941.99 122525472 48572.06 EURO 448782 300.54 595724 286.42 AUD 161626 56.39
ii) Payables Outstanding USD 18610098 9166.18 29694024 11934.03 EUR 706015 506.72 4063999 2584.70 JPY 1847128 7.95 28418597 114.73 Others – 27.37 48.41
iii) Advance Paid GBP 272591 229.34 707210 562.41 SGD 11280 3.29 11280 3.29 USD 5357900 2719.40 4670000 1845.58 Eur 10247544 7014.70 566045.48 352.87 CHF 130390 60.03
iv) FCCB USD 154660000 79170.45 194710000 78098.18 v) Loans availed USD 47394502 24261.25 62098487 24887.03
(Rs. lakh)
d) The MTM loss amounting to Rs. 3934.45 lakh on the derivatives outstanding as on March 31, 2009 has been recognised in the accounts and includedunder exchange rates loss/(gain) account
22. The Board of Directors of Ogna Farma have decided to close the operations and filed application with the appropriate authorities for Liquidation. Accordinglythe accounts of the Company have not been prepared on going concern basis. The consolidated accounts also have been prepared accordingly.
23. Sundry Debtors shown in the Balance sheet are subject to confirmations. The Company has sent confirmation letters to all the debtors. In view of therecessionary trend, some of the debtors have been requesting for discounts and the Company is in the process of negotiations with such customers. TheCompany has made adequate provisions for such estimated claims under the head “Provision for Rebates / Discounts”.
24. Previous year's figures have been regrouped wherever necessary to conform to current year's classification.
b) The purpose for which the instruments have been acquired is for hedging the foreign currency exposures.
c) The Foreign Currency Exposures that are not hedged by a derivative instrument or otherwise
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
77Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
CONSOLIDATED CASH FLOW STATEMENT for the year ended March 31, 2009
31.03.2009 31.03.2008A. CASH FLOW FROM OPERATING ACTIVITIES
Net Profit before taxation and extraordinary item (3381.65) 22856.50
Adjustment for:
Depreciation 13399.25 10067.84
Dividend Income (4.00) (1.80)
Loss/ (Profit) on sale of Fixed Assets 229.06 15.05
Gain on cancellation of FCCBs-net (6730.53) –
Provision for doubtful advances written back (1833.73) –
Foreign Exchange Rate Fluctuations - Unrealised (4726.79) (6590.87)
Interest Expense 15645.00 8200.05
Provision for Rebates/Discounts 4000.00 –
Provision for doubtful debts – 1552.39
Operating Profit before Working Capital Changes 16596.61 36099.16
Adjustments for:
Trade and other Receivables (3905.77) (13998.50)
Inventories (11909.93) (3754.09)
Trade Payables 4090.08 5910.36
Cash generated from Operations 4870.99 24256.93
Income Taxes Paid (280.84) (3227.98)
Net Cash from Operating Activities 4590.15 21028.95
B. CASH FLOW FROM INVESTING ACTIVITIES
Purchase of Fixed Assets (48132.03) (54560.49)
Proceeds from Sale / Deletion of Fixed Assets 431.08 91.20
Purchase / Sale of Investments – (72.82)
Dividends received 4.00 1.80
Net cash used in Investing Activities (47696.95) (54540.31)
(Rs. lakh)
78 Orchid Chemicals & Pharmaceuticals Ltd.
CONSOLIDATED CASH FLOW STATEMENT (Contd.) for the year ended March 31, 2009
31.03.2009 31.03.2008C. CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of Share Capital (net of expenses) 10951.54 67.88
Proceeds from Working Capital Borrowings 6722.49 16433.04
Proceeds from Long Term Borrowings 93007.15 43889.14
Repayment of LongTerm Borrowings (29422.62) (33143.14)
Proceeds from issue /cancellation of FCCBs (net of expenses) (5632.39) –
Proceeds from / (Repayment of) Short Term Borrowings (9995.99) 12000.00
Proceeds from HP Finance (29.23) (20.95)
Interest paid (20186.24) (12179.18)
Dividend paid (2306.31) (2310.46)
Net cash from Financing Activities 43108.41 24736.33
D. NET INCREASE IN CASH AND CASH EQUIVALENTS 1.60 (8775.03)
Cash and Cash equivalents at the beginning of period 2447.21 11222.24
Cash and Cash equivalents at the end of period 2448.84 2447.21
Reconciliation statement
Cash and bank Balances as per Balance sheet 5250.67 3103.90
Less : Margin Money Deposit 2746.62 604.08
Unclaimed Dividend 55.21 52.61
Cash and cash Equivalents as per cash flow 2448.84 2447.21
(Rs. lakh)
On behalf of the Board
As per our report of even date
For SNB Associates K. Raghavendra RaoChartered Accountants Managing Director
B. Mahalingam Dr C. Bhaktavatsala Rao Dr M. R. Girinath Dr I. Seetharam NaiduPartner Deputy Managing Director Director Director
Place: Chennai S. Krishnan Bhoomijha MuraliDate: June 29, 2009 Head-Finance & Business Planning GM-Legal & Company Secretary
79Annual Report 2008-09
Orchid Chemicals & Pharmaceuticals Ltd.
S. N
0Pa
rtic
ular
s20
08–0
920
07–0
820
06–0
720
05–0
620
04–0
520
03–0
420
02–0
320
01–0
220
00–0
119
99–0
0
A)Fi
nanc
ial R
esul
ts S
umm
ary
1To
tal
Sale
s &
Ope
ratin
g In
com
e12
2155
12
5018
93
418
8887
7 68
929
7134
1 54
141
4255
2 37
125
3595
5
2O
ther
Inco
me
451@
124@
156
133
82
123
111
75
131
377
3To
tal I
ncom
e12
2606
12
5142
93
574
8900
9 69
012
7146
4 54
253
4262
8 37
256
3633
2
4EB
IDTA
2483
1 41
734
2913
7 26
060
1631
1 15
049
1096
3 97
72
1016
5 11
086
5Pr
ofit/
(Los
s) A
fter
Tax
-521
718
454
9663
82
90
3101
31
03
1954
63
1 35
76
3859
6Pa
id-u
p Eq
uity
Sha
re C
apita
l70
44
6585
65
82
6462
34
13
3238
32
38
2800
28
00
2800
7Sh
areh
olde
rs’ N
et w
orth
79
971
8038
7 59
361
8650
9 54
568
4969
0 48
049
3701
7 39
765
3742
3
B)Ke
y Ra
tios
& P
aram
eter
s
(I)Pr
ofita
bilit
y re
late
d Ra
tios
& P
aram
eter
s
1EB
IDTA
Mar
gin
- %
20.2
533
.35
31.1
429
.28
23.6
421
.06
20.2
122
.92
27.2
830
.51
2N
et P
rofit
Mar
gin
- %
-4.2
614
.75
10.3
39.
314.
494.
343.
601.
489.
6010
.62
(II)
Shar
ehol
der
rela
ted
Ratio
s &
Par
amet
ers
1EP
S-Rs
./Sha
re-7
.61
28.0
3 14
.70
14.8
59.
559.
586.
612.
2512
.77
18.6
7
2Bo
ok V
alue
- R
s./Sh
are
#11
5.05
122.
0790
.19
133.
8815
9.87
153.
4514
8.38
132.
2014
2.00
133.
66
(III)
Grow
th r
elat
ed R
atio
s &
Par
amet
ers
1G
row
th in
Tot
al In
com
e -
%-2
.03
33.7
45.
1328
.98
-3.0
032
.00
27.0
014
.42
2.54
8.18
2G
row
th in
EBI
DTA
- %
-40.
5043
.23
11.8
159
.77
8.00
37.0
012
.00
-3.8
7-8
.30
26.7
8
3G
row
th in
PAT
- %
-128
.27
90.9
716
.56
167.
33–
59.0
021
0.00
-82.
37-7
.34
8.58
# Ra
tio c
alcu
late
d as
(Fre
e Re
serv
es &
Sur
plus
+ D
efer
red
Tax
Liab
ility
) ove
r Equ
ity S
hare
Cap
ital
@ D
oes
not
incl
ude
exch
ange
rate
gai
n on
FCC
Bs
(Rs.
lakh
)Ke
y Fi
nanc
ial P
aram
eter
s an
d Ra
tios
at a
Gla
nce
80 Orchid Chemicals & Pharmaceuticals Ltd.
3mm Spine
FORWARD-LOOKING STATEMENTIn this Annual Report we have disclosed forward-looking
information to enable investors to comprehend our prospects and
take informed investment decisions. This report and other
statements that we periodically make contain forward-looking
statements that set out anticipated results based on the
management’s plans and assumptions. We have tried wherever
possible to identify such statements by using words such as
‘anticipate’, ‘estimate’, ‘expects’, ‘projects’, ‘intends’, ‘plans’,
‘believes’, ‘targets’ and words of similar substance in connection
with any discussion of future performance.
We cannot guarantee that these forward-looking statements will
be realized, although we believe we have been prudent in our
assumptions. The achievement of results is subject to risks,
uncertainties and estimates taken as assumptions. Should known
or unknown risks or uncertainties materialize, or should underlying
assumptions prove inaccurate, actual results could vary materially
from those anticipated, estimated or projected.
CONTENTS
Corporate information 01 Strategic review 02 Directors’ Report 04 Corporate Governance Report 13
General shareholders’ information 20 Management discussion and analysis 26 Financial section 31
20901409_Orchid_AR_2k8-2k9_Ordinary_Cover:Layout 2 03/09/09 7:08 PM Page 2
Regd. Office
‘Orchid Towers’ 313, Valluvar Kottam High Road, Nungambakkam, Chennai 600034, India
Tel : (91)-44-28211000 Fax : (91)-44-28211002 e-mail: [email protected]
Website: www.orchidpharma.com Health portal: www.healthorchid.com
Orchid Chemicals& Pharmaceuticals Limited
Annual Report 2008-09
3mm Spine20901409_Orchid_AR_2k8-2k9_Ordinary_Cover:Layout 2 03/09/09 7:08 PM Page 1